{
  "responseHeader":{
    "status":0,
    "QTime":4,
    "params":{
      "q":"(Background: breast cancer Doc_title: breast cancer) AND (Background: ERBB2 OR Doc_title: ERBB2)"}},
  "response":{"numFound":493,"start":0,"docs":[
      {
        "Meeting_name":" MET and ERBB2 are coexpressed in ERBB2+ breast cancers and contribute to innate resistance.",
        "Background":"['Breast cancers display a remarkable phenotypic diversity that is exploited to promote both tumor progression and therapeutic resistance. Recent studies in several types of cancer have highlighted the significance of intratumoral heterogeneity on both innate and acquired resistance to tyrosine kinase inhibitors. Tumor plasticity is supported by the heterogeneous expression of receptor tyrosine kinases (RTKs) and the robustness that the overlapping signaling networks provide. Therefore a thorough understanding of the intratumoral heterogeneity is necessary for the development of effective therapeutic strategies.The receptor tyrosine kinase MET is overexpressed in 20-30% of breast cancers and correlates with poor patient outcome. Previously, we determined that high MET expression correlated with ERneg/ERBB2neg and basal-like breast cancers. These results and the efficacy of MET inhibitors in other cancers suggest that MET may be an effective clinical target for aggressive breast cancer subtypes. Recent studies have exposed interactions between MET and the ERBB receptor family in the progression and therapeutic resistance of several cancers. Since MET, ERBB2, and EGFR are known to be highly expressed in aggressive breast cancer subtypes, it is critical that we understand the relationships between these receptors in order to develop effective treatment strategies.In this study, we interrogated the relationship between MET expression/activity and the expression/activity of the ERBB receptor family in human breast cancers and a breast cancer cell line. Using coimmunostaining and quantitative multispectral analysis, we observed that a significant percentage of ERBB2+ tumors coexpress MET and ERBB2. These tumors display significant heterogeneity and have subpopulations of cells that are METhigh/ERBB2low, METlow/ERBB2high, and METhigh/ERBB2high. In a METhigh/ERBB2high breast cancer cell line, we observed that MET depletion results in increased ERBB2 activation and conversely ERBB2 depletion results in increase MET activation. Neither EGFR or ERBB3 compensated for MET or ERBB2 knockdown. The loss of both MET and ERBB2 led to a decrease in PI3K/AKT signaling and increased dependency on MAPK. MET and ERBB2 knockdown did decrease proliferation but neither alone was able to abolish all cell growth. These results in addition to the heterogeneous expression of MET and ERBB2 in breast cancers have significant clinical implications on potential therapeutic strategies for breast cancer patients.']",
        "Doc_id":"AACR_2013-3022",
        "Doc_title":" MET and ERBB2 are coexpressed in ERBB2+ breast cancers and contribute to innate resistance.",
        "_version_":1606189030827884544},
      {
        "Meeting_name":" Targeting MET and ERBB2 signaling in aggressive breast cancers",
        "Background":"['In spite of clinical advancements, tumors that no longer depend on ER/PR and ERBB2 signaling are clinically aggressive and have the poorest prognosis. Few effective treatment options exist for basal or trastuzumab-resistant ERBB2 breast cancers. Understanding the signaling pathways that drive these aggressive breast cancer subtypes is critical to the development of successful therapeutics. The receptor tyrosine kinase MET is overexpressed in 20-30% of breast cancers and correlates with poor patient outcome, independent of ERBB2 expression. Previously, we determined that MET is expressed in the majority of breast cancers. Most importantly, we determined that high MET expression correlated with ERneg/ERBB2neg tumors and the basal subtype. These studies indicate that MET may serve as a novel therapeutic target for those patients with the most aggressive tumors and currently, the fewest therapeutic options. We are utilizing breast cancer cell lines and xenograft mouse models to examine how MET and ERBB2 uniquely influence breast cancer progression. To investigate the effects of MET and/or ERBB2 inhibition we are utilizing lentiviral shRNA knockdown in both basal and luminal cells. We observed that both MET and ERBB2 depletion decrease cell proliferation and invasion. In addition, we have profiled the effects of MET and ERBB2 knockdown on the phosphorylation of 42 receptor tyrosine kinases (RTK) and 44 tyrosine kinases. We observed that downstream signaling at the tyrosine kinase level is minimally affected by downregulation of MET or ERBB2; however, there is significant signaling compensation that occurs at the RTK level through the ERBB family members, EGFR and ERBB3. Currently, we are examining the interaction between MET and the ERBB family in both basal and luminal breast cancer cell lines. In addition, we are measuring the effect of MET or ERBB2 depletion on growth of breast cancer cells in 3D culture. In addition, we have evaluated MET and ERBB2 expression in human invasive breast carcinomas using coimmunostaining and quantitative analysis with the CRi Nuance multispectral imager. We observe that a significant percentage of tumors coexpress MET and ERBB2. Many tumors have significant heterogeneity of MET and ERBB2 expression and have patterns of cells that are METhigh/ERBB2low, METlow/ERBB2high, and METhigh/ERBB2high. We hypothesize that breast cancer cells expressing both MET and ERBB2 (METhigh/ERBB2high) are highly tumorigenic and have an increased proliferative capacity, metastatic potential and chemoresistance. Currently, fresh primary human breast cancer tissue is being transplanted into mammary glands of NOD-SCIDIL2R mice to determine the impact of MET and ERBB2 expression on tumor growth and metastasis in vivo. These studies will reveal whether MET and ERBB2 have synergistic or exclusive roles in breast cancer progression and how these oncogenes can be targeted for successful therapy.']",
        "Doc_id":"AACR_2012-4864",
        "Doc_title":" Targeting MET and ERBB2 signaling in aggressive breast cancers",
        "_version_":1606189026118729728},
      {
        "Meeting_name":" Novel regulation of Jagged1 by ErbB2 in breast cancer",
        "Background":"['We have demonstrated that Notch1 is required for trastuzumab resistance in ErbB2 positive breast cancer. This indicates that ErbB2 suppresses Notch1 in breast cancer and therapeutic intervention targeting ErbB2 might have an unintended consequence which is aberrant up regulation of Notch1 which is a breast oncogene.However, the mechanism of action by which ErbB2 restricts Notch1 activation is unknown. In this current study, we investigated the role of cis- and trans-activation of Notch signaling by Notch ligands which are developmentally conversed to tightly regulate Notch activation. To address this hypothesis, we performed co-culture studies using fibroblasts expressing no Notch ligands or over-expressing human Jagged1 or Deltalike1 and ErbB2 positive breast cancer cells. We performed flow cytometry to isolate breast cancer cells after co-culture and extracted RNA to measure expression of Notch gene targets as a measure of Notch activity. The results showed that trastuzumab, Lapatinib, or ErbB2 knockdown increased overall Notch activition. Similarly, Co-culture with Jagged1-expressing fibroblasts increased overall Notch activation. However, Knocked down of Jagged1 in the breast cancer cells had little effect on ligand-induced Notch activation relieving the possibility of cis-inhibition. In contrast, Jagged1 knocked down abrogated trastuzumab-induced Notch activation in the breast cancer cells. These results suggest that ErbB2 might restrict Notch activation by preventing Jagged1-mediated trans activation of Notch and not by promoting cis-inhibition. Confocal immunofluorescence showed that Jagged1 is localized with Notch1 when ErbB2 is hyperactive but is trafficked to the cell surface in response to trastuzumab. K44ADynamin abrogated Jagged1 expression on the cell surface as measured by IF and surface biotinylation studies. Furthermore, K44ADynamin expression abrogated trastuzumab-induced Notch1 activation. Importantly, we measured growth consequences of Jagged1-mediated Notch activation in response to trastuzumab and found that Jagged1 is necessary for survival of ErbB2 positive breast cancer cells and trastuzumab resistance as measured by cell cycle analysis and Annexin V staining. These results taken together indicate that ErbB2 restricts Notch by limiting Jagged1-mediated trans-activation.']",
        "Doc_id":"AACR_2014-1823",
        "Doc_title":" Novel regulation of Jagged1 by ErbB2 in breast cancer",
        "_version_":1606189031567130624},
      {
        "Meeting_name":" ERBB2 amplicon passenger genes",
        "Background":"['DNA copy number amplification at the ERBB2 locus on 17q12-21 is a frequent genomic event, present in 10-15% of breast tumors. This gene-dense amplicon contains several genes that are aberrantly overexpressed in ERBB2+ breast cancer. We hypothesized that a subset of amplicon genes with minimal expression in normal tissue could serve as candidates for shared tumor-specific antigens. We eliminated from consideration other amplicon genes with high expression in specific tissues or broad expression in normal tissues due to the potential for autoimmune toxicity. Immunohistochemistry of a breast tumor microarray showed expression of MIEN, GRB7, PGAP3 proteins specifically in ERBB2+ tumor cells but not in stroma or in ERBB2 non-amplified breast tumor samples. We tested several peptide epitopes with predicted high affinity for HLA-A2 (<50 nM) and confirmed that these could stabilize MHC expression on T2 cells. In vitro sensitization of normal donor lymphocytes with the predicted epitopes led to production of IFN-. Moreover, Dendritic cells pulsed with lysate from SKBR3 (ERBB2 amplified) but not MCF7 breast cancer cells could sensitize autologous lymphocytes to epitopes from amplicon proteins. This suggests that the natural abundance of the amplicon proteins in ERBB2 positive tumors is sufficient to provide cross-priming. To test whether the amplicon proteins could serve as tumor-rejection antigens we used the murine TM15 breast cancer cell line which has amplification of a syntenic region surrounding the murine Her2/neu gene. Quantitative PCR showed 50-fold overexpression of the amplicon gene pnmt in TM15 cells. Mice vaccinated with recombinant murine or human PNMT protein, but not ovalbumin, rejected challenge with TM15 tumor without any overt toxicity and developed memory against delayed re-challenge.These data indicate that normal host genes which are in immediate proximity to the oncogene ERBB2 are abnormally expressed at high levels in ERBB2+ breast tumor cells. Although the molecular mechanism leading to aberrant expression is unknown, analysis of several breast cancer microarray databases as well as TCGA data also show a very high correlation between ERBB2 overexpression and high expression of these passenger genes so this seems to be a general phenomenon. T lymphocytes normally have tolerance to non-mutated host proteins however tolerance can be reversed with proper sensitization conditions. Antigen overexpression in tumor cells might allow effector T cells to surpass an activation threshold while preserving tolerance for normal tissue. DNA copy number amplification of specific oncogenes is a frequent genomic event in cancer so the general strategy of targeting passenger genes on amplicons may have broader use in cancer immunotherapy.']",
        "Doc_id":"AACR_2014-2897",
        "Doc_title":" ERBB2 amplicon passenger genes",
        "_version_":1606189034685595648},
      {
        "Meeting_name":" Genomic alterations in ERBB2 define a subset of pleomorphic invasive lobular breast cancer",
        "Background":"['Background. Pleomorphic invasive lobular carcinoma represents a unique histologic subset of breast cancer with poorer outcomes as compared with classic invasive lobular carcinoma of the breast. With the recent finding of ERBB2 alterations in recurrent invasive lobular carcinoma, the goal of this study is to define the relationship of ERBB2 alterations in the distinct subset of pleomorphic invasive lobular carcinomas.Methods. Using the provisional invasive breast cancer data set of 962 cases in The Cancer Genome Atlas (TCGA), all breast cancers with CDH1 alterations were identified and pathologic review was performed. Independent identification of ERBB2 genomic alterations was done. The frequency and nature of genomic alterations in ERBB2, PTEN, PIK3CA, and TP53 were determined. FFPE specimens from an additional 18 cases from our own institution have been evaluated using the combination of the RainDance ThunderBolts Cancer Panel for validation.Results. Of 116 TCGA breast cancers with CDH1 alterations, 86 were invasive lobular breast cancer. Within this subset, 21 pleomorphic lobular breast cancers were identified based on morphologic review. Nine ERBB2 mutations (42.9%) and three amplifications (14.3%) were found in pleomorphic invasive lobular carcinoma, but none in classic invasive lobular carcinoma (p value 1.92e-9). There were no significance differences in the frequency of TP53, PTEN or PIK3CA alterations in pleomorphic invasive lobular carcinoma as compared to classic invasive lobular carcinoma. Data from the additional 18 validation cases will be presented.Conclusions. Genomic alterations in ERBB2 strongly associate with the finding of pleomorphic invasive lobular but not classic invasive lobular histology. The presence of ERBB2 alterations has therapeutic implications specific to this rare breast cancer subset that could impact outcomes. Comprehensive genomic profiling identifies ERBB2 mutations that are not detected with standard clinical immunohistochemistry or FISH.']",
        "Doc_id":"AACR_2015-4798",
        "Doc_title":" Genomic alterations in ERBB2 define a subset of pleomorphic invasive lobular breast cancer",
        "_version_":1606189041050451968},
      {
        "Meeting_name":" LPP promotes ErbB2 overexpressing breast cancer cell migration, invasion and metastasis",
        "Background":"['Metastatic breast cancer remains a major hurdle to the successful treatment of this disease. Overexpression of the HER2/ErbB2 receptor tyrosine kinase in breast cancer is associated with metastatic disease and correlates with poor patient prognosis. Growing evidence demonstrates that TGF can potentiate ErbB2 signaling to enhance the invasive and metastatic behavior of breast cancer cells. Nonetheless, the mechanisms underlying the synergy between TGF and ErbB2 signaling pathways remain to be elucidated.We previously identified Lipoma Preferred Partner (LPP) as an indispensable mediator of TGF-induced migration, invasion and focal adhesion turnover of ErbB2-expressing breast cancer cells. Furthermore, we established domains within LPP that are required for its localization to focal adhesions and for its interaction with -Actinin, an actin cross-linking protein, to promote cell migration and invasion.Herein, we examine the requirement of LPP in tumorigenesis and metastasis formation. We observe that LPP is dispensable for primary tumor growth. Nonetheless, the loss of LPP leads to decrease in spontaneous lung metastasis formation of ErbB2-expressing breast cancer cells injected into the mammary fat pads of mice. Furthermore, we observe that LPP is a critical determinant for efficient dissemination of breast cancer cells. We show that shRNA-mediated reduction of LPP significantly impairs pulmonary metastasis formation in experimental metastasis tail vein assay.Overall, we have identified LPP as a novel mediator that integrates TGF and ErbB2 signaling to promote the migration, invasion and metastasis of breast cancer cells. We identify LPP as a pro-metastatic mediator of ErbB2 overexpressing breast cancer cells and a potential new biomarker of metastatic breast cancer.']",
        "Doc_id":"AACR_2014-2093",
        "Doc_title":" LPP promotes ErbB2 overexpressing breast cancer cell migration, invasion and metastasis",
        "_version_":1606189021673816064},
      {
        "Meeting_name":" Complex genomic regions associated with ERBB2 amplification in breast cancer",
        "Background":"['Repeated DNA segments (Low Copy Repeats, Segmental Duplications) are highly homologous sequences within the human genome. They are typically 10-300 kb in length, and bear >95% sequence identity. In germline, repeated DNA segments mediate recurrent DNA rearrangements and thus cause specific genetic disorders called genomic disorders. Repeated genomic segments could also be prone to rearrangements in somatic cells and thus could mediate recurrent rearrangements in cancer. However, the important role of repeated genomic segments in genome instability in cancer remains elusive, mainly because such regions are less accessible by current genomic technologies due to the difficulty in assembling and interrogating sequences. Gene amplification is a cellular process characterized by the production of multiple copies of a particular gene through DNA rearrangements. ERBB2, an epidermal growth factor receptor gene, is amplified in 15-20% of breast tumors. Due to excessive cell growth signaling, this recurrent amplification is associated with advanced stages and poor prognosis. Despite the clinical importance, the mechanisms giving rises to recurrent ERBB2 amplification remains unclear. We hypothesized that, similar to the recurrent rearrangements for genomic disorders, repeated genomic segments cause DNA rearrangements for ERBB2 amplification. To test the hypothesis and understand the mechanism of ERBB2 amplification, we mapped a common copy-number breakpoint for primary ERBB2-amplified (HER2-positive) breast tumors. Copy number breakpoints were examined at every 300-kilo bases (kb) from the location of ERBB2 to its telomeric region using real-time PCR based assays. The breakpoint that marked a region between normal copy number and low level amplification resided within a 300-kb complex genomic region at the 1.5 mega-bases telomeric side of ERBB2. The region contains many repeated segments from two gene families. Furthermore, the HapMap SNPs, a set of SNPs that tag haploblocks in the human genome, are less well-defined, indicating the difficulty in interrogating the genomic region by current genomic technologies. Normal copy-number variations seem common, as there is several deletion polymorphisms reported in the region. Two sub-regions, each covering 40-kb region, are particularly complex due to a number of direct and inverted repeats. The prevalence of this copy number breakpoint in HER2-positive breast tumors was also shown in a study by Sircoulomb et al.,(BMC Cancer 2010), in which common amplifications and deletions were determined for 54 HER-2 positive breast tumors. Defining (1) the copy-number breakpoint with very high resolution and (2) critical DNA sequences for ERBB2 amplification will lead to better understanding the amplification mechanism underlying this aggressive type of breast cancer.']",
        "Doc_id":"AACR_2012-3117",
        "Doc_title":" Complex genomic regions associated with ERBB2 amplification in breast cancer",
        "_version_":1606188988178104320},
      {
        "Meeting_name":" DBNL is a pro-survival adaptor in ErbB2+ breast cancer",
        "Background":"['DBNL, also known as mAbp1, Hip-55, or SH3P7, is a fairly novel, ubiquitously expressed, multidomain adapter protein consisting of an N-terminal F-actin binding domain, an internal proline-serine-and threonine-rich domain, and a C-terminal SH3-domain. The N-terminal and C-terminal domains of DBNL are highly conserved from mammal to yeast and are implicated in a multitude of cellular processes that include, endocytosis, migration, signaling, and viability. Recently, a proteomics analysis identified DBNL as a pro-survival signaling node in various cancers. Here we demonstrate that siRNA knockdown of DBNL reduces ErbB2+ breast cancer viability by arresting cell growth at the G1/S phase and by enhancing caspase-mediated apoptosis. Furthermore, knockdown of DBNL reduces cell surface levels of ErbB2 and decreases Akt phosphorylation. Elucidating the downstream signaling mechanisms that drive DBNL-mediated pro-survival will further aid in identifying new targets to ErbB2+ cancers as well as define additional roles of DBNL in cell biology.']",
        "Doc_id":"AACR_2015-3905",
        "Doc_title":" DBNL is a pro-survival adaptor in ErbB2+ breast cancer",
        "_version_":1606188982701391872},
      {
        "Meeting_name":" ARRY-380, a potent, small molecule inhibitor of ErbB2, increases survival in intracranial ErbB2+ xenograft models in mice",
        "Background":"['ARRY-380 is an orally active, potent small molecule targeting ErbB2 inhibitor currently in clinical development in patients with ErbB2+ metastatic breast cancer (MBC). This compound has shown excellent activity in numerous SC mouse tumor models including breast (BT-474, MDA-MB-453), ovarian (SK-OV-3) and gastric (N87) carcinoma models. In breast cancer patients, brain metastases are a serious unmet medical need. Patients with ErbB2+ breast cancer have a significantly increased incidence of brain metastases following trastuzumab therapy. Here we demonstrate significant single agent activity of ARRY-380 in two ErbB2+ intracranial mouse xenograft models. For these studies, female nude mice received intracranial implantations of tumor cells (either NCI-N87 or BT-474) by direct injection into the brain parenchyma (via the sagittal suture). In pilot studies, we demonstrated that the blood brain barrier was not disrupted by mechanical injections and that increasing tumor burden correlates negatively with neurologic outcome, body weight and survival. In the N87 studies, animals received treatments beginning on Day 2 post-implantation and continuing for up to 6 weeks. Dose groups (n=12/group) were vehicle, ARRY-380 at MTD (75 mg/kg, PO, BID) or lapatinib at MTD (50 mg/kg, PO, BID). All animals in the vehicle- or lapatinib-treated groups did not survive beyond Day 22. In the ARRY-380-treated-group, 75% of the animals were alive on Day 43. Brain PK/PD was also evaluated in the N87 model. ARRY-380 and its active metabolite caused a significant reduction in brain pErbB2 (80%). In the BT-474 model, animals received treatments beginning on Day 2 post-implantation and continuing for up to 8 weeks. Dose groups (n=13/group) were vehicle, ARRY-380 at MTD (75 mg/kg, PO, BID), lapatinib at MTD (50 mg/kg, PO, BID) or neratinib at MTD (40 mg/kg, PO, QD). On Day 56, survival in the ARRY-380 group was 69% while survival rates in the vehicle, lapatinib or neratinib-treated groups were 23%, 8% and 23%, respectively. Thus ARRY-380 treatment significantly enhances survival in two ErbB2 driven intracranial tumor xenograft models, with superior activity compared to other ErbB2 agents in these studies. Additionally, ARRY-380 has demonstrated durable clinical activity in heavily pre-treated patients with ErbB2+ MBC. These preclinical and clinical data suggest that ARRY-380 may provide benefit to patients with ErbB2+ MBC with brain metastases.']",
        "Doc_id":"AACR_2012-852",
        "Doc_title":" ARRY-380, a potent, small molecule inhibitor of ErbB2, increases survival in intracranial ErbB2+ xenograft models in mice",
        "_version_":1606188983307468800},
      {
        "Meeting_name":" Negative regulation of ErbB2 611-CTF by LRIG1.",
        "Background":"['The ErbB family of receptor tyrosine kinases is composed of four members', 'EGFR, ErbB2, ErbB3, and ErbB4; these are membrane bound proteins that control important cell functions through the activation of signaling cascades such as the Ras-mitogen-activated protein kinase (MAPK) and the phosphatidylinoditol3-kinase (PI3K)-Akt pathways. Deregulated expression of the ErbB family by gene amplification and/or protein over-expression is associated with the development and progression of a variety of cancer types.Notably, ErbB2 over expression is observed in approximately 25% of human breast tumors. The negative regulator, LRIG1 is a transmembrane protein that can directly interact with all members of the ErbB family leading to receptor degradation. In addition, in vitro experiments have shown that loss of LRIG1 is sufficient to drive an increase in ErbB2 protein levels and signaling while ectopic expression of LRIG1 decreases ErbB protein expression and signaling.Recently, a group of ErbB2 C-terminal fragments (CTFs) collectively known as p95HER2have captured the attention of the scientific community becausea) they are capable of inducing more aggressive tumors compared with those expressing full length ErbB2 and because b) they have been directly implicated in therapeutic resistance to Herceptin, the standard of care for ErbB2-positive breast cancer. ErbB2 CTFsare generated by two independent mechanisms; 1) initiation of translation at alternative methionine codons, producing two fragments known as 611-CTF and 687-CTF; 2) Proteolytic shedding of full length ErbB2, generating 648-CTF and 676-CTF fragments. Clinical data indicate that p95HER2 positive patients have lower survival rates compared with those expressing low p95HER2 levels.Among the p95HER fragments, 611-CTF is the most interesting because it is hyperactive and has been associated with increased cell migration, tumor progression and metastasis. Currently, nothing is known of the mechanisms which govern p95HER2 down-regulation. Insight into these mechanisms could ultimately lead to the development of new therapeutics which may improve the response rate of p95HER2-positive breast cancer. In this study we examined whether 611-CTF is susceptible to LRIG1-mediated down-regulation. We find that these proteins interact and that ectopic expression of LRIG1 is sufficient to decrease 611-CTF protein expression in three different cell lines. Furthermore, LRIG1 is capable of reducing 611-driven tumor cell proliferation and migration. Our results are surprising because LRIG1 is thought to recognize its targets through mutual ecto-domain interactions and 611-CTF lacks a large portion of the ErbB2 ecto-domain.Citation Format', ' Maria E. Cedano-Prieto, Lakmal Kotelawala, Colleen Sweeney. Negative regulation of ErbB2 611-CTF by LRIG1. [abstract]. In', ' Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA)', ' AACR; Cancer Res 2013;73(8 Suppl)', 'Abstract nr 3033. doi', '10.1158/1538-7445.AM2013-3033']",
        "Doc_id":"AACR_2013-3033",
        "Doc_title":" Negative regulation of ErbB2 611-CTF by LRIG1.",
        "_version_":1606189022248435713},
      {
        "Meeting_name":" Concomitant mutation and amplification of the ERBB2 (HER2) gene in human tumors.",
        "Background":"['Background', '  Amplification of the ERBB2 (HER2) gene is a well-known genetic aberration in many tumor entities. Up to 20% of breast and gastric cancer show ERBB2 gene amplification and anti-HER2 targeting therapies are well established for these tumors. In other tumor entities such as lung cancer, colorectal cancer and bladder cancer the fraction of ERBB2 amplified tumors is considerably lower. In contrast to breast cancer, these tumors show heterogeneity of ERBB2 amplification in a substantial proportion. Oncogenic EGFR mutation with subsequent EGFR amplification is a common phenomenon in lung cancer. In analogy, primary ERBB2 mutation could explain the observed heterogeneity of ERBB2 amplification in some tumors. Methods', '  100 tumors showing ERBB2 amplification by fluorescence in situ hybridization were examined for ERBB2 mutation', ' 50 breast cancer samples, including 10 cases with borderline gene amplification, 10 cases with heterogeneous gene amplification and 11 samples of metastatic lesions as well as 15 colorectal carcinomas, 12 gastric carcinomas, 12 non-small cell lung cancers and 10 urothelial carcinomas. Tumor DNA was extracted and examined for mutations in the tyrosine kinase domain (exons 18-23) of the ERBB2 gene by Sanger sequencing. Results', '  ERBB2 mutation was found in two metastatic lesions of breast cancer, two lung cancers and two colorectal cancers. In five of these cases short in-frame insertions in exon 20 were found. In one case of a breast cancer lung metastasis a missense mutation in exon 19 (p.L755S) was detected. The semi-quantitative chromatograms show an overrepresentation of the mutations indicating a selective amplification of the mutated allele. Conclusions', '  In certain tumor entities the heterogeneity of ERBB2 amplification indicates a late genetic event. The finding of a concomitant mutation in ERBB2 amplified tumors might explain the heterogeneity in some of these tumors. The effect of a primary oncogenic ERBB2 mutation might be increased by selective amplification of the mutated allele resulting in an additional growth advantage. If ERBB2 amplified tumors with a primary ERBB2 mutation also benefit from an HER2 targeted therapy needs to be elucidated.']",
        "Doc_id":"ASCO_133558-144",
        "Doc_title":" Concomitant mutation and amplification of the ERBB2 (HER2) gene in human tumors.",
        "_version_":1606188998316785664},
      {
        "Meeting_name":" The ErbB3/4 receptor ligand Heregulin negatively regulates ErbB2 and ErbB3 receptor levels",
        "Background":"['ErbB2 is overexpressed in 30% of breast cancers and its overexpression is associated with poor prognosis. In addition, the ErbB2/3 heterodimer forms the most potent mitogenic receptor in vitro and is key to the proliferation of breast cancer cells. Despite the importance of this heterodimer in breast cancer progression, the negative regulation of these ErbB tyrosine kinases is still poorly understood. We demonstrate here for the first time that the ErbB3/4 ligand Heregulin (HRG) reduces mRNA and protein levels of both ErbB2 and ErbB3 in human breast cancer cell lines. We have found that after 24h of HRG treatment, ErbB2 expression decreased at both the RNA and protein levels in ErbB2 overexpressing AU565, BT474 and LTLT-Ca breast cancer cell lines. In contrast, EGFR levels were unaffected by HRG treatment. An initial decline in steady state mRNA levels was first noted at 1 hour after HRG treatment. ErbB3 levels also decreased in LTLT-Ca cells after HRG treatment. Lapatinib, which inhibits ErbB2 and EGFR kinase activity and HRG induced-ErbB3 phosphorylation, diminished the HRG- induced decrease in ErbB2 and ErbB3 in AU565 and LTLT-Ca cells. This finding suggests that the kinase activity of EGFR/ErbB2 may be involved in the HRG-induced down-regulation. HRG did not change the activity of ErbB2 promoter reporter constructs spanning 215 kb to 6007 kb upstream of the ErbB2 transcription start site as indicated by luciferase assays. An ongoing study suggests that HRG could be involved in decreasing ErbB2 mRNA stability. Our findings suggest that resistance to Lapatinib may be due in part to the fact that inhibition of ErbB2/ EGFR kinase activity dampens the negative effect of HRG on ErbB2 expression, resulting in elevated levels of ErbB2 in breast cancer cells.']",
        "Doc_id":"AACR_2012-1063",
        "Doc_title":" The ErbB3/4 receptor ligand Heregulin negatively regulates ErbB2 and ErbB3 receptor levels",
        "_version_":1606189028852367360},
      {
        "Meeting_name":" Novel transforming ErbB2 mutations in leukemia",
        "Background":"['The ErbB2/Her2 type 1 transmembrane receptor tyrosine kinase heterodimerizes with ligand-bound EGFR, ErbB3, or ErbB4 to activate multiple signaling pathways. ErbB2 is commonly amplified in breast, stomach, cervical, and bladder tumors and point mutations are found in many cancers. However, little is known about aberrant ErbB2 in hematologic malignancies. Deep sequencing was performed on primary leukemia patient samples and point mutations were identified within the extracellular receptor binding domains and the intracellular C-terminal region of ErbB2. Expression of these mutations in NIH 3T3 fibroblasts exhibited a transformed morphological phenotype and in Ba/F3 pro-B cells led to IL-3-independent growth and differential signaling within the MAPK and PI3K pathways. Further characterization of the mutations will assess migration properties, differential sensitivity to ErbB-family drug inhibitors, and heterodimer formation using bimolecular fluorescence complementation microscopy. Overall, this work identifies novel transforming ErbB2 mutations and may provide insight into effective therapy for leukemia patients harboring ErbB2 mutations.']",
        "Doc_id":"AACR_2014-4772",
        "Doc_title":" Novel transforming ErbB2 mutations in leukemia",
        "_version_":1606188969812295680},
      {
        "Meeting_name":" The role of ErbB2 in regulating survival in matrix-detached inflammatory breast cancer cells",
        "Background":"['Inflammatory breast cancer (IBC) is a rare and highly invasive type of breast cancer, and patients diagnosed with IBC often face a very poor prognosis. IBC is characterized by the lack of primary tumor formation and the rapid accumulation of cancerous epithelial cells in the dermal lymphatic vessels. Given that normal epithelial cells require attachment to the extracellular matrix (ECM) for survival, a comprehensive examination of the molecular mechanisms underlying IBC cell survival in the lymphatic vessels is of paramount importance to our understanding of IBC pathogenesis. Here we demonstrate that in contrast to normal mammary epithelial cells, IBC cells evade ECM-detachment-induced apoptosis (anoikis) and maintain ATP levels following ECM detachment. Exogenous ErbB2 overexpression leads to increased ATP production and soft agar growth in IBC cells that normally lack ErbB2 amplification. Additionally, ErbB2 knockdown in KPL-4 cells, an IBC cell line characterized by high levels of ErbB2, resulted in diminished ATP levels, decreased colony growth, and increased caspase activation following ECM detachment. Further studies reveal that the protection from anoikis in IBC cells is dependent on activation of the ERK-MAPK pathway, but does not depend on modulation of the levels of the pro-apoptotic factor Bim. These results demonstrate that ErbB2 is necessary and sufficient for IBC cell survival in the absence of ECM attachment. Understanding the molecular mechanism utilized by IBC cells to survive in matrix-detached conditions could lead to more specific and effective therapeutics to prevent IBC metastasis from occurring and to treat patients in which metastasis has already occurred.']",
        "Doc_id":"AACR_2012-2080",
        "Doc_title":" The role of ErbB2 in regulating survival in matrix-detached inflammatory breast cancer cells",
        "_version_":1606189007337684993},
      {
        "Meeting_name":" Amplification of mutant ERBB2 drives resistance to the irreversible kinase inhibitor neratinib in ERBB2-mutated breast cancer patients",
        "Background":"['Overexpression of human epidermal growth factor receptor 2 (ERBB2), often accompanied by ERBB2 gene amplification, is present in 25% of early-stage breast cancers. In a relatively small subset of breast cancer patients (4,000 cases each year in the US) ERBB2 is alternatively activated by gain-of-function mutations without gene amplification and receptor overexpression. These somatic mutations frequently occur in the kinase domain of ERBB2 and induce receptor phosphorylation, PI3K/AKT pathway hyperactivation, and malignant transformation. Breast cancer patients bearing ERBB2-mutated tumors are candidates for treatment with the irreversible kinase inhibitor neratinib. Although this therapeutic strategy is showing remarkable activity in a significant proportion of patients, emergence of acquired resistance inevitably occurs. The aim of this study is to identify the possible mechanisms of acquired resistance to neratinib therapy in ERBB2-mutated breast cancers. As part of the ongoing phase II SUMMIT basket study of neratinib in ERBB2-mutant cancers (NCT01953926), we have identified a common genomic alteration in tumors from three patients that progressed following initial benefit from neratinib treatment. Targeted exome sequencing of biopsies collected at time of disease progression revealed increased copy number of the ERBB2-mutant allele. In one case, the resistant lesions were confirmed to be avid for zirconium-89-trastuzumab and the patient responded to subsequent antibody-based anti-ERBB2 therapy. In an attempt to confirm that increased expression of the mutant allele was sufficient to limit neratinib sensitivity, we measured the antitumor activity of this agent in MCF10A cells stably expressing several activating mutations of ERBB2 compared to cells expressing equal levels of the wild type receptor. We found that higher concentrations of neratinib were needed to inhibit the proliferation of ERBB2-mutant cells compared to wild-type. Further, enhanced receptor activity in the ERBB2-mutant cells correlated with increased formation of ERBB2/ERBB3 dimers, activation of the PI3K/AKT pathway and in vivo tumorigenic potential. Combined ERBB2 and ERBB3 inhibition efficiently inhibited phosphorylation of ERBB2/ERBB3 and cell proliferation. We plan to overexpress the ERBB2-mutant allele in cell lines/organoids obtained from ERBB2-mutant patient-derived xenografts, phenocopying our results from the clinical specimens. We hypothesize that this manipulation will be sufficient to induce increase ERBB2/ERBB3 dimerization and resistance to neratinib. In summary, we believe that amplification of mutated ERBB2ERBB2 promotes increased ERBB2/ERBB3 dimerization, ERBB3 activation, and subsequent downstream signaling activation. Dual ERBB2/ERBB3 blockade may be a potential strategy to delay or prevent resistance to neratinib in ERBB2-mutant breast tumors.']",
        "Doc_id":"AACR_2016-298",
        "Doc_title":" Amplification of mutant ERBB2 drives resistance to the irreversible kinase inhibitor neratinib in ERBB2-mutated breast cancer patients",
        "_version_":1606188989044228096},
      {
        "Meeting_name":" Pak1 links the Wnt/-catenin pathway to ErbB2 signaling in breast cancer cells",
        "Background":"['Several studies suggest that Pak1 plays an important role in the genesis of breast cancer, but despite the similarity in their sequences, the contribution of the closely related enzyme Pak2 to this disease remains unclear. To establish the function of Paks in ErbB2 driven transformation, we used a three-dimensional tissue culture system of human mammary epithelial cells that stably co-express a chemically-activatable form of ErbB2 and doxycycline (DOX) inducible shRNAs against Pak1 or Pak2. We observed that silencing of Pak1 but not of Pak2 has a dramatic effect in cell proliferation and apoptosis. As expected, activation of ErbB2 induced growth factor-independent proliferation and disruption of 3D acinar-like structures via ERK and Akt signaling. In contrast, silencing of Pak1 compromised activation of ERK, resulting in reversion of the malignant phenotype and restoration of normal acinar architecture. Surprisingly, silencing of Pak2 also compromised ERK activation, but cannot restore normal morphology. Further, we found that ErbB2-amplified breast cancer cells expressing a DOX inducible shRNA against Pak1 formed significantly smaller tumors than cells expressing either GFP or a DOX inducible shRNA against Pak2 in SCID mice as the result of the inhibition of ERK. A phosphoproteomic analysis showed that several signaling pathways, e.g. Wnt and Mdm2-p53, are down regulated in our Pak1 deficient cell line. We found that the shPak1 cell line, but not the shPak2 deficient cell line has a dramatic reduction in total -catenin levels, and that blocking -catenin with chemical inhibitors restored normal acinar architecture. Finally, we found that targeting Pak and/or -catenin in combination with trastuzumab sensitized trastuzumab-resistant breast cancer cells to trastuzumab, suggesting the potential clinical application of this strategy to overcome trastuzumab resistance.']",
        "Doc_id":"AACR_2012-4865",
        "Doc_title":" Pak1 links the Wnt/-catenin pathway to ErbB2 signaling in breast cancer cells",
        "_version_":1606188988497920000},
      {
        "Meeting_name":" Assessment of ESR1 and ERBB2 mutations in estrogen receptor positive (ER+) metastatic breast cancers (MBC).",
        "Background":"['Background', ' Mutations (mut) in ESR1 have been reported in ER+ breast cancers (BC) as an acquired resistance mut to aromatase inhibitor (AI) therapy. Acquired ERBB2 mut have also been reported in MBC patients (pts) that cause activated ERBB2 signaling. The emergence of acquired secondary mut presents challenges in effective treatment approaches. Methods', ' Comprehensive genomic profiling was performed on 83 BC samples with 48 metastatic; 34 primary samples. Targeted next-generation sequencing was performed on 562 cancer associated genes in paired tumor and blood DNA (germline) samples. Results', ' ESR1-mut were found in 23%(11/48) of ER+ MBC tissues with no mut detected in primary ER+ BCs. Mutations-D538G, Y537S and E380Q in the ligand binding domain of ER were the most common alterations, found in 54.5%, 18% and 18% of ESR1 mut samples, respectively. An ER+ HER2- liver biopsy obtained after 20 mos on AI + everolimus had ESR1-D538G and TSC2 structural event. Protein array showed high expression of androgen receptor (AR) and p-AR and activation of ERBB1/2/3, p-SRC and p-4EBP1 in this sample. Further, a functionally uncharacterized ESR1 mut was found in ER+, HER2+ and a triple negative MBC tissue (the primary BC had been ER+). Mut in PI3K pathway (PIK3CA, ARID1A, TSC1/2, PTEN) were present in 8/11 samples with ESR1 mut. Activating mut in ERBB2 were found in 3/83 samples; all 3 were in ER+ MBC samples with one case harboring mut in both ERBB2 and ESR1 (E380Q  uncertain degree of constitutive activity). Interestingly, a BC sample with ER+ HER2- liver met harbored both ERBB2 (V777L) and ERBB3 (E928G) mut; this pt responded well to trastuzumab/pertuzumab (HP) therapy. A pt with ER+ HER2-ERBB2- L755S mut met to gallbladder found after 7 mos on letrozole/palbociclib therapy responded well to HP and T-DM1 therapy. All 3 ERBB2-mut cancers had a CDH1 frameshift mut suggesting enrichment in pretreated lobular MBCs (Ross J. CCR, 2013). Conclusions', ' This study shows a 23% and 6% ESR1 and ERBB2 mut rate in MBC samples. No ESR1 and ERBB2 mut were present in primary BC samples. Our findings suggest that pts with lobular MBC should be monitored for acquired ERBB2 mut, and that ERBB2 mut may not arise in BCs which harbor known constitutively active ESR1 mut.']",
        "Doc_id":"ASCO_181735-199",
        "Doc_title":" Assessment of ESR1 and ERBB2 mutations in estrogen receptor positive (ER+) metastatic breast cancers (MBC).",
        "_version_":1606188971074781184},
      {
        "Meeting_name":" ErbB2 activation up-regulates glutaminase 1 expression via NF-B pathway",
        "Background":"['Active glutamine utilization is essential for cell proliferation in many tumors, for it provides critical carbon and nitrogen sources. Glutaminolysis represents the first and rate-limiting step of glutamine utilization and is catalyzed by glutaminase. Previous studies have shown that c-Myc regulates glutaminolysis by increasing glutaminase expression in tumor cells. However, it remains unclear whether other oncogenic signaling pathways promote glutaminolysis. Breast cancer is the second most common cause of death for women in the United States and ErbB2 activation is one of the major causes of breast cancer. Using MCF10A and MCF10A-derived NeuT cells, we studied the effect of ErbB2 activation on glutaminase expression, and found that ErbB2 activation increased glutaminase 1 expression at both mRNA and protein levels. Knockdown of ErbB2 decreased glutaminase 1 expression in several human ErbB2-positive cell lines. Consistently, blocking ErbB2 signaling pathway by trastuzumab repressed glutaminase 1 expression. We further showed that in these cells, ErbB2-mediated up-regulation of glutaminase 1 was independent of c-Myc expression. In addition, we found that activation of PI3K/Akt or MAPK pathway was not sufficient to up-regulate glutaminase 1 expression. Instead, inhibition of NF-B down-regulated glutaminase 1 expression whereas stimulation of NF-B induced glutaminase 1 expression, suggesting a PI3K/Akt-independent activation of NF-B signaling pathway up-regulates glutaminase 1. Finally, inhibition of glutaminase activity significantly decreased human breast cancer cell proliferation. Our data indicate that ErbB2 activation promotes glutaminase 1 expression via NF-B in breast cancer cells, identifying another oncogenic signaling pathway which stimulates glutamine utilization. These findings may facilitate the identification of novel targets for cancer therapy.']",
        "Doc_id":"AACR_2012-5143",
        "Doc_title":" ErbB2 activation up-regulates glutaminase 1 expression via NF-B pathway",
        "_version_":1606188987915960320},
      {
        "Meeting_name":" Oncogenic extracellular domain mutations of ERBB2 in cancer",
        "Background":"['The ERBB2 receptor tyrosine kinase gene is frequently amplified and mutated in human cancer. However, mutations characterized to date have been located in the kinase domain of the receptor. Using publically-available sequencing datasets, we have found that extracellular domain mutations of ERBB2 located beneath the dimerization arm recur in lung, breast, and ovarian cancers. We expressed cDNAs harboring these mutations in NIH-3T3 cells and found that the mutants support anchorage-independent proliferation. We furthermore found that substitution of any one of a number of amino acids in this region of the protein is oncogenic. We sought to biochemically characterize the extracellular domain mutations of ERBB2 and found that they cause oncogenic transformation by one of two mechanisms', ' elevation of C-terminal tail phosphorylation, or reduction-sensitive covalent dimerization unaccompanied by increases in C-terminal phosphorylation. Analysis of tyrosine phosphorylated proteins in the cell by stable isotope labeling followed by mass spectrometry (SILAC) revealed that both classes of mutant receptor phosphorylated the same set of proteins to effect transformation. The most prominent targets were proteins involved in cytoskeletal and membrane dynamics, controlling cell motility. STAT3 was also phosphorylated to a limited extent in ERBB2-transformed cells. Interestingly, STAT3 phosphorylation was mediated solely by a JAK-dependent autocrine loop in cells transformed by the ERBB2 mutants activated by reduction-sensitive dimerization; whereas both ERBB2 and JAK family kinases contributed to STAT3 phosphorylation in cells transformed by ERBB2 mutants exhibiting increased C-terminal phosphorylation. In order to characterize inhibitor sensitivity, we transformed Ba/F3 cells to IL-3 independence with the ERBB2 extracellular domain mutants. All extracellular domain mutants tested were sensitive to irreversible inhibitors of ERBB2, suggesting that treatment with such inhibitors may benefit patients harboring mutations of the extracellular domain of ERBB2.']",
        "Doc_id":"AACR_2012-1",
        "Doc_title":" Oncogenic extracellular domain mutations of ERBB2 in cancer",
        "_version_":1606189017431277568},
      {
        "Meeting_name":" Triple fluorescence analysis of estrogen receptor alpha (ER) and ErbB2 status of circulating tumor cells (CTC) in breast cancer",
        "Background":"['Purpose', ' Hormone therapy and anti-ErbB2 (HER-2) therapy are prescribed according to the hormone status (ER/PR protein expression) and ErbB2 expression of the initial tumor. Several trials have shown the prognostic relevance of circulating tumor cells (CTC) in early and metastatic breast cancers. As it appears that the CTC, and consequently the metastatic cells, may have a very different receptor status than the related primary tumors, it is of the highest relevance to analyze ER and ErbB2 expression of the CTC. Experimental procedures', ' We developed a triple fluorescence technique to visualize simultaneously cytokeratin (8/18, 8/19), ER and ErbB2 on each individual cell. Using this protocol, we analyzed ER and ErbB2 expression in various breast cancer cell lines (MCF-7, T47D, Cama-1, ZR75, SK-Br-3, HCC 3153, MDA-MB-231), and compared ER expression in the different cell lines using also immunostaining. We were then able to test the CTC presence (CK positivity) and ER and ErbB2 expressions on blood samples (cytospins) collected from 15 metastatic breast cancer patients. Results', ' The 2-step triple fluorescence protocol was optimized to visualize CK in green (DyLight488 conjugate), ER in red (cy3 conjugate) and ErbB2 in blue (AMCA conjugate). Using in parallel this triple fluorescence protocol and the reference immunostaining technique, we could analyze that ER-positive cell lines express very different levels of ER and within one cell line, cells can express low, moderate and/or high levels of ER. The identification of cells that express a very low level of ER is compulsory as the CTC from one unique patient can potentially express differently ER. Consequently, ER-positivity and -negativity have to be clearly defined. CTC analysis from patient blood samples was then performed with an individual assessment, for each single isolated cell, of cytokeratin (epithelial marker that peripheral blood cells should not express) and of ER and ErbB2 expressions. We were able to identify, among the CTC positive patients, changes between primary tumor status and CTC status, e.g. ER-positive primary tumors with both ER-positive and ER-negative CTC. Those ER-negative CTC may direct towards tamoxifen resistance and have to be identified among other ER-positive cells, similarly as any ErbB2 negative CTC. Conclusion', ' We demonstrated that triple immunofluorescence is very relevant, first to identify CTC, and then to allow an individual assessment of ER and ErbB2 expression, at the protein level. Moreover, the approach we developed allows to characterize a population of CTC with a very low expression of ER. Large multicentric cohorts of breast cancer patients treated with adjuvant therapy should now be analyzed for both ER and ErbB2 status of the CTC, compared to the primary tumor profile. The expected results should lead to optimal individualized treatments.']",
        "Doc_id":"AACR_2012-2386",
        "Doc_title":" Triple fluorescence analysis of estrogen receptor alpha (ER) and ErbB2 status of circulating tumor cells (CTC) in breast cancer",
        "_version_":1606189011970293761},
      {
        "Meeting_name":" LRIG1 decreases cell proliferation and motility through downregulation of ErbB2 611-CTF",
        "Background":"['The receptor ErbB2 is a membrane bound protein that controls important cell functions including cell cycle progression; deregulated expression of this protein is associated with the development of a variety of cancer types. Notably, ErbB2 over-expression is observed in approximately 25% of human breast tumors.Trastuzumab, an FDA approved therapeutic currently used to treat ErbB2 positive breast cancer patients, is a monoclonal antibody that directly binds the ErbB2 extracellular domain. Unfortunately, only a fraction of patients treated with trastuzumab durably respond to the treatment. Moreover, patients that are treated long term with this antibody develop resistance. One of the proposed mechanisms of trastuzumab resistance is the expression of 611-CTF, a C-terminal fragment of ErbB2 which lacks most of its extracellular domain. Remarkably, 611-CTF is hyperactive and has been associated with increased cell migration, tumor progression and metastasis.Currently nothing is known regarding mechanisms which lead to 611-CTF down-regulation. This represents a significant knowledge gap in our understanding of 611-CTF and receptor fragments in general. Since 611-CTF is associated with poor clinical outcome and therapeutic resistance, it is essential to clarify the mechanisms by which this ErbB2 fragment is regulated. This knowledge could ultimately lead to the development of new therapeutics which could improve the response rate of 611-CTF-positive breast cancer.LRIG1 is a tumor suppressor that directly interacts with ErbB2 leading to receptor degradation. In this study we examined whether 611-CTF is susceptible to LRIG1-mediated down-regulation. We find that these proteins interact and that expression of LRIG1 is sufficient to decrease 611-CTF protein expression in three different cell lines. Furthermore, LRIG1 is capable of reducing 611-CTF-driven tumor cell proliferation and migration. Our results are unexpected because LRIG1 is thought to recognize its targets through mutual extracellular domain interactions and 611-CTF lacks a large portion of the ErbB2 extracellular domain.']",
        "Doc_id":"AACR_2014-3337",
        "Doc_title":" LRIG1 decreases cell proliferation and motility through downregulation of ErbB2 611-CTF",
        "_version_":1606189025104756736},
      {
        "Meeting_name":" Developing a novel immunotoxin that targets cells overexpressing ErbB2",
        "Background":"['Immunotoxins are chimeric proteins comprising a specific cellular targeting domain linked to a cytotoxic factor. Here we describe the design and use of a novel, peptide-based immunotoxin that can initiate selective cytotoxicity on ErbB2-positive cells. ErbB2 is a receptor tyrosine kinase that is overexpressed in the tumor cells of approximately 30% of breast cancer patients. Immunotoxin candidates were designed to incorporate a targeting ligand with affinity for ErbB2 along with a membrane lysin-based toxin domain. The use of a membrane lysin as the toxin domain distinguishes our immunotoxins from numerous others in that internalization of the toxin is not required to induce cell death. One particular peptide candidate, NL1.1-PSA, demonstrated selective cytotoxicity towards ErbB2-overexpressing cell lines. We utilized a bioengineering strategy to show that recombinant NL1.1-PSA immunotoxin expression by Escherichia coli also conferred selective cytotoxicity towards ErbB2-overexpressing cells. Our findings hold significant promise for the use of effective immunotoxins in cancer therapeutics. While Herceptin treatment has been effective in patients with ErbB2 positive breast cancer, our novel immunotoxin may ultimately prove to be a novel and efficacious addition to the arsenal of approaches used to eliminate Herceptin-resistant breast cancer cells.']",
        "Doc_id":"AACR_2016-347",
        "Doc_title":" Developing a novel immunotoxin that targets cells overexpressing ErbB2",
        "_version_":1606188985001967616},
      {
        "Meeting_name":" Microscopy based high throughput screen for the mechanistic analyses of ErbB2 degradation in response to Hsp90-targeted therapeutics",
        "Background":"['ErbB2 expression is observed in 25 - 30 % of invasive breast cancers and is associated with reduced response to chemotherapy, and shorter time to relapse and reduced overall survival of breast cancer patients. Malignant mammary epithelial cells that overexpress ErbB2 exhibit enhanced proliferation, invasion of mammary tissue and metastasis. The stability of overexpressed mature ErbB2 at the plasma membrane of mammary epithelial cells is critically dependent on its interaction with the chaperone protein, heat shock protein 90 (Hsp90). Thus, Hsp90 promotes the proliferation and survival of malignant mammary epithelial cells and interruption of this interaction is expected to inhibit the growth of ErbB2-overexpressing tumors. 17-AminoAllyl-Geldanamycin (17-AAG), an Hsp90 inhibitor, is a semi-synthetic ansamycin antibiotic currently in phase II clinical trials for breast cancer treatment (www.clinicaltrials.gov). Because it preferentially binds to Hsp90 of the chaperone complex in malignant mammary epithelial cells, treatment of ErbB2-overexpressing breast cancer with 17-AAG is expected to destabilize ErbB2 and inhibit tumor growth. While a number of Hsp90 client proteins have been identified, ErbB2 is amongst the most sensitive to Hsp90 inhibition. These facts provide strong rationale for using 17-AAG as a part of the targeted therapy against ErbB2-overexpressing breast cancer. However the cellular machinery responsible for 17-AAG induced degradation of ErbB2 is not completely understood. At present it is unclear whether internalization of ErbB2 occurs via Clathrin-dependent or -independent endocytosis. Furthermore it is unresolved if the degradation of ErbB2 is dependent upon proteasomal or lysosomal proteolysis. And although C-terminus of Hsp70 Interacting Protein (CHIP) and Cullin 5 were identified as E3 ligases responsible for the ubiquitination of ErbB2, it is unknown if these ligases are the sole E3s responsible for the ubiquitnation of ErbB2. Also vague is if the rerouting of ErbB2 from the recycling pathway to the degradative pathway in response to 17-AAG is exclusively dependent upon ubiquitnation. In this current work we attempt to bridge these critical gaps in our knowledge of the mechanisms of 17-AAG induced degradation of ErbB2 using an automated microscopy-based analysis to identify genes whose siRNA-dependent suppression reduces 17AAG-induced ErbB2 degradation. We expect that this work will identify additional targets for therapeutic intervention and potential biomarkers of response to breast cancer drug therapy with Hsp90 inhibitors.']",
        "Doc_id":"AACR_2012-1221",
        "Doc_title":" Microscopy based high throughput screen for the mechanistic analyses of ErbB2 degradation in response to Hsp90-targeted therapeutics",
        "_version_":1606188993688371200},
      {
        "Meeting_name":" Stochastic control of abnormal morphogenesis induced by the ErbB2 oncoprotein",
        "Background":"['Activation of the receptor tyrosine kinase ErbB2 causes multiacinar structures in 3D culture that are reminiscent of early-stage breast tumors. The penetrance of the multiacinar phenotype is incomplete and random, and dimerization with other ErbB family members gives rise to quantitative differences in penetrance. Our goal is to understand the mechanism by which a multiacinus initiates and why only a random fraction of the cultured acini exhibit the morphogenetic defect when ErbB2 is activated. Our working hypothesis is that acute differences (dichotomies) in gene expression develop among acini and give rise to the distinct 3D phenotypes induced by ErbB2. The transcriptional dichotomies that exist before the appearance of the multiacinar phenoptype will be the ones most likely to control it. We are using a new technique, called stochastic profiling, that our lab developed for discovering transcriptional dichotomies in a seemingly uniform cell population. We have established single ErbB2 dimer clones with similar expression levels of ErbB2 and its dimerization partner. Expression of the ErbB2 constructs was also validated at the single-cell level in frozen acinar sections by RNA FISH. Laser capture microdissection was used to select a small number of cells (10-100 cells) from the fresh frozen 3D sections followed by RNA extraction and small-sample cDNA amplification. The amplification parameters were optimized for the ErbB2 clones in different culture formats. We observed good quantitative linearity and amplification efficiencies for a wide range of high- and low-abundance targets in a 2D-culture format. We are working to improve the amplification efficiency of samples microdissected in the 3D-culture format. The long-term goal is to link upstream acinus-specific expression programs to downstream morphogenetic heterogeneities. The results from this project could explain mechanistically why only a fraction of ErbB2-overexpression breast cancers respond positively to ErbB2-targeted therapeutics.']",
        "Doc_id":"AACR_2012-1082",
        "Doc_title":" Stochastic control of abnormal morphogenesis induced by the ErbB2 oncoprotein",
        "_version_":1606188997987532800},
      {
        "Meeting_name":" Dendritic cell-targeted lentiviral vector vaccines overcome tolerance to generate a protective T-cell immune response to breast cancer antigens ERBB2 and -lactalbumin",
        "Background":"['Breast cancer immunotherapy is a potent treatment option, with antibody therapies such as trastuzumab increasing 2-year survival rates by 50%. In contrast, active immunotherapy through therapeutic vaccination has yet to be proven clinically effective for breast cancer. One potential means of improving vaccine therapy is by delivering breast cancer antigens to dendritic cells (DCs) for enhanced antigen presentation. To achieve this in vivo, we have pseudotyped lentiviral vector vaccines with a modified Sindbis Virus glycoprotein that targets the C-type lectin DC-SIGN, which is expressed on DCs. We hypothesized that utilizing these DC-targeting lentiviral vectors as a breast cancer vaccine could lead to an improved immune response against self antigens found in breast cancer tumors. Such an improved immune response may help to prevent or slow tumor growth in breast cancer models. To test these hypotheses, we have constructed lentiviral vectors encoding each of the breast cancer antigens, human Her2 (ERBB2) and mouse alpha-lactalbumin (Lalba). Single injections were able to amplify antigen-specific CD8 T cells to 1.6% of total CD8 T cells in BALB/cJ mice and 0.7% in transgenic ERBB2 mice. This compares favorably with recently published vector vaccines, which have elicited 0.9% and <0.1% antigen-specific CD8 T cells under similar conditions. In addition, DC-targeted immunization of these mice completely inhibited tumor growth in a foreign antigen environment (ERBB2 + wt BALB/cJ), while it significantly reduced the rate of tumor growth in a self-antigen environment (Lalba + BALB/cJ or ERBB2 + FVB/Tg.MMTV.f.huHER2 #5). Our data show that these vectors alone can provide an effective therapy. Future studies may be able to improve these responses by combining DC-targeted immunization with established methods of reducing cancer immunosuppression. Thus, lentivector vaccines may be an excellent component to future clinical vaccine trials, either by themselves or in combination with other chemo- and immunotherapies.']",
        "Doc_id":"AACR_2014-2888",
        "Doc_title":" Dendritic cell-targeted lentiviral vector vaccines overcome tolerance to generate a protective T-cell immune response to breast cancer antigens ERBB2 and -lactalbumin",
        "_version_":1606188989570613248},
      {
        "Meeting_name":" Identification of autocrine motility factor (AMF) receptor, HER2 (ErbB2) in breast cancer cells",
        "Background":"['Overexpression of HER2 (ErbB2) oncoprotein is associated with approximately 25% of aggressive breast carcinoma. Although a humanized monoclonal antibody (Trastuzumab) against HER2 is currently considered one of the most effective treatments, a significant number of patients are initially or eventually become resistant to Trastuzumab based therapy. Here, we demonstrate that secreted phosphoglucose isomerase (PGI)/ autocrine motility factor (AMF), an orphan -CXXC- cytokine directly binds to HER2 and activates PI3K and MAPK through HER2 autophosphorylation, and also induces immediately HER2 cleavage in metalloprotease dependent fashion. We therefore speculate that AMF/HER2 signaling pathways play a physiological role in HER2 overexpressing breast cancer cells and contribute to Trastuzumab resistance and propose that AMF can be a novel therapeutic target in Trastuzumab resistant breast cancer.']",
        "Doc_id":"AACR_2012-1079",
        "Doc_title":" Identification of autocrine motility factor (AMF) receptor, HER2 (ErbB2) in breast cancer cells",
        "_version_":1606188984649646080},
      {
        "Meeting_name":" Circulating tumor cells and genomic profiling of patients with ERBB2 mutant, HER2 non-amplified metastatic breast cancer treated with neratinib.",
        "Background":"['Background', ' ERBB2 mutations in the absence of gene amplification are rare, with an incidence of 2-4%. Neratinib is a HER2/EGFR tyrosine kinase inhibitor being evaluated for use in ERBB2 mutated breast cancer. Neratinib has been found to have clinical activity on heavily pre-treated ERBB2 mutant breast cancer patients. We are evaluating the response and genomic profiles of 3 postmenopausal patients with metastatic ERBB2 mutant/non-amplified breast cancer receiving neratinib and fulvestrant NCT01953926, NCT01670877. Methods', ' Samples were collected at different points during treatment and CTCs were identified. Other representative cells were tracked but not classified as CTCs. CD45-CK+ cells with cytoplasmic and/or nuclear apoptosis were defined as CTC-Apoptotic. CD45- cells expressing little to no CK but otherwise meeting morphological criteria for CTCs are CTC-LowCK. CD45-CK+ cells with small nuclear size are CTC-SmallCK. Single CTCs will be analyzed using whole genome copy number variation to determine chromosomal alterations. Results', ' The patients had an average of 4.7 lines of therapy for metastatic disease before neratinib. Two had stable disease and one had progression. The patient who progressed had a rise in the number of CTCs from 37 to 52 cells/ml and drop in apoptotic cells from 5 to 0 cells/ml. Conclusions', ' The high CTC count of the patient who progressed may suggest more aggressive disease. The drop in the apoptotic cell count may correlate with a failure to respond to therapy. Samples have been sent for copy number variation profiling. The goal is to identify any genomic amplifications or deletions associated with clinical response and progression after targeted therapy. We hope to demonstrate the timeframe of tumor evolution in response to therapy and provide a framework for the use of fluid biopsies to monitor disease progression. Correlation of enumeration data with treatment.PatientDay since 1st sampleERBB2 mutationResponseCTC/mLApoptotic/mLLow-CK/mLSmall-CK/mLA1S310F01.190.59127SD1.091.0965.29065SD00147.15B1P780_Y781insGSp5.951.0958.461.9829SD1.90104.463.8C1S653C37.085.386.518.8337PD52.49041.724.04']",
        "Doc_id":"ASCO_186368-199",
        "Doc_title":" Circulating tumor cells and genomic profiling of patients with ERBB2 mutant, HER2 non-amplified metastatic breast cancer treated with neratinib.",
        "_version_":1606189038669135872},
      {
        "Meeting_name":" A genome wide RNAi screen identify STAT3 activation as essential for ErbB2 mediated transforamtion of breast cancer cells",
        "Background":"['The generation of multidimensional datasets characterizing genetic, epigenetic, and functional properties of large normal and tumor-related samples is creating unique opportunities for the systems-level dissection of mechanisms associated with malignant phenotypes. Integrated data sets may lead to more efficient and specific approaches for the elucidation of therapeutic targets and biomarkers and for the identification of specific small molecule inhibitors. However, the power of these computational methods to study human cancer from an unbiased global perspective is severely compromised by the low through-put approaches necessary to functionally validate the in silico predictions. During the last years, RNA interference (RNAi) emerged as a very powerful genetic strategy to functionally interrogate the entire genome by loss-of-function studies. This cellular process can be experimentally controlled to knock down the expression of any specific gene. Our group has pioneered the development of RNAi-based genetic tools to translate RNAi studies to mammalian systems generating a shRNA-mir pooled lentiviral library that allows performing functional studies at genome-wide level. ErbB2 is a receptor tyrosine kinase found overexpressed in 20-40% of breast tumors correlating with a malignant phenotype and worse prognosis. Different targeted therapies have been developed to specifically inhibit its activity such the monoclonal antibody Herceptin, or the small tyrosine kinase inhibitor Lapatinib. Despite of the success of these inhibitors in the treatment of tumors that overexpress ErbB2, about 30% of them become resistant making necessary to look for alternative targets in these cases. The combination of the state-of-the-art computational analysis and RNAi-based technology toward system biology studies must represent a powerful tool to dissect the regulatory networks that govern the homeostasis of breast tumors. Applying this combined approach to an overexpressing ErbB2 breast cancer model we have identified the genes that are critical in those cells.']",
        "Doc_id":"AACR_2012-5137",
        "Doc_title":" A genome wide RNAi screen identify STAT3 activation as essential for ErbB2 mediated transforamtion of breast cancer cells",
        "_version_":1606188972817514496},
      {
        "Meeting_name":" Simultaneous copy number gains of NUPR1 and ERBB2 predicting poor prognosis in early-stage breast cancer.",
        "Background":"['The full extent of chromosomal alterations and their biological implications in early breast carcinogenesis has not been well examined. In this study, we aimed to identify chromosomal alterations associated with poor prognosis in early-stage breast cancers (EBC). A total of 145 EBCs (stage I and II) were examined in this study. We analyzed copy number alterations in a discovery set of 48 EBCs using oligoarray-comparative genomic hybridization. In addition, the recurrently altered regions (RARs) associated with poor prognosis were validated using an independent set of 97 EBCs. A total of 23 RARs were defined in the discovery set. Six were commonly detected in both stage I and II groups (> 50%), suggesting their connection with early breast tumorigenesis. There were gains on 1q21.2-q21.3, 8q24.13, 8q24.13-21, 8q24.3, and 8q24.3 and a loss on 8p23.1-p22. Among the 23 RARs, copy number gains on 16p11.2 (NUPR1) and 17q12 (ERBB2) showed a significant association with poor survival (P=0.0186 and P=0.0186, respectively). The patients simultaneously positive for both gains had a significantly worse prognosis (P=0.0001). In the independent replication, the patients who were double-positive for NUPR1-ERBB2 gains also had a significantly poorer prognosis on multivariate analysis (HR=7.31, 95% CI 2.65-20.15, P=0.0001). The simultaneous gain of NUPR1 and ERBB2 can be a significant predictor of poor prognosis in EBC. Our study will help to elucidate the molecular mechanisms underlying early-stage breast cancer tumorigenesis. This study also highlights the potential for using combinations of copy number alterations as prognosis predictors for EBC.']",
        "Doc_id":"AACR_2013-805",
        "Doc_title":" Simultaneous copy number gains of NUPR1 and ERBB2 predicting poor prognosis in early-stage breast cancer.",
        "_version_":1606188992950173696},
      {
        "Meeting_name":" Combinations of lapatinib and all-trans retinoic acid control the coordinate expression of microRNA modules and target-mRNAs in ERBB2+/RARA+ breast carcinoma cells",
        "Background":"['In a recent report (Paroni et al, Oncogene, 31', '3431-43, 2012), we demonstrated that 25% of all ERBB2+ breast cancers present with a co-amplification of the RARA locus, encoding the nuclear retinoic acid receptor, RAR. ERBB2+/RARA+ breast cancer cell lines, like SKBR3 and AU565, are sensitive to the anti-proliferative and cyto-differentiating effects of all-trans retinoic acid (ATRA), whereas the ERBB2+/RARA counterparts are refractory. Simultaneous targeting of RAR with ATRA and ERBB2 with lapatinib in SKBR3 and AU565 cells leads to synergistic interactions as to growth inhibition and cyto-differentiation. In addition, combinations of ATRA and lapatinib exert an apoptotic effect, which is not observed with the single components. This suggests that ERBB2+/RARA+ breast cancer patients may benefit from lapatinib+ATRA regimens and represent the rationale of an ongoing clinical trial.The use of lapatinib and ATRA for the stratified therapy of ERBB2+/RARA+ patients requires knowledge of the molecular mechanisms underlying the cross-talk between the two compounds. We evaluated the effects of lapatinib and/or ATRA on the expression profiles of more than 1,000 microRNAs in SKBR3 cells using an appropriate microarray platform. Both lapatinib and ATRA caused up- and down-regulation of numerous microRNAs. The combination of the two compounds enhanced the action of the single components of the mixture and resulted in the up- and down-regulation of novel target microRNAs as well. We integrated these results with microRNA-target-gene prediction algorithms and whole-genome gene-expression data looking for significant correlations between microRNA and potential/established target mRNA levels. Network analysis led to the identification of two highly interconnected microRNA/target-mRNA modules controlled in opposite directions by lapatinib+ATRA. The first one consists of six microRNAs (miR-1207-5-p, miR-874, miR-134, miR-762, miR-1181 and miR-320c) which are up-regulated by lapatinib+ATRA and control a common set of down-regulated target mRNAs in a coordinate fashion. Most of the mRNAs of the module control cell proliferation in a positive fashion. The second network consists of seven microRNAs (miR-203, miR-125a-5p, miR-193a-5p, miR-210, miR-362-5p, miR-532-5p and miR-342-3p) which are down-regulated by lapatinib+ATRA and control a series of up-regulated target-mRNAs. In this case, the majority of regulated genes is involved in negative regulation of cell proliferation. Coordinated regulation of microRNA sets controlling a common group of genes and functions represents a new concept that deserves further studies. Currently, we are in the process of establishing the functional significance of the identified microRNA modules for the anti-tumor effects of lapatinib and ATRA.']",
        "Doc_id":"AACR_2013-3088",
        "Doc_title":" Combinations of lapatinib and all-trans retinoic acid control the coordinate expression of microRNA modules and target-mRNAs in ERBB2+/RARA+ breast carcinoma cells",
        "_version_":1606188982905864192},
      {
        "Meeting_name":" An analysis of ERBB2 alterations (amplifications and mutations) found by next-generation sequencing (NGS) in 2000+ consecutive solid tumor (ST) patients.",
        "Background":"['Background', '  Testing for ERBB2 amplification by FISH and IHC is routine in breast and gastro-esophageal cancer. There are 3 approved and multiple targeted therapies in clinical trials that rely on the results of these tests. ERBB2 amplification and activation by mutation/fusion has also been described in a wide variety of other ST. As these alterations are not routinely tested for but may predict response to anti-ERBB2 agents we sought to determine their frequency in an unselected cohort of specimens from advanced ST patients.    Methods', '  We reviewed genomic profiles from the first 2,223 formalin-fixed, paraffin-embedded specimens received and analyzed by our CLIA-certified lab (Foundation Medicine) with our NGS platform. 3,230 exons in 182 cancer-related genes and 14 genes frequently rearranged were assayed for base pair substitutions, small insertions/deletions (indels), amplifications, and rearrangements.   Results', '  110/2,223 (4.9%) specimens had 116 ERBB2 alterations', ' 67 (58%) amplifications, 29 (25%) substitutions, 16 (14%) indels, 2 (2%) splice site variants and 2 (2%) translocations, including a potential fusion. Six samples (5%) had multiple alterations, and two had both ERBB2 substitution and amplification.  14 ST types had evidence of ERBB2 alterations including 29% of esophageal, 20% of uterine, 14% of breast, and 12% of stomach carcinomas. 6% of all lung cancer samples had ERBB2 alterations. Amplifications predominated, but lung specimens had predominantly indels. Durable responses exist to anti-ERBB2 agents in STs with activating ERBB2 mutations.  Conclusions', '  Use of a broad NGS panel identifies an unprecedented number of actionable genomic changes including a significant rate of ERBB2 alterations across 14 different solid tumor types. The discovery of unanticipated ERBB2 amplifications and activating mutations in a wide variety of ST highlights the need to study a broad range of genes at a high level of sensitivity and specificity when searching for novel targets of therapy. Widespread use of this approach could provide more treatment options and enable more rapid accrual to ongoing and planned trials of agents targeting pathways under study.']",
        "Doc_id":"ASCO_114501-132",
        "Doc_title":" An analysis of ERBB2 alterations (amplifications and mutations) found by next-generation sequencing (NGS) in 2000+ consecutive solid tumor (ST) patients.",
        "_version_":1606188981924397056},
      {
        "Meeting_name":" Differential clonal selection in tumor tissue and cell-free DNA from a neratinib-treated refractory breast cancer patient harboring an activating ERBB2 (HER2) mutation",
        "Background":"['The ongoing Copenhagen Prospective Personalized Oncology (CoPPO) research program aims to offer patients with exhausted treatment options, targeted therapy against actionable driver mutations identified in freshly obtained biopsies by whole exome sequencing (WES). Mutations are tracked in circulating cell free DNA (cfDNA) to examine the clonal selection of tumor cells evoked by therapy. Here we report the results from a patient with metastasizing HER2 negative and estrogen receptor (ER) positive breast cancer (Luminal A) previously exposed to seven lines of chemotherapy as well as ER antagonists and aromatase inhibitors. After enrollment in the program, examination of liver metastases by whole exome sequencing, RNA-Seq and microarray expression analysis revealed high expression of the estrogen receptor 1 (ESR1) as well as a mutation in the ligand-binding domain of ESR1 (H524L). Moreover, somatic variants in ERBB2 and PIK3CA were identified, including an activating mutation in ERBB2 (S310Y), and consequently the patient treated with neratinib, an irreversible pan-HER (EGFR/ERBB2/ERBB4) tyrosine kinase inhibitor, through a compassionate use program (Puma Biotechnology Inc.). Neratinib caused a rapid decrease in the allelic frequency of ERBB2 (S310Y) cfDNA after 2 days with a continuous decline during the next 7 days. Consistent with this neratinib treatment effect, MRI scans showed regression of the liver metastases. In contrast, the PIK3CA mutation showed an increase in the allele frequency, indicating the existence of a subclone that was insensitive to neratinib. Two months later, the total amount of cfDNA increased and continued to do so. After 5 months on neratinib, the patient progressed with the appearance of brain metastases which were surgically removed and subject to WES. The vast majority of the mutations, including the ERBB2 mutation, observed in the liver metastasis could not be identified in the brain metastases, except for the PIK3CA mutation. More than 300 new variants were exclusively identified in the brain metastases, among these, ERBB3 as well as new PIK3CA, and ESR1 mutations, that were not present in the pre-treatment cfDNA samples. After 4 months of treatment, an increase in the mutation frequency of the liver metastasis specific ESR1 and ERBB2 mutations was observed. In conclusion, neratinib was able to suppress an activating ERBB2 mutation in a heavily pre-treated ER+ breast cancer patient. However, refractory tumor clones harboring ERBB3, PIK3CA and ESR1 mutations developed in brain. These data indicate that combining neratinib with fulvestrant or inhibitors of the HER3/PI3K/AKT/mTOR pathway might prove beneficial to overcome potential resistance mechanisms to therapy.The two first authors contributed equally.']",
        "Doc_id":"AACR_2016-3140",
        "Doc_title":" Differential clonal selection in tumor tissue and cell-free DNA from a neratinib-treated refractory breast cancer patient harboring an activating ERBB2 (HER2) mutation",
        "_version_":1606189027989389312},
      {
        "Meeting_name":" Targeting oncoprotein stability overcomes lapatinib-resistance due to ERBB2 kinase domain mutations",
        "Background":"['ERBB2 kinase domain mutations were recently reported in some solid cancers. Moreover, certain ERBB2 mutations were shown to cause lapatinib resistance in vitro thus predicting their emergence in treated patients. We have recently shown that ERBB2-L755S, ERBB2-L755P and ERBB2-T798M mutants cause lapatinib resistance by stabilizing the active kinase conformation (DFG-in), which is incompatible with lapatinib binding (DFG-out). Using an in vitro cell-based drug resistance screen we also showed that these lapatinib resistant mutations might cause secondary resistance in patients treated with lapatinb. Thus, it is important to search for alternate treatment strategies to overcome lapatinib resistance. ERBB2 kinase is a client for HSP90 and is degraded by HSP90 inhibitor treatment. We thus tested if targeting ERBB2 mutant stability by inhibiting HSP90 overcomes lapatinib resistance. Since the kinase domain is important for the ERBB2 interaction with HSP90, we tested whether ERBB2 kinase domain mutants retained their interaction with the chaperone. Co-immunoprecipitation analysis showed that the interaction of ERBB2 mutants with HSP90 is intact. Importantly, HSP90 inhibitor treatment resulted in the degradation of lapatinib-resistant ERBB2 mutants as observed with the wild type ERBB2 kinase. Thus, HSP90 inhibitors may offer an alternative treatment option to overcome primary or secondary lapatinib resistance in patients harbouring ERBB2 mutations. Moreover, combined targeting of different physiological aspects (enzyme activity and protein stability) may prevent the emergence of secondary drug resistance due to kinase domain mutations.']",
        "Doc_id":"AACR_2012-1887",
        "Doc_title":" Targeting oncoprotein stability overcomes lapatinib-resistance due to ERBB2 kinase domain mutations",
        "_version_":1606189010120605696},
      {
        "Meeting_name":" Routine tumor next-generation sequencing (NGS) to identify rare germline lung cancer risk mutations in EGFR and ERBB2.",
        "Background":"['Background', ' New insights into lung cancer genomics has required a new look at genetic determinants of inherited lung cancer risk. There are now four germline mutations in lung cancer oncogenes (EGFR T790M, V843I, R776H; and ERBB2 G660D) which have been reported in kindreds with a high prevalence of lung cancer in nonsmokers. We hypothesized that routine tumor NGS could be used to find rare kindreds with inherited lung cancer risk. Methods', ' An institute-wide database of tumor NGS results was queried for cases positive for one of the reported germline risk alleles in EGFR or ERBB2. At our center, tumor NGS is performed using a hybrid-capture platform spanning exons and key introns of ~400 cancer related genes, and is available for patients (pts) with consent to a research protocol. For living pts with a mutation detected at an allelic fraction (AF) > 25%, and excluding acquired T790M, genetic counseling and CLIA germline testing was provided. For pts with EGFR T790M, testing was performed on the INHERIT EGFR study (NCT01754025; ALCMI). Results', ' 51 cases were identified from a total of 13,488 cancers with NGS results', ' 45 with EGFR T790M (all lung cancer), 4 with EGFR R776H (NSCLC, endometrial cancer, and 2 glioma), 2 with ERBB2 G660D (NSCLC and glioblastoma). 34 pts with T790M detected after EGFR inhibitor were excluded, leaving 17 pts of interest. Germline testing was performed on 9 living pts with > 25% AF on NGS, and was positive in 8; 6 of these had germline EGFR T790M. Additionally, germline EGFR R776H was found in a never-smoker with metastatic endometrial cancer; she had a prior a history of NSCLC, and family history was notable for multiple members with lung, breast, and colon cancer. Germline ERBB2 G660D was found in a young never-smoker with metastatic NSCLC and a family history significant for lung cancer in multiple first-degree relatives. Conclusions', ' Rare germline lung cancer risk mutations in EGFR and ERBB2 can be identified on routine tumor NGS, and may indicate a risk of inherited lung cancer. Our study includes the second known report of a germline EGFR R776H or ERBB2 G660D mutations. Commercial germline NGS assays could be expanded to cover these rare but potentially high-penetrance variants.']",
        "Doc_id":"ASCO_186794-199",
        "Doc_title":" Routine tumor next-generation sequencing (NGS) to identify rare germline lung cancer risk mutations in EGFR and ERBB2.",
        "_version_":1606188991229460480},
      {
        "Meeting_name":" Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutics antibody cetuximab",
        "Background":"['<Background> The epidermal growth factor receptor directed antibody, cetuximab (Cmab), is an effective therapy for patients (pts) with colorectal cancer (CRC) particularly with KRAS and BRAF wild type. Treatment in all pts is limited eventually by the development of acquired resistance but little is known about the underlying mechanism. <Methods> We established 3 Cmab resistant cell lines HCC827CR, GEOCR and A431CR through the exposure to increasing concentration of Cmab. In order to determine why these cell lines were resistant to Cmab we performed genome wide copy number analyses and analysis of ERBB family ligands. We analyzed the growth of Cmab sensitive and resistant cells in vitro and in vivo. Furthermore, we obtained clinical specimens from colon cancer pts treated with Cmab based therapy. Specimens obtained prior to therapy and at the time of Cmab resistance were evaluated. <Result> Genome-wide copy number analysis detected the localized genomic amplification in HCC 827CR, which was identified as ERBB2 and confirmed using FISH. Amplification of ERBB2 was also detected in the GEO CR cells. ERBB2 inhibition, with either trastuzumab or lapatinib, restored the Cmab sensitivity in those cell lines. In drug sensitive cell lines, Cmab effectively inhibited growth and ERK1/2 signaling both of which were inhibited in presence of ERBB2 amplification. In contrast, despite detecting ERBB2 activation in the A431 CR cells we did not identify ERBB2 amplification. Instead we detected increased levels of the ERBB3 ligand heregulin. The disruption of ERBB2/ERBB3 herterodimerization using pertuzumab restored Cmab sensitivity in A431CR in vitro and in vivo. CRC patients with ERBB2 amplification (n=13) treated with Cmab based therapy survived significantly shorter than pts without ERBB2 amplification (n=220) (The median OS 89 vs 149 days, p=0.0013; log-rank test). We also identified evidence of ERBB2 amplification at the time of acquired drug resistance using either tumor biopsies or by analyzing serum HER2 extracellular domain (ECD). We further analyzed plasma heregulin from CRC patients and the concentrations ranged widely (Median, 1622 pg/ml; range 0-18,045 pg/ml). Pts who achieved response to Cmab therapy (n=16) had significantly lower heregulin concentration than pts without response (n=49) (Mean, 1,050 vs 3,601 pg/ml, p<0.001; unpaired t test). In addition we identified a significant increase in plasma heregulin levels obtained at the time of clinic cetuximab resistance compared to pre-treatment specimens (p=0.0313). <Conclusion> We identify activation of ERBB2 signaling, either through ERBB2 amplification or through heregulin upregulation, as a mechanism of both de novo and acquired cetuximab resistance. These results suggest that ERBB2 inhibitors, in combination with Cmab, may represent a rational therapeutic strategy in Cmab-resistant cancers.']",
        "Doc_id":"AACR_2012-4833",
        "Doc_title":" Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutics antibody cetuximab",
        "_version_":1606188987876114432},
      {
        "Meeting_name":" A case series of ERBB2 indel driver mutations in non-small cell lung cancer identified by cell-free circulating tumor DNA NGS",
        "Background":"['Background', ' In-frame insertions between codons 775 and 881 in exon 20 of the ERBB2 gene, of which a 12 base pair YVMA insertion is the most common, are activating mutations in 2%-4% of non-small cell lung cancers (NSCLC), and have also been reported in exon 19 and 20 in breast cancer. These driver mutations are not captured with IHC or FISH staining because in the majority of cases, the ERBB2 gene is not amplified and HER2 protein is not overexpressed. Next generation sequencing (NGS) of circulating cell-free DNA (cfDNA) provides a non-invasive means of identifying these potential driver mutations.Method', ' Guardant360TM is a targeted cfDNA NGS panel using hybrid capture and complete exon sequencing for single nucleotide variant detection in 70 genes, copy number amplifications (CNA) in 16 genes, and fusions in six genes and indels in EGFR, ERBB2 and MET exon 14 skipping. De-identified pathology and genotyping reports were reviewed for consecutive patients in which ERBB2 indels were identified in clinical practice.Results', ' Guardant360 identified ERBB2 indels in 27 of 2,093 (1.3%) of non-squamous NSCLC cases, with a single concomitant ERBB2 gene amplification. For this ERBB2 indel series, pathology reports revealed no patients with HER2 amplification via IHC or FISH, nor ERBB2 point mutation via NGS, but were only available in 25% of cases. Eight of the ERBB2 indels were confirmed by tissue NGS reports with zero false positives (100% PPV). 80% of ERBB2 indels were the common p.Tyr772_Ala775dup (YVMA insertion) in exon 20 followed by other insertions in codons 772 through 814. A single ERBB2 exon 20 p.Leu755_Glu757delinsProLys net deletion at 3.9% mutant allele fration (MAF) was noted in one patient, for whom outcome data was available. Initial tissue was IHC negative for HER2 overexpression at the referring hospital where the archival tissue biopsy was exhausted and so could not be sequenced. Based on the cfDNA finding of ERBB2 indel, the patient was switched from cytotoxic chemotherapy to trastuzumab with objective response on PET/CT and a repeat Guardant360 showed the ERBB2 indel MAF had dropped below the test limit of detection. After four months the patient progressed and it was decided to switch to ado-emtansine trastuzumab (T-DM1) in late November.Results', ' ERBB2 indels can be identified without tissue in NSCLC patients with 100% PPV in this modest cfDNA series. In a patient whose tissue was not available for sequencing, an objective response with trastuzumab was obtained.']",
        "Doc_id":"AACR_2016-2240",
        "Doc_title":" A case series of ERBB2 indel driver mutations in non-small cell lung cancer identified by cell-free circulating tumor DNA NGS",
        "_version_":1606189013979365376},
      {
        "Meeting_name":" The clinical utility of ERBB2 amplification detection in breast carcinoma using a 341 gene hybrid capture-based next generation sequencing (NGS) assay",
        "Background":"['Background', '    Approximately 15-20% of invasive breast carcinomas (BCA) show HER2/ERBB2 gene amplification which determines eligibility for treatment by targeted therapy. Traditionally, HER2 status is determined by IHC and FISH. NGS methods can be used to assess HER2 status in clinical practice but concordance with IHC/FISH is not well established. We report our experience using NGS for the assessment of HER2 amplification in conjunction with the detection of potentially targetable mutations.   Methods', '    BCA samples ( > 10% tumor) were analyzed in a CLIA-certified lab using a hybrid capture-based NGS assay (MSK-IMPACT) designed to detect somatic genetic alterations in 341 genes, including copy number alterations. Tumor percentage and concurrent IHC/FISH results were recorded (using ASCO/CAP 2013 guidelines). Criteria for amplification by NGS were defined as a fold change (FC)   2, p-value <0.05.  Results', '    A total of 133 BCA samples (63 primaries, 70 mets) were analyzed. Compared to the combined IHC/FISH methodology, ERBB2 amplification status by NGS had an overall concordance of 97% (129/133) (sensitivity = 82%, specificity = 100%, PPV = 100%). Discordant cases showed low tumor purity, heterogeneous IHC staining, and/or low level amplification by FISH. One sample status post trastuzumab was negative by IHC but ERBB2 amplified by FISH (ratio 4.0) and NGS (FC 2.3). The assay also uncovered somatic alterations in 133 cancer genes including TP53, PIK3CA, CDH1 and ESR1. ER and PR IHC results were available for 94 cases; 1/13 triple negative cases showed an actionable PIK3CA E542K mutation. Of the 22 ERBB2 amplified cases, 6 had actionable PIK3CA mutations (H1047R or E545K); 4/6 were metastatic lesions in patients previously treated with trastuzumab.   Conclusions', '    HER2 status can be reliably determined by hybrid capture NGS methods and allows the concurrent testing for other potentially actionable genomic alterations, particularly in limited material. Samples with low tumor content, heterogeneity and low level amplification may result in false negatives.']",
        "Doc_id":"ASCO_149127-156",
        "Doc_title":" The clinical utility of ERBB2 amplification detection in breast carcinoma using a 341 gene hybrid capture-based next generation sequencing (NGS) assay",
        "_version_":1606189020048523264},
      {
        "Meeting_name":" In vitro-based biochemical studies of erbb2 gene variation to address racial disparities in breast cancer mortality",
        "Background":"['According to a 2012 study by the U.S. Center for Disease Control and Prevention (CDC), African-American women had a 41% higher rate of breast cancer mortality during 2005-2009 than did Caucasian women. Although overall cancer mortality rates have declined significantly in the U.S. since the early 1990s, the black-white mortality gap has been steadily growing. The underlying causes of this racial disparity are likely diverse, and include factors such as lower quality of care and reduced access to mammographic screening. However, more aggressive tumor biology may also contribute significantly to racial disparity in breast cancer outcomes.Recently, a low frequency single nucleotide polymorphism (SNP) of the HER2 receptor tyrosine kinase, W452C, which occurs predominantly in African-American women (about 10% frequency), was significantly correlated with breast cancer. This study reported that tumors from patients harboring W452C do not amplify the erbB2 (HER2) gene or overexpress the protein, suggesting that this variant may contribute to breast cancer development through a mechanism distinct from the amplification common to HER2-positive breast cancer patients. Understanding the structural and functional differences associated with W452C will allow us to identify new strategies for customized breast cancer treatments for African American women.To address the role of the W452C SNP in breast cancer we applied a cell-free in vitro reconstitution system that uses nanolipoprotein particles (NLPs) to solubilize and support functional membrane proteins. Cell-free produced wild type HER2 and W452C were tested for tyrosine phosphorylation as well as specific binding to therapeutic anti-HER2 monoclonal antibodies trastuzumab and pertuzumab. Our results showed comparable tyrosine phosphorylation levels for both wild type and W452C HER2, suggesting that the variant itself might not alone be a driver of cancer. We observed a decreased binding affinity of trastuzumab for W452C compared to wild type HER2, suggesting that W452-positive patients might not respond to trastuzumab treatment. On the other hand, we found that W452C has a higher affinity for pertuzumab. Overall, our studies suggest that the W452C variant may be differentially sensitive to clinically pertinent therapeutic agents. Further characterization of this variant will be important for the development of more effective and precise therapeutic interventions. This in turn could lead to targeted measures that help address racial disparity problems in breast cancer mortality.']",
        "Doc_id":"AACR_2014-3333",
        "Doc_title":" In vitro-based biochemical studies of erbb2 gene variation to address racial disparities in breast cancer mortality",
        "_version_":1606189001634480129},
      {
        "Meeting_name":" MicroRNA-193a-5p suppresses tumor proliferation and enhances radio-sensitivity through ERBB2 in esophageal squamous cell carcinoma",
        "Background":"['Esophageal cancer is the ninth leading cause of cancer death in Taiwan. Esophageal squamous cell carcinoma (ESCC) is usually managed with combined modalities, but the prognosis for ESCC patients is still dismal. MicroRNAs (miRNAs) have been implicated in a variety of human cancers progression, and their expression signatures can provide insight into the diagnosis and prognosis of human cancers. However, the dysregulated miRNAs promoted tumor progression in ESCC remain unclear. To address this goal, 1097 miRNAs were analyzed in nine pairs of ESCC and corresponding normal parts with microarray. Tumor suppressive miRNA, miR-193a-5p, was characterized and inversely correlated with poor prognosis of ESCC patients. Manipulating miR-193a-5p in ESCC cell lines and mouse tumor model, the cell proliferation was decreased and the radio-sensitivity was increased. We further used reporter assay to identify ERBB2 as the target of miR-193a-5p. Restored the ERBB2 expression abolished the effects of miR-193a-5p on cell proliferation and radio-sensitivity. These results indicated that miR-193a-5p played a tumor suppressive role through suppressing ERBB2, expression in esophageal squamous cell carcinoma.Key words', ' miR-193a-5p, esophageal squamous cell carcinoma, radiotherapyNote', ' This abstract was not presented at the meeting.']",
        "Doc_id":"AACR_2014-5209",
        "Doc_title":" MicroRNA-193a-5p suppresses tumor proliferation and enhances radio-sensitivity through ERBB2 in esophageal squamous cell carcinoma",
        "_version_":1606189012376092673},
      {
        "Meeting_name":" DNA sequencing of the small bowel adenocarcinomas to identify targetable ErbB2 mutations.",
        "Background":"['Background', ' Small bowel adenocarcinoma (SBA) is a rare malignancy of the digestive tract with limited knowledge about its genetic alterations. Methods', ' Eighteen tumor and normal matched samples were sequenced using the whole-exome-Illumina platform. Various agnostic analysis methods were used to identify relevant somatic mutations and the results were compared with the available TCGA datasets. To test potential targetable mutations we developed eight patient-derived xenografts (PDX) and three cell lines from freshly-collected primary or metastatic SBA tissues. Two kinase-activating ErbB2 mutations (V842I and Y803H) and one wild-type (wt) ErbB2 (n = 30) PDX models were used to measure the effect of Dacomitinib (Daco) on tumor growth. ErbB2-mutant tumor-derived cell lines were tested for Daco and Lapatinib (Lapa) response in-vitro. Reverse-phase-protein-arrays (RPPA) were used to identify molecular changes. Results', ' Several unexpected oncogenic mechanisms were suggested by the pattern of somatic mutations across the dataset, including mutations in the Notch and Hippo pathways. In addition, we found 6/18 APC truncating mutations exclusive to mutations in ZNRF3 or RNF43 genes, suggesting that non-APC wnt-activating mechanisms are important in SBA, while considered a minority in CRC. Importantly, 6/18 samples displayed ErbB2 mutations, of which 4 resided in the kinase domain, D769Y, V777L, Y803H and V842I. Nanomolar doses of both Lapa and Daco significantly inhibited ErbB2-mutants cell proliferation in-vitro. Target inhibition was confirmed by the RPPA results', ' EGFR-Y1068, ErbB2-Y1248 and PKC-S657 dephosphorylation, PCNA reduction and PARP cleavage increase. In-vivo-administered Daco resulted in significant tumor reduction in ErbB2-V841I (39%, p = 0.03) and ErbB2-Y803H (59%, p = 0.03) tumors, and had no anti-tumor effect on wt-ErbB2 tumors. Conclusions', ' The generation of in-vitro and in-vivo model systems from rare cancers is possible and provides a valuable resource into understanding potentially relevant targetable mutations. Our findings suggest that SBA patients with ErbB2-activating mutations should be considered for clinical trials targeting this alteration.']",
        "Doc_id":"ASCO_193722-199",
        "Doc_title":" DNA sequencing of the small bowel adenocarcinomas to identify targetable ErbB2 mutations.",
        "_version_":1606188977472143360},
      {
        "Meeting_name":" A randomized phase II study (VEG108838) of lapatanib plus pazopanib (L+P) versus lapatanib (L) in patients with ErbB2+ inflammatory breast cancer (IBC).",
        "Background":"['Background', '  ErbB2 amplification is frequently reported in IBC and there is evidence of positive association between ErbB2 and VEGF expression. We evaluated the combination of anti ErbB2 and VEGF therapy in ErbB2+ IBC.  Methods', '  We conducted a multicenter, randomized clinical trial for patients (pts) with relapsed ErbB2+ IBC.  Cohort 1', '  Pts stratified (prior trastuzumab; cutaneous disease only vs systemic) and randomized 1', '1 to receive L 1500 mg + placebo  or L 1500 mg + P 800 mg, QD.  Due to high incidence of Grade 3/4 diarrhea in pts treated with L 1500 mg+ P 800 mg in another study, Cohort 1 was closed after 76 pts randomized. Cohort 2 (87 pts )', '  Pts were stratified (prior trastuzumab) and randomized 5', '5', '2 to receive L 1500 mg + placebo or L 1000 mg + P 400 mg (double-blind) or P 800 mg (open-label), respectively, QD.  Treatment continued until PD, unacceptable toxicity or death.  Primary endpoint was ORR.  Secondary endpoints included PFS, OS, and safety.   Results', '  Cohort 1', '  76 pts were randomized and treated', '  L, n=38; L+P, n=38.  ORR was 29% for the L arm, and 45% for the L+P arm.  Median PFS was 16.1 and 14.3 wks, respectively, for the L and L+P arms.  The most frequent Grade 3 AEs  were diarrhea (0% vs 18%) vomiting (0% vs 8%), ALT increased (0% vs 8%), neutropenia (3% vs 13%), and bilirubin increased (0% vs 5%).  Dose reductions due to AE were 3% and 21% and dose interruptions due to AE were 11% and 55% in the L and L+P arms, respectively.  Cohort 2', '  88 pts were randomized (87 treated)', '  L, n=36; P, n=14; L+P, n=38.  The ORR was 47%, 31%, and 58% for the L, P, and L+P arms, respectively.  Median PFS was 16.0, 11.4, and 16.0 wks for the L, P, and L+P arms, respectively.  The most frequent Grade 3 AEs were ALT increased (0%, 0%, 21%), AST increased (0%, 0%, 18%), diarrhea (3%, 8%, 8%), and fatigue (3%, 8%, 8%).  Dose reductions due to AE occurred in 0%, 0%, and 13% of pts and dose interruptions due to AE occurred in 22%, 23%, and 39% of pts in the L, P, and L+P arms, respectively.  Conclusions', '  This prospective, randomized study confirmed the clinical activity of lapatinib single agent in metastatic ErbB2+ IBC. Furthermore, we demonstrated increased toxicity associated with the combination without a clinically meaningful improvement in efficacy.']",
        "Doc_id":"ASCO_98203-114",
        "Doc_title":" A randomized phase II study (VEG108838) of lapatanib plus pazopanib (L+P) versus lapatanib (L) in patients with ErbB2+ inflammatory breast cancer (IBC).",
        "_version_":1606189038296891393},
      {
        "Meeting_name":" Overexpression of TSH and ERBB2 (HER2) receptors is associated with sharply decreased survival in high grade serous ovarian cancer",
        "Background":"['Objective. To test if hormone or growth factor receptor expression is associated with survival among patients with high grade serous ovarian cancer (HGS OvCa) we analyzed tumor mRNA expression microarray and clinical data from The Cancer Genome Atlas (TCGA).Methods. HGS OvCa patients were surgically staged prior to treatment with IP (n = 90) or IV-only (n = 398) chemotherapy. Multivariate Cox proportional-hazards regression tested associations of expression of 9 hormone or growth factor receptors with progression free survival (PFS) and overall survival (OS). Hazard ratios are hazard per each one standard deviation increase in gene expression. Expression was analyzed as a continuous variable by restricted mean survival analysis. Mean PFS or OS were compared between IP and IV groups by permutation testing stratified by expression. P-values were two-tailed.Results. Expression of ESR1, PGR, FSHR, LHCGR, MET, and EGFR were not associated with PFS or OS. TSHR expression was associated with decreased OS (HR 1.22 (1.06-1.41), p = 0.005) and PFS (HR 1.18 (1.05-1.33), p = 0.006) among IV-only treated patients. ERBB2 expression was associated with decreased OS (HR 1.48 (1.05-2.10), p = 0.027) among patients who received IP chemotherapy. Using multigene (ESR2, PGR, TSHR, and ERBB2) analysis, among the IP group, ERBB2 (HR 1.76 (1.11-2.79), p = 0.015) and ESR2 (HR 0.28 (0.08-0.93), p = 0.037) were associated with OS. Only TSHR expression was associated with decreased OS (HR 1.22 (1.06-1.41), p = 0.005) and decreased PFS (HR 1.18 (1.05-1.33), p = 0.007) on multigene analysis of IV-only treated patients. OS and PFS decreased steeply at high expression of TSHR and ERBB2. Among patients with upper 10th percentile TSHR expression, no significant difference in mean OS or PFS was observed between patients treated with IP versus IV-only chemotherapy. Patients with lower TSHR expression (< 90% percentile) experienced a mean 13.7-month increased OS and 16.4-month increased PFS associated with IP chemotherapy (p < 0.0001).Conclusions. Among HGS OvCa patients treated with IV-only chemotherapy, increased tumor TSHR expression was associated with decreased OS and PFS. High TSHR expression characterized patients who did not benefit from IP chemotherapy.']",
        "Doc_id":"AACR_2016-4754",
        "Doc_title":" Overexpression of TSH and ERBB2 (HER2) receptors is associated with sharply decreased survival in high grade serous ovarian cancer",
        "_version_":1606188979104776193},
      {
        "Meeting_name":" Phenformin down-regulates mammary aromatase expression via the AMPK pathway in humanized aromatase expressing ERBB2 mice",
        "Background":"['Local mammary estrogen production may be vital for breast cancer development because about 70% of breast cancers occur in postmenopausal women. Aromatase is a key enzyme essential for estrogen biosynthesis, and aromatase inhibitors (AIs) are the most effective endocrine treatment for estrogen-responsive breast cancer in postmenopausal women. However, they are also accompanied a number of severe side-effects on bone and joints. Many researchers are currently focusing on developing the novel mammary-specific AIs to prevent or treat breast cancer to minimize the side effects of treatment. Phenformin, an antidiabetic drug, lowers serum glucose levels via activating the AMP-activated protein kinase (AMPK) pathway and reduces tumor burden and prolongs survival in non-small cell lung cancers. In vitro studies show that activated AMPK inhibits human mammary adipose tissue aromatase expression via suppression of binding of cAMP-responsive element binding protein (CREB) to aromatase promoters I.3/II, leading to decreased estrogen formation. We hypothesized that phenformin will be an effective adipose-specific AI for prevention and treatment of breast cancer. However, one of the major obstacles to define in vivo effects of phenformin on mammary aromatase expression is the lack of suitable mouse models because aromatase expression, present in the human breast, is absent in the mouse mammary gland. We developed a unique humanized aromatase mouse model (Aromhum) to mimic the human aromatase expression pattern and physiology in the mouse. We observed that tumorigenesis was accelerated in the mice overexpressing ERBB2 that were crossed with Aromhum mice (AE mice). Phenformin treatment (i.p., 70 mg/kg /day for 14 days) significantly decreased blood glucose levels by 37% in AE mice as compared to vehicle treatment. Phosphorylation of CREB, a downstream effector of the AMPK pathway, which mediates aromatase expression, was significantly decreased. Furthermore, after phenformin administration, mammary aromatase mRNA expression in AE mice was significantly decreased by 58% and estrogen response genes (SUSD3 and cyclin D1) were also reduced by about 65%. Real-time PCR showed that mammary AMPK1 mRNA expression is 10-fold higher compared with AMPK2 mRNA. Moreover, phenformin treatment significantly decreased AMPK1 mRNA levels by 53% but not AMPK2 mRNA expression in AE mice. Interestingly, daily oral phenformin treatment for 7 days significantly reduced mammary tumor volume of AE mice by 76%. In conclusion, phenformin decreased mammary aromatase expression and possible estrogen production, and reduced tumorigenesis via upregulation of the AMPK pathway in breast tissue of AE mice. This study provides justification for future testing of the adipose-specific preventive and therapeutic potential of the metabolic drug phenformin in postmenopausal breast cancer with minimal side-effects.']",
        "Doc_id":"AACR_2014-2102",
        "Doc_title":" Phenformin down-regulates mammary aromatase expression via the AMPK pathway in humanized aromatase expressing ERBB2 mice",
        "_version_":1606189000664547328},
      {
        "Meeting_name":" Breast cancer ErbB2 status in Asian women",
        "Background":"['Background', ' Breast cancer incidence is']",
        "Doc_id":"ASCO_30619-65",
        "Doc_title":" Breast cancer ErbB2 status in Asian women",
        "_version_":1606188995703734273},
      {
        "Meeting_name":" Role and activation mechanisms of myeloid zinc finger-1 (MZF1) in ErbB2-induced breast cancer invasion",
        "Background":"['ErbB2 overexpression gives rise to a highly invasive, aggressive phenotype associated with an increased activity of lysosomal cysteine cathepsins B and L and with a pericellular accumulation of lysosomes at the close vicinity of the cell membrane, enabling lysosomal exocytosis and secretion of lysosomal contents to the extracellular space. We recently showed that ErbB2 expression level correlates positively with cysteine cathepsin B and L levels in primary breast cancer and that ErbB2 regulates the expression of cathepsins B and L leading to their increased activity in several ErbB2-positive breast cancer cell lines. We found that the increased cysteine cathepsin activity is essential for the invasion of ErbB2 overexpressing breast cancer cells in 3-dimensional (3D) Matrigel cultures and that it is mediated by a novel signaling network that involves TGFR, ERK2-MAPK, PAK4, PKC and CDC42bp kinases and two transcription factors, Myeloid Zinc Finger 1 (MZF1) and ETS1, which regulate the ErbB2-induced expression of cathepsins B and L.We currently work on understanding the mechanisms that increase the transcriptional activity of MZF1 in breast cancer. Thus far we have identified two basic mechanisms that can increase MZF1 target gene expression', ' cancer-induced, increased levels of MZF1 and ErbB2 signaling-induced, increased transcriptional activity of MZF1. Our results thus far show that the level of MZF1 can be directly downregulated by specific, non-coding RNAs. The cancer-induced increase in the MZF1 level is most likely due to changes in the expression of these non-coding RNAs. Preliminary data employing two-dimensional SDS-PAGE as well as the factual involvement of several kinases downstream of ErbB2 for its transcriptional activity, suggests that MZF1, a prominent phosphoprotein, is activated by phosphorylation in response to ErbB2 signaling. Towards this end we have set up various experiments to verify the phosphorylation of MZF1 in response to ErbB2 signaling. We now aim at the identification of the ErbB2-regulated phosphorylation sites. With this work we expect to collect more information about the molecular mechanisms underlying ErbB2-induced invasion. Increased knowledge of the mechanisms is expected to enable the development of novel therapies and biomarkers for aggressive, ErbB2-positive breast cancer.']",
        "Doc_id":"AACR_2015-1975",
        "Doc_title":" Role and activation mechanisms of myeloid zinc finger-1 (MZF1) in ErbB2-induced breast cancer invasion",
        "_version_":1606189009212538880},
      {
        "Meeting_name":" Estrogen accelerates the development of estrogen receptor-negative breast cancer.",
        "Background":"['Long-term cumulative exposure to estrogen increases the breast cancer risk in women. Breast tissue must have a normal complement of estrogen receptor (ER) and progesterone receptor (PGR) for the normal development of breast tissue. Clinically, about 22% of patients with breast cancer overexpress the ERBB2 (HER2/neu) receptor tyrosine kinase. However, many HER2/neu-positive mammary tumors do not express ER or PGR by the time they are clinically recognizable. So far, the role of estrogen in the development of ER-negative breast cancers is not clearly defined. Aromatase is a key enzyme for estrogen biosynthesis and its expression pattern between human and mouse is drastically different. We generated transgenic humanized aromatase (Aromhum) mice to mimic the human aromatase distribution pattern in the mouse. Aromhum mice exhibited an increased incidence of lobuloalveolar breast hyperplasia associated with increased estrogen levels locally in mammary glands but not in the circulation. To demonstrate the important role of ER signaling in ER-negative breast tumor development and eventually to test a prevention strategy using aromatase inhibitors in this mouse model, Aromhum mice were crossed with ERBB2 transgenic mice to generate wild-type (WT), Aromhum, ERBB2 and Aromhum/ERBB2 (AE) mice. WT or Aromhum transgenic mice were free of tumors during the 26 week of follow-up. On the other hand, 56% of ERBB2 (only) mice developed mammary tumors, as expected. Interestingly, AE mice had a significantly higher (86%, p<0.05) tumor incidence compared with ERBB2 mice. Thus, it appeared that the human aromatase transgene increased the rate of ERBB2induced mammary tumor growth. The tumors that arose in either ERBB2 or AE mice were histological adenocarcinomas as was previously reported for the ERBB2 transgenic mice. Levels of ER and PGR in benign mammary epithelial cells were higher in Aromhum and AE mice as compared to WT and ERBB2 mice. We further measured the dynamic change of sex hormone receptor status from normal mammary epithelial cells to fully developed tumors. Different stages of mammary tumors were chosen from nonpalpable microscopic visible early stage tumor to various sizes of late stage tumors. ER and PGR were present in early stage tumor but gradually decreased and eventually were absent in late stage tumors. The estrogen response gene, cyclin D1 was higher in benign and malignant mammary epithelium of Aromhum and AE mice compared with WT mice. Cell proliferation evaluated by Ki67 staining was significantly higher in benign mammary epithelium and tumors of AE mice as compared to those of ERBB2 mice. In conclusion, estrogen expedited the early development of ER-negative mammary tumors caused by a primary genetic hit (HER2/neu) via increasing cell proliferation through ER-mediated signal transduction. This study provides a fundamental mechanism for testing prevention strategies using aromatase inhibitors in this mouse model.']",
        "Doc_id":"AACR_2013-90",
        "Doc_title":" Estrogen accelerates the development of estrogen receptor-negative breast cancer.",
        "_version_":1606189013460320256},
      {
        "Meeting_name":" Stat3 signaling in erbB3-mediated epithelial-mesenchymal transition in erbB2-positive breast cancer cells",
        "Background":"['Introduction', ' Understanding the mechanism of metastatic program is essential to reducing the mortality of cancer patients. It is well known that epithelial-mesenchymal transition (EMT) contributes to cancer metastasis. Recently, numerous studies have documented the role of erbB3-mediated oncogenic signaling in breast cancer progression. In this study, we have focused on investigating the effect of Stat3 activation on EMT-induced by erbB3 receptor in erbB2-positive (erbB2+) breast cancer cells.Methods', ' Immunofluorescence analyses were performed to study the localization and expression of EMT markers in erbB2+ breast cancer cells. Lentiviral vector containing shRNA was used to specifically knockdown erbB3. Western blot analyses were performed to assess the expression and activation of proteins. Cell growth (MTS) assays were used to determine cell viability. Wound healing and transwell assays were used to examine the motility and migration of cells.Results', ' We discovered that ectopic expression of erbB3 facilitated EMT, as evidenced by change of cell morphology, induction of mesenchymal markers Vimentin, Snail, Slug, ZEB1 and repression of the epithelial marker E-cadherin in erbB2+ breast cancer cells. Wound healing and transwell assays indicated that the capability of cell motility and migration was enhanced. In contrast, specific knockdown of erbB3 abrogated the observations described above. Moreover, elevated expression of erbB3 potently stimulated activation of Stat3, which has been validated to act as a promoter of tumor invasion and metastasis in many type cancers. Suppression of Stat3 signaling via its inhibitor, S3I-201, significantly alleviated EMT and cell motility/migration that were triggered by activation of erbB3. To further assess the clinical relevance of erbB3 signaling in cancer metastasis, we took advantage of a publicly accessible portal that allows analysis of the effect of genes on survival using 4,142 breast cancer samples (http', '//kmplot.com/analysis/). Kaplan-Meier survival curves showed that the erbB2+ breast cancer patients with erbB3-high expression tended to have a shorter Distance Metastasis-free Survival (DMFS).Conclusion', \" Activation of Stat3 signaling by erbB3 promotes EMT and shifts the cellular phenotype toward a mesenchymal state that is advantageous for cancer metastasis. Our data shed a new sight on erbB3's role in erbB2+ breast cancer metastasis and may facilitate the development of novel strategy for treatment of tumor progression.Keywords\", ' ErbB3, Stat3, EMT, Metastasis, Breast Cancer']",
        "Doc_id":"AACR_2016-1593",
        "Doc_title":" Stat3 signaling in erbB3-mediated epithelial-mesenchymal transition in erbB2-positive breast cancer cells",
        "_version_":1606189027555278848},
      {
        "Meeting_name":" Use of an RNA interference screen-derived mitotic and ceramide pathway metagene to predict response to paclitaxel combination chemotherapy in primary breast cancer.",
        "Background":"['Background', ' Addition of taxanes to preoperative chemotherapy in breast cancer increases the rate of pathological complete response (pCR). Despite this improvement, a significant proportion of patients do not respond and the prognosis for patients with ER-/PR-/ERBB2- disease failing to achieve a pCR remains particularly poor. Identification of such patients in a reliable manner is the first step towards determining who might benefit from alternative treatment regimens within clinical trials. We previously reported an RNA interference screen in 3 cancer cell lines, including an ER-/PR- /ERBB2- breast cancer cell line, identifying genes involved in mitosis or ceramide metabolism that influenced sensitivity to paclitaxel. Our goal was to evaluate these genes as a predictor of pCR to paclitaxel combination chemotherapy in ER-/PR-/ERBB2- breast cancer. Methods', ' We derived a paclitaxel response metagene based on mitotic and ceramide genes identified by functional genomics studies. We used AUC and multivariate logistic regression to evaluate the metagene in five ER-/PR-/ERBB2- neoadjuvant chemotherapy breast cancer clinical trial cohorts; two treated with paclitaxel and four treated without paclitaxel. Results', ' The paclitaxel response metagene was predictive of pCR in ER-/PR-/ERBB2- patients in paclitaxel-treated cohorts (AUC = 0.79, 0.72) in contrast to non-paclitaxel-treated cohorts (AUC = 0.53, 0.36, 0.53, 0.59). Following multivariate logistic regression analysis, the paclitaxel response metagene was associated with pCR (p = 0.02) and a test for interaction of the metagene with paclitaxel regimen was significant (p = 0.009). Conclusions', ' The paclitaxel response metagene shows promise as a paclitaxel-specific predictor of pCR in ER-/PR-/ERBB2- breast cancer patients. In contrast to predictive microarray signatures developed through associative learning strategies, these results highlight the potential for RNA interference screens to identify genes required for drug response in vivo and accelerate predictive biomarker development without the need for training clinical trial cohorts.']",
        "Doc_id":"ASCO_40960-74",
        "Doc_title":" Use of an RNA interference screen-derived mitotic and ceramide pathway metagene to predict response to paclitaxel combination chemotherapy in primary breast cancer.",
        "_version_":1606189002194419712},
      {
        "Meeting_name":" Regulation of PAX2 activity by estradiol in breast cancer cells",
        "Background":"['Most breast cancer deaths arise from tumour cells ability to produce distant metastases. Among breast tumour subtypes, luminal A tumours, which express the highest levels of estrogen receptor alpha, are associated with the poorest metastatic phenotype and with longest relapse-free survival. Usually active during embryogenesis, PAX2, a homeobox transcription factor, is of a particular interest in this context. It is preferentially activated in luminal A tumours in vivo and it was shown to downregulate the expression of ERBB2 (erythroblastic leukemia viral oncogene homolog 2, HER-2/neu), a well-documented proinvasive and pro-metastastic gene, in these cells in response to estradiol in vitro. However, the ability of estradiol to regulate PAX2 activity and ERBB2 expression in non-luminal breast cancer cells, and the intracellular mechanisms involved in estradiol-induced PAX2 activity in breast cancer cells, have not been investigated. Objective', ' The objective of our work was to compare the impact of estradiol exposure on PAX2 activation in luminal and non-luminal breast cancer cells, and to determine the molecular mechanisms mediating estradiol-induced activation in breast cancer cells. Hypothesis', ' Estradiol would induce PAX2 activity in breast cancer cells of the luminal subtype only, in an estradiol receptor alpha-dependent manner. Results', ' Basal PAX2 activity was higher in cell lines from luminal compared to non-luminal subtype. Activation of PAX2 by estradiol, as assessed by measuring PAX2 phosphorylation on serine 393 residue and ERBB2 expression, was selectively achieved in breast cancer cell lines of the luminal subtype. This process was blocked by estrogen receptor alpha antagonist ICI 182780. Conclusion', ' PAX2 activation by estradiol is selectively achieved in breast cancer cells of the luminal subtype, via ER. We are currently investigating intracellular signaling pathways downstream of estrogen receptor alpha which could mediate estradiol-induced activation of PAX2 in luminal breast cancer cells.']",
        "Doc_id":"AACR_2012-1295",
        "Doc_title":" Regulation of PAX2 activity by estradiol in breast cancer cells",
        "_version_":1606189021235511296},
      {
        "Meeting_name":" Regulation of tamoxifen sensitivity by a PAK1-EBP1 signaling pathway in breast cancer.",
        "Background":"['EBP1, an ErbB3 binding protein isolated in our laboratory, sensitizes breast cancer cells to tamoxifen in part by decreasing ErbB2 protein levels. The p21 regulated serine/threonine kinase PAK1, implicated in tamoxifen resistance, phosphorylates EBP1 in vitro and in vivo at T261. Phosphorylation of EBP1 at this site induces tamoxifen resistance. We thus postulated that inhibition of PAK1 activity, by restoring EBP1 function, could ameliorate the hormone refractory phenotype of ErbB2 overexpressing breast cancer cells. Transient transfection studies indicated that an EBP1 T261E mutant, which mimics EPB1 phosphorylated by PAK1, increased ErbB2 protein levels. An EBP1 T261A mutant, unable to be phosphorylated by PAK1, ameliorated PAK1-induced tamoxifen resistance, suggesting that phosphorylation of EBP1 by PAK1 contributes to tamoxifen resistance. We then tested if pharmacological inhibition of PAK1 activity might render hormone resistant cells, which endogenously overexpress PAK1 and ErbB2, tamoxifen sensitive. Transfection of EBP1 sensitized cells to tamoxifen. The T261A EBP1 mutant more potently sensitized cells to tamoxifen than wild type EBP1. IPA-3, a specific small MW PAK1 inhibitor, sensitized cells to tamoxifen only when EBP1 was ectopically expressed. However, IPA-3 did not further affect sensitivity of T261A overexperssing cells, suggesting that the phosphorylation of EBP1 by PAK1 played a role in the EBP1-induced hormone sensitivity. IPA had no effect on tamoxifen resistance in T47D cells in which EBP1 protein had been ablated by shRNA. The IPA-induced increase in tamoxifen sensitivity was accompanied by a decrease in ErbB2 levels in EBP1 overexpressing, but not vector control cells. These studies suggest that phosphorylation of EBP1 may be a novel additional mechanism of PAK1-induced hormone resistance. In addition, strategies that increase the pool of functional EBP1 and decrease PAK1 activity may affect hormone resistant cell growth. Our results also suggest that PAK1 directed therapies may be more effective in patients that express high levels of EBP1.*contributed equally to this work']",
        "Doc_id":"AACR_2013-4397",
        "Doc_title":" Regulation of tamoxifen sensitivity by a PAK1-EBP1 signaling pathway in breast cancer.",
        "_version_":1606189010773868544},
      {
        "Meeting_name":" Hypoxia induces lapatinib resistance in ErbB2-positive breast cancer cells via regulation of DUSP2",
        "Background":"['Breast cancer is one of the most common cancers among women. Many factors are associated with this disease including overexpression/amplification of the tyrosine kinase HER2/ErbB2. ErbB2 belongs to the EGFR-family of receptor tyrosine kinases and its overexpression can activate multiple signaling pathways that can promote tumor progression via regulation of cell growth, proliferation, and survival. Breast cancer patients with ErbB2 amplifications are currently treated with lapatinib, a small-molecule kinase inhibitor that blocks the active site of ErbB2 to inhibit EGFR/ErbB2 downstream signaling. While lapatinib has displayed clinical efficacy in breast cancer patients, acquired resistance has been reported and the mechanism of this resistance is poorly understood.Hypoxia or low oxygen tension occurs in many breast cancers and is associated with poor patient survival. One of the major players in the cellular response to hypoxia is stabilization of the transcription factor hypoxia inducible factor 1 (HIF-1). HIF-1 is a transcription factor that regulates cell growth, proliferation and survival. As a result, hypoxic tumors often exhibit weak response to chemotherapeutic agents and are associated with poor prognosis.Here, we show that hypoxia, via HIF-1, blocks lapatinib-mediated effects on ErbB2-expressing mammary epithelial and ErbB2-positive breast cancer cells. Lapatinib-mediated growth inhibition and apoptosis in three dimensional (3D) cultures are decreased under hypoxic conditions (1%O2) Consistent with these results, we find that hypoxia can maintain activation of signaling pathways downstream from ErbB2 including AKT and ERK in the presence of lapatinib. This protective effect depends on HIF-1 expression as cells expressing HIF-1 RNAi no longer are resistant to lapatinib treatment. Moreover, overexpression of stable HIF-1 in ErbB2-expressing cells under normoxic conditions is sufficient to inhibit lapatinib-mediated effects on proliferation and survival and maintain ERK and AKT signaling. Moreover, hypoxia-mediated activation of ERK signaling, but not AKT, is required for lapatinib resistance as MEK inhibitors (including clinically approved tramatinib) reverses hypoxia-mediated lapatinib resistance in standard and 3D cultures. HIF-1 may bypass lapatinib-treated inhibition of the ERK pathway via its regulation of dual-specificity phosphatase 2 (DUSP2). DUSP2 is a negative regulator of the ERK pathway and we show that cells exposed to hypoxia contain decreased DUSP2 levels and correlate with increased Erk activation. Indeed, reducing DUSP2 expression via RNAi in ErbB2-positive breast cancer cells is sufficient to reduce lapatanib-mediated effects under normal oxygen. Thus, hypoxia, via HIF-1, causes lapatinib resistance in ErbB2-expressing breast cancer cells and suggests that targeting MEK/ERK pathway in hypoxic breast cancer may increase sensitivity to ErbB2-targeted therapy.']",
        "Doc_id":"AACR_2014-1824",
        "Doc_title":" Hypoxia induces lapatinib resistance in ErbB2-positive breast cancer cells via regulation of DUSP2",
        "_version_":1606188976128917504},
      {
        "Meeting_name":" Snail inhibits lung colonization and metastasis in luminal type A breast cancer cells",
        "Background":"['Breast cancer is the most common malignant disease in Western women. In these patients, it is not the primary tumor, but its metastases at distant sites that are the main cause of death. Breast cancer include five biologically distinct subgroups including Luminal A (ER+ ck8h/ck18h), Luminal B (ER+ ck8l/ck18l), Basal (ER- ck5+/ck17+) and ERBB2+ (ER- ERBB2+ GFRBP7+) and normal breast-like types. The time to distant metastasis and overall survive rate were distinct among these subgroups. Luminal type has the best prognosis, while basal type or ERBB2+ has the worst prognosis. What mechanism involves in this difference remains to be elucidated. In the current study, we demonstrated (1) Luminal type A tumor such as MCF7 when overexpressed with active mutant form of Snail gene increased in the expression of markers for epithelial mesenchymal transition such as Vimentin, N-cadherin and Fibronectin but decreased in the expression of E-cadherin compared to cells overexpressed with control vectors of wild type Snail gene. Moreover, these cells increased in the capacity of migration and invasion. (2) While, MCF7 overexpressed with active mutant form of Snail decreased in the ability to survive and form sphere in serum-free medium, the in vitro colonization, and were unable to metastasize to lung.Therefore, the elucidation of the differences in molecules or signaling pathways involve in controlling migration, invasion and distant metastasis may have a therapeutically beneficial effect on breast cancer treatment.']",
        "Doc_id":"AACR_2014-1127",
        "Doc_title":" Snail inhibits lung colonization and metastasis in luminal type A breast cancer cells",
        "_version_":1606188976872357889},
      {
        "Meeting_name":" Extracellular matrix metalloprotease inducer (EMMPRIN) and CD44 protein complexes are exclusively formed in basal- and normal-like breast cancer cell lines",
        "Background":"['Extracellular Matrix Metalloprotease Inducer (EMMPRIN) is a multifunctional glycoprotein that is involved in tumor cell invasion and metastasis, and is a predictor for tamoxifen resistance in breast cancer. EMMPRIN is implicated in development of therapy resistance by forming a functional transporter complex through interaction with CD44 and monocarboxylate transporter 4. Presence of EMMPRIN transporter protein complexes may therefore be a better predictor for therapy resistance and a direct target for drugs. In this study, we aimed to identify EMMPRIN-CD44 protein interactions in a large panel of breast cancer cell lines. EMMPRIN-CD44 protein interaction was investigated in a panel of 41 breast cancer cell lines, which represent the luminal (n=12), ErbB2 (n=13), basal (n=7), and normal-like (n=9) intrinsic subtypes, using in situ Proximity Ligation Assay (isPLA). In addition, protein expression of both EMMPRIN and CD44 in the cell lines was evaluated by immunohistochemistry (IHC). IHC and isPLA read-out was performed by bright field microscopy and 0-1-2-3 scoring was applied to none-weak-moderate-strong staining (IHC) or interaction (isPLA), respectively. Moderate and strong EMMPRIN expression was observed in 50% of luminal, 36% of ErbB2, 86% of basal, and 100% of normal-like cell lines, and moderate to high CD44 expression was detected in 64%, 83%, 86%, and 100% in luminal, ErbB2, basal, and normal-like cell lines, respectively. Interestingly, moderate to strong EMMPRIN-CD44 interaction was exclusively detected in basal (64%) and normal-like (67%) cell lines, whereas luminal and ErbB2 cells lines had no detectible, or only very weak, EMMPRIN-CD44 interaction (square = 23.5, P<0.0001). Our results indicate that EMMPRIN-CD44 protein complexes are formed exclusively in basal and normal-like breast cancer cell lines. These breast cancer subtypes are associated with an aggressive phenotype and poor patient survival. We speculate that active EMMPRIN-CD44 transporters are involved in drug resistance, resulting in poor clinical outcome, and will investigate this in more detail in clinical breast cancer specimens.']",
        "Doc_id":"AACR_2012-806",
        "Doc_title":" Extracellular matrix metalloprotease inducer (EMMPRIN) and CD44 protein complexes are exclusively formed in basal- and normal-like breast cancer cell lines",
        "_version_":1606189039347564544},
      {
        "Meeting_name":" Multiplatform molecular profiling of invasive lobular breast cancer",
        "Background":"['Introduction', ' Invasive lobular breast cancer (ILC) is the second most common subtype of invasive breast cancer accounting for 10% of breast cancer diagnosis. ILC has particular histological and clinical characteristics and a distinct response to therapy. Characterizing the molecular alterations in ILC may lead to an improved understanding of its biology and provide new therapeutic options. The purpose of this study is to describe the molecular profile of ILC and compare it to the one of invasive ductal cancer (IDC).Methods', ' Three-hundred and thirty nine pure ILC specimens profiled from January 2012 - November 2015 were evaluated (Caris Life Sciences, Phoenix, AZ). Multiplatform profiling consisted of gene sequencing (next generation sequencing [NGS]), gene amplification (CISH or FISH), and protein expression (immunohistochemistry [IHC]). Molecular characteristics of estrogen receptor (ER) positive and human epidermal growth receptor factor 2 (HER2) negative pure ILC (n = 236) and IDC (n = 286) were compared.Results', ' By IHC, ER expression was present in 87.7% (277/316), progesterone receptor in 59.6% (198/313), HER2 in 3.5% (11/313), androgen receptor in 87% (262/301), PD-L1 in 8.1% (12/148) and PTEN in 63.3% (198/313). Amplifications were detected in MYC (7.7%, 2/26), EGFR (8.3%, 2/24), ERBB2 (4.5%, 13/290) and TOP2A (1.3%, 3/236). Mutations were detected in AKT1 (4.7%, 9/191), ATM (3.7%, 7/190), BRCA1 (4.2%, 4/96), BRCA2 (9.5%, 9/95), ERBB2 (7.5%, 14/186), PIK3CA (54.5%, 103/189), PTEN (7.9%, 15/189), and TP53 (13.4%, 25/186). A comparison of ER-positive/HER2-negative invasive lobular and ductal carcinomas revealed significant differences in AR expression (89.7% vs 79.6%, p = 0.0022), and mutations in CDH1 (10.1% vs 0.0%, p = 0.0001), ERBB2 (8.2% vs 2.1%, p = 0.0079), and TP53 (10.3% vs 31.8%, 0.0001).Conclusions', ' Multiplatform testing of this large series of ILC reveals recurrent alterations and a distinct molecular profile when compared to IDC. These support the definition of ILC as biologically distinct entity. High AR expression and high rates of dysregulation along the PIK3CA/AKT/mTOR pathway are consistent with recent reports in the literature.']",
        "Doc_id":"AACR_2016-123",
        "Doc_title":" Multiplatform molecular profiling of invasive lobular breast cancer",
        "_version_":1606188973293568000},
      {
        "Meeting_name":" Thrombopoietin expression and effects of eltrombopag in prostate, breast, lung, and ovarian solid tumors.",
        "Background":"['Background', ' Eltrombopag is a novel, oral thrombopoietin receptor (TPO-R; MPL) agonist that interacts with the TPO-R on bone marrow progenitors to stimulate megakaryocyte production, thus increasing platelet counts. TPO-R is expressed on lymphoma and leukemia cell lines, but little data are available on TPO-R expression on solid tumors including prostate cancer. The objective of the present study was to assess the effects of eltrombopag and expression of MPL mRNA on a variety of tumor types. Methods', ' Proliferation was measured by Cell Titer Glo assay on 3 breast, 4 lung, 3 ovarian, and 2 prostate cancer cell lines from the ATCC treated with 0.1-100 g/mL eltrombopag for up to 72 hours. MPL mRNA expression was determined by microarray analysis and qRT-PCR on patient tumors and normal tissue. Results', ' Eltrombopag, at clinically achievable concentrations ( 4 g/mL), decreased proliferation of all cancer cell lines (IC50 range of 3.7-49.7 g/mL). Eltrombopag did not increase proliferation at any eltrombopag concentration tested, consistent with very low or undetectable levels of MPL expression observed in normal tissue and 40 samples each of breast, lung, ovarian or prostate tumors. In comparison, erythropoietin receptor (EPOR) mRNA was expressed at low-to-moderate levels in lung and prostate tumors and at higher levels in ovarian and breast tumors. HER2neu/ErbB2 receptor (ERBB2) mRNA was also expressed at low-to-moderate levels in all tumor types. Insulin-like growth factor-1 receptor mRNA (IGF1R) was expressed at low to undetectable levels in all tumor types. Microarray data on an additional set of breast tumor (n = 118) and lung cancer (n = 48) samples showed similarly low levels of MPL. These breast cancer samples also had low levels of EPOR and IGF1R and higher levels of ERBB2, while the lung cancer samples had moderate to high levels of EPOR, ERBB2, and IGF1R. Conclusions', ' Eltrombopag causes a dose-dependent decrease in proliferation at concentrations  4 g/mL. The undetectable or very low levels of MPL expression in patient tumors supports the proliferation results.']",
        "Doc_id":"ASCO_52812-74",
        "Doc_title":" Thrombopoietin expression and effects of eltrombopag in prostate, breast, lung, and ovarian solid tumors.",
        "_version_":1606189016298815488},
      {
        "Meeting_name":" Clinical genomic profiling of 1000 metastatic breast cancer patients",
        "Background":"['Most large genomic profiling efforts in breast cancer have focused on primary breast tumors. Profiling of metastatic breast cancer (MBC) could more accurately define actionable genomic alterations and reveal novel alterations that arise under the selective pressure and clonal evolution of prior therapy. Utilizing a 410-gene targeted capture-based sequencing platform (MSK-IMPACT), we analyzed 920 tumors (62% metastatic, 38% primary) from 874 MBC patients for somatic mutations, DNA copy number alterations, and structural rearrangements (planned final analysis 1000 patients). Detailed clinical data including treatment outcomes was collected for all patients. The cohort was representative of the well characterized clinical subtypes of breast cancer with 71% ER+ or PR+ and HER2-, 17% HER2+, and 12% triple negative breast cancer (TNBC).Our analysis revealed recurrent alterations in multiple pathways including PI3K/AKT/mTOR (56%), cell cycle regulation (42%), RTK signaling (40%), epigenetic regulation (33%) and MAPK/ERK (19%) pathways. The most frequent actionable alterations include', ' PIK3CA mutation (36%), ERBB2 amplification (15%), FGFR1 amplification (12%), ESR1 mutation (11%), PTEN mutation/deletion (10%), AKT1 mutation (6%), and ERBB2 mutation (5%). The genomic landscape was significantly different across breast cancer subtypes. For example, the PI3K/AKT/mTOR pathway was altered in ER+ MBC mainly through activating PIK3CA mutations whereas PTEN deletion/mutations were most common in TNBC. We also identified significant differences in the genomic profiles of metastatic and primary tumor samples. Gene enrichment analyses revealed a subset of genes more frequently altered in metastatic tumors (STK11', ' 13 vs 2; ROS1', ' 14 vs 2; FGFR4', ' 15 vs 1) suggesting that mutations in these genes may play a role in breast tumor metastasis and/or therapy resistance. ESR1 mutations were predominantly present in metastatic tumors (88%) and were significantly associated with duration of prior hormonal therapy (P<0.0001). ESR1 mutations were also associated with a poor response to the ER degrader fulvestrant (median PFS', ' 4.8 vs 13.7 months, mutated vs wild type; P = 0.01). Analysis for potentially novel hotspot mutations revealed recurrent RHOA G17 mutations in 6 MBC patients, nominating RHOA, a GTPase transducer of membrane receptors, as a candidate driver in a subset of breast cancers. While identified previously in other tumors, RHOA G17 has never been implicated in breast cancer.In summary, our genomic analyses of this large cohort of MBC patients revealed actionable alterations in over 60% of the patients. 29% of patients with these alterations were enrolled in clinical trials of matched targeted therapies to date (PIK3CA 27%, AKT1 30%, ESR1 23%, ERBB2 39%) suggesting that prospective genomic characterization can accelerate enrollment of patients with MBC onto therapeutic clinical trials.']",
        "Doc_id":"AACR_2016-4509",
        "Doc_title":" Clinical genomic profiling of 1000 metastatic breast cancer patients",
        "_version_":1606189035411210240},
      {
        "Meeting_name":" Breast cancer companion diagnostic platform based on objectively defined tumor co-expression patterns stratifies multiple clinical and therapeutic endpoints comparison to existing molecular subtyping definitions",
        "Background":"['Gene expression profiles of human breast tumors have greatly expanded our understanding of the genes and pathways that underlie breast cancer. Profiling studies have also supported a molecular classification of breast cancer. The resulting molecular subtypes Luminal, Basal-like, ERBB2+, and Normal-like were shown to have different prognostic and predictive characteristics. Related studies have led to a proliferation of multigene prognostic and predictive diagnostic tests. Two independent multigene tests, OncoType Dx and MammaPrint, have been shown to be helpful in predicting the risk of recurrence of patients with early stage breast cancer. Current multigene tests consistently prioritize the proliferation, estrogen receptor (ER), and ERBB2 pathways. An alternative approach to identifying key molecular variables within breast cancer is based on a definition of objectively defined tumor co-expression patterns. To this end, we defined co-expression patterns within 56 independent breast cancer molecular profiling datasets representing >5,000 unique patients. We then performed a meta-analysis across datasets to define the most robust, consistently occurring co-expression patterns. These patterns, termed modules, recapitulate the proliferation, ER, and ERBB2 pathways, but also monitor expression of other important variables including core cancer cell growth pathways, immune signaling and microenvironment, and hallmark genomic aberrations. An important feature of co-expression patterns is that a small number of genes serve as an effective surrogate for each module. Thus, we created a single multigene qPCR test that measures the expression of 18 distinct breast cancer modules and validated the test for use with formalin-fixed paraffin-embedded (FFPE) tumor samples. In retrospective microarray scoring analyses with key clinical datasets, and with analysis of FFPE specimens from breast cancer cohorts, we demonstrate that breast cancer modules can be used to recapitulate the molecular subtypes of breast cancer and to have prognostic and predictive properties similar to the current multigene tests. Because they recapitulate existing molecular tests, while also reading out many additional axes of molecular variability, breast cancer modules provide a universal assay with broad application to companion diagnostics development.']",
        "Doc_id":"AACR_2012-3664",
        "Doc_title":" Breast cancer companion diagnostic platform based on objectively defined tumor co-expression patterns stratifies multiple clinical and therapeutic endpoints comparison to existing molecular subtyping definitions",
        "_version_":1606189030603489280},
      {
        "Meeting_name":" Phosphorylated and SUMO-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression.",
        "Background":"['Progesterone receptors (PR) are emerging as important breast cancer drivers. Elevated mitogen activated protein kinase (MAPK) and cyclin dependent kinase 2 (CDK2) signaling is common in breast cancer and these kinases drive direct PR-B, but not PR-A, Ser294 phosphorylation. Post-translational modifications, including phosphorylation and SUMOylation, dramatically impact PR transcriptional activity. Phospho-Ser294 PRs are less SUMOylated on Lys388 (i.e. a repressive modification). Thus, active mitogenic kinase signaling provides a mechanism for PR derepression (i.e. transcriptional activation) during breast cancer progression. A broad range of PR protein expression is observed clinically; PR-negative tumors are generally more aggressive. However, clinical (IHC) assays do not measure phospho-PRs, which turnover rapidly and may appear undetectable, confounding the true level of activated PR within tumors. A PR gene signature would provide a valuable marker of PR contribution to breast cancer progression. Global gene expression patterns were measured in T47D and MCF-7 breast cancer cells expressing either wild type or K388R (SUMOylation-deficient) PRs and subjected to pathway analysis. Target genes sensitive to changes in PR SUMOylation included those required for proliferative and pro-survival signaling. DeSUMOylated K388R receptors were preferentially recruited to enhancer regions of derepressed genes. SUMO-deficient (i.e. phospho-Ser294) PR gene signatures were significantly associated with human epidermal growth factor 2 (ERBB2)-positive luminal breast tumors and predictive of early metastasis and shortened survival. Furthermore, treatment with antiprogestin or MEK inhibitors abrogated expression of SUMO-sensitive PR target-genes and inhibited progestin-driven proliferation in BT-474 (estrogen receptor (ER)+/PR+/ERBB2+) breast cancer cells. Similarly, treatment of T47D cells expressing deSUMOylated PR with ERBB2 inhibitors blocked progestin-dependent growth. Potential mechanisms of differential promoter selection were investigated. Notably, genes preferentially up-regulated by SUMO-deficient PR contain RUNX binding motifs located near their transcriptional start sites. Herein, we demonstrated that RUNX2 directly interacts with PR. Further, RUNX2 knockdown in breast cancer cells reduced SUMO-deficient PR dependent gene expression. Our studies suggest that deSUMOylated PR cooperates with RUNX2 to mediate promoter selective gene expression. We conclude that reversible PR SUMOylation/deSUMOylation profoundly alters PR target gene selection in breast cancer cells, in part via regulation of PR interactions with gene-specific co-factors, such as RUNX2. Patients whose ER+/PR+ tumors are driven by hyperactive phospho-PRs may benefit from endocrine (antiestrogen) therapies that also contain an antiprogestin.']",
        "Doc_id":"AACR_2013-3569",
        "Doc_title":" Phosphorylated and SUMO-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression.",
        "_version_":1606189011911573504},
      {
        "Meeting_name":" Impact of brain metastases on health care costs in metastatic breast cancer",
        "Background":"['Background', ' Incidence of brain metastases (BM) are thought to be particularly high among patients with ErbB2+ (HER2+) breast cancer and have been associated with a poor survival prognosis. A previous study identified such patients as a considerable financial burden for health systems in Germany and France when compared to metastatic breast cancer (MBC) without BM. The objective of this study was to extend that analysis to estimate health care costs in Italy, Spain and the UK. Methods', \" Patient treatment histories, including drugs, specialist visits, procedures, inpatient stays etc, were collected retrospectively from a panel of oncologists for women with MBC across Italy, Spain and the UK, last seen by the responding oncologist during Q3-Q4 2006 or Q3-Q4 2007. To identify ErbB2+ patients they all had to have received/were receiving trastuzumab (TZ) for MBC. Patients were sampled so as to ensure the collection contained a minimum of 50 cases with BM and 200 histories overall (remainder controls). All costs within the observation period (initiation of TZ to date last seen) were calculated from a payer's perspective for patients who had developed BM and those who had not. Linear stepwise regression took into account potential confounding of time related covariates. Results\", ' The study included 268 Italian (146 cases), 215 Spanish (126 cases) and 243 UK patients (103 cases). BM diagnosis was associated with significantly more expensive treatment histories than those patients without. Service costs such as radiotherapy and hospital visits were found to be key drivers for these differences (p<.001). Conclusions', ' The significantly greater cost associated with treatment of BMs in ErbB2+ MBC patients from Italy, Spain and the UK is consistent with results from identical French and German analyses. Therapies that reduce the incidence of BMs may therefore decrease the overall financial burden of ErbB2+ MBC. CountryMean cost ()', ' BM casesMean cost ()', ' ControlsIncremental cost () of BM diagnosis (95% CI) Italy15,51910,7784,741 (2,908, 6,574) Spain32,39222,34510,047 (5,307, 14,787) UK21,24018,2792,962 (802, 5,130) France*53,17340,78012,993 (3,767, 21,019) Germany*46,41441,0545,360 (-1,224, 11,946)*Data included for comparison']",
        "Doc_id":"ASCO_30879-65",
        "Doc_title":" Impact of brain metastases on health care costs in metastatic breast cancer",
        "_version_":1606189007792766976},
      {
        "Meeting_name":" Managing metastatic breast cancer via serial monitoring with circulating cell-free tumor DNA next generation sequencing testing",
        "Background":"['Background', ' Metastatic breast cancer (MBC) is an incurable disease with complex molecular features including somatic mutations that evolve in relation to genomic instability and selective treatment pressure. Patients with treatment-refractory MBC may benefit from tumor genomic evaluation using next generation sequencing (NGS). Furthermore, analysis of circulating tumor DNA (ctDNA) in patients with advanced disease offers the possibility of non-invasive molecular monitoring.Methods', ' A patient with MBC was tested at each progression with a ctDNA NGS panel (Guardant360) that includes all NCCN-recommended somatic genomic variants for solid tumors and sequences complete exons of >50 genes to report single nucleotide variants (SNVs), fusions, amplifications, and indels with high sensitivity and ultra-high specificity (>99.9999%). The patient was diagnosed with invasive breast cancer at age 44 and treated with surgery and hormonal therapy. At age 61, she had axillary adenopathy and liver metastases. Treatment details are in Table 1.Results', ' ctDNA analysis was performed at the time of metastatic diagnosis and at 5 additional time points over the course of treatment. All samples revealed an ERBB2 exon 19 indel (p.Leu755_Glu757delinsSer), and multiple SNVs and gene amplifications. ERBB2 amplification was seen in 4 of 6 samples. Mutant allele fractions (Table 1) correlated with clinical response to treatment and progression.Conclusions', ' Analysis of ctDNA in this patient identified an ERBB2 exon 19 indel, which are present in 2-4% of non-small cell lung cancers but 1-2% in breast cancer. Treatment with anti-HER2 monoclonal antibody or dual anti-EGFR/ERBB2 tyrosine kinase inhibitor therapies may show clinical benefit. ctDNA analysis can detect emergence of actionable resistance mutations with the advantage of serial evaluation, allowing capture of inter- and intra-tumor heterogeneity and illustration of molecular progression and response.']",
        "Doc_id":"AACR_2016-172",
        "Doc_title":" Managing metastatic breast cancer via serial monitoring with circulating cell-free tumor DNA next generation sequencing testing",
        "_version_":1606189004621873152},
      {
        "Meeting_name":" CCN5 down regulates HER2/ neu expression in HER2 positive breast cancer cells",
        "Background":"['Breast cancers are broadly classified into four different subtypes which are Luminal A, Luminal B, Basal type and Her2 positive cancers. The cells in Her2 positive tumor lesions overexpress the tyrosine kinase receptor ErbB2 or Her2 which serve as the major oncoprotein and drives the unrestrained proliferation of the cells which is one of the major hallmarks of cancer. About 25% of the breast cancer overexpress Her2 (ErbB2) proto-oncogene resulting in aggressive tumor phenotype and is associated in poor prognosis in patients. Though Her2 targeted therapies are being used hugely in clinical practice, a significant fraction of the Her2 positive tumors develop mechanisms to evade the targeted therapies of Her2 inhibition. CCN5 or Wisp2 is a matricellular protein which is now considered as an anti-invasive gene. It has been already that established from multiple evidences that CCN5 protein inhibits progression of triple negative breast cancer. The goal of the study is to investigate if CCN5 can regulate Her2 in Her2 positive breast cancer. We have found that CCN5 treatment also negatively regulates expression and activity of Her2 receptor in Her2 overexpressed breast cancer cells. It has been indicated from Her2 promoter assays that Wisp2/CCN5 negatively regulates the expression of Her2 in a transcriptional level. Wisp2 /CCN5 treatment of Her2 overexpressed breast cancer cell lines, SKBR3 and Bt474, exerts a negative impact on the migration and proliferative properties of the cancer cells. Thus it can be concluded that our initial studies on effect of CCN5 on Her2 positive cells can pave the way for a novel approach of therapy to control Her2 overexpressed tumor cell growth.']",
        "Doc_id":"AACR_2015-134",
        "Doc_title":" CCN5 down regulates HER2/ neu expression in HER2 positive breast cancer cells",
        "_version_":1606189000341585921},
      {
        "Meeting_name":" Disparities in the prognostic significance of proliferation amongst different molecular subtypes in node-negative breast cancer.",
        "Background":"['Background', '  Proliferation has an important prognostic impact in breast cancer. We examined the importance of proliferation amongst different molecular subtypes (luminal, basal-like, erbB2-like) in 766 node-negative breast cancer patients without adjuvant systemic therapy.  Methods', '  Microarray based gene-expression data of three independent and previously published cohorts of node-negative breast cancer patients (Mainz, Rotterdam, TRANSBIG) were analysed. After unsupervised hierarchical cluster analysis co-regulated genes related to proliferation were identified. Then a metagene as a surrogate for all genes within the proliferation cluster was calculated. The patients were assigned to different molecular subtypes according to the gene-expression of estrogen receptor (ESR1) and erbB2 (ERBB2). Metastasis-free survival (MFS) was compared with the Log-rank test as well as univariate and multivariate Cox regression which accounted for traditional prognostic factors like age, tumor size, estrogen receptor, histological grade and erbB2.  Results', '  Patients with higher expression of the proliferation metagene showed worse MFS in the whole cohort of patients (HR 1.65, 95% CI 1.39-1.96, p<0.001). Using multivariate Cox regression, the proliferation metagene retained its independent prognostic significance (HR 1.58, 95% CI 1.16-2.27, p=0.004). Besides the proliferation metagene only tumor size (HR 1.79, 95% CI 1.18-2.72, p=0.007) showed an independent association with MFS. 521 patients (68%) belonged to the luminal subtype, 106 (14%) were erbB2-like, and 139 (18%) basal-like, respectively. Prognostic impact of IGKC was limited to the luminal subtype (HR 2.30, 95% CI 1.80-2.95, p<0.001). The proliferation metagene failed to show an association with survival both in erbB2-like (HR 0.95, 95% CI 0.50-1.78, p=0.868) as well as basal-like (HR 0.83, 95% CI 0.55-1.25, p=0.371) subtypes, respectively.  Conclusions', '  Proliferation plays a crucial and independent role in the whole cohort of node-negative patients. However, the prognostic significance of proliferation is confined to the luminal subtype and lost in basal-like and erbB2-like breast cancer, respectively.']",
        "Doc_id":"ASCO_80814-102",
        "Doc_title":" Disparities in the prognostic significance of proliferation amongst different molecular subtypes in node-negative breast cancer.",
        "_version_":1606188988519940096},
      {
        "Meeting_name":" Correlations of estrogen receptor (ER) related genomic transcription and ER gene expression with increasing AJCC stage of ER-positive breast cancer.",
        "Background":"['Background', ' Advanced stages of ER-positive breast cancer may have decreased tumor dependence on estrogen, possibly due to biological selection and/or progression. The sensitivity to endocrine therapy (SET) index measures transcriptional activity of the ER genomic pathway (165 ER-related genes). We investigated whether expression of genes for receptors ER (ESR1), progesterone receptor (PGR), or HER-2 (ERBB2), the SET index, or a housekeeper gene (GAPDH) vary by stage of ER-positive breast cancer. Methods', \" We evaluated gene expression profiles (Affymetrix U133 microarrays, Affymetrix, Santa Clara, CA) from 956 patients' clinical samples of ER-positive breast cancer, including 290 new samples profiled at MDACC and 666 samples from published datasets. Microarray data were uniformly normalized, log-transformed, and expression levels for single genes and the SET index were compared to pathologic AJCC stage (315 patients were stage I, 362 stage IIA, 151 stage IIB, 29 stage III, 27 stage IV at initial presentation, and 72 stage IV previously treated and/or at relapse) using a median ordered regression analysis (p < 0.05 was significant). Results\", ' SET index significantly decreased with advancing pathologic stage (p < 0.001), and PGR expression levels showed a similar, but lesser, effect (p = 0.014). However, expression levels of ESR1 and ERBB2 did not vary by stage. Overall, GAPDH gene expression increased with stage (p < 0.001), but that effect was only observed in stages III and IV. Expression of these genes was not significantly different between stage IV disease at initial presentation or at relapse. Conclusions', ' Expression levels of ESR1 and ERBB2 receptor genes did not vary, but ER-related genomic transcription (SET index and, to a lesser extent, PGR) declined significantly with increasing pathologic stage. This suggests that ER-positive breast cancer tends to have less transcriptional dependence on estrogen with increasing pathologic stage. The observed increase in expression of GAPDH in stages III and IV might reflect higher metabolic activity in advanced ER-positive breast cancer and deserves further study.']",
        "Doc_id":"ASCO_35155-65",
        "Doc_title":" Correlations of estrogen receptor (ER) related genomic transcription and ER gene expression with increasing AJCC stage of ER-positive breast cancer.",
        "_version_":1606189008913694721},
      {
        "Meeting_name":" Targeting ERBB2-induced, lysosome-mediated invasion",
        "Background":"['ErbB2 overexpression is strongly associated with invasive cancer with high recurrence and poor prognosis. Similarly, increased expression of lysosomal proteases, cysteine cathepsins, is observed in several cancers and correlates with enhanced angiogenesis, invasion and metastasis. We recently showed that ErbB2 level correlates positively with cysteine cathepsin B and L levels in primary breast cancer and that ErbB2 regulates the expression of cathepsins B and L leading to their increased activity in several ErbB2-positive breast cancer cell lines. The increased cysteine cathepsin activity is essential for the invasion of ErbB2 overexpressing breast cancer cells in 3-dimensional (3D) Matrigel cultures and is mediated by novel signaling network that involves TGFR, ERK2-MAPK, PAK4, PKC and CDC42bp kinases and two transcription factors, MZF1 and ETS1.With a pharmacological protein kinase inhibitor screen, using the ErbB2 inhibitor Lapatinib as positive control, we have now identified three inhibitors putatively targeting this novel ErbB2-induced signaling network. Our data shows that the treatment of ErbB2-positive, highly invasive breast or ovarian cancer cells with any of these inhibitors specifically reduces cysteine cathepsin expression, activity and invasion of these cancer cells in 3D Matrigel cultures. It also reverses lysosomal distribution from the invasion supporting pericellular position to less-invasive perinuclear position, where the lysosomal exocytosis and secretion of lysosome contents to extracellular space to assist extracellular matrix proteolysis becomes less likely. In this study we have identified novel inhibitors for ErbB2-induced invasion and discovered a novel, function for clinically used ErbB2 inhibitor Lapatinib in the regulation of lysosomal function and trafficking.']",
        "Doc_id":"AACR_2014-3149",
        "Doc_title":" Targeting ERBB2-induced, lysosome-mediated invasion",
        "_version_":1606188975475654656},
      {
        "Meeting_name":" Genomic analysis identifies drug targetable pathways and predicts immune infiltration in inflammatory breast cancer tumors",
        "Background":"['BackgroundInflammatory breast Cancer (IBC) is a rare aggressive breast cancer in which cancer cells block the lymph vessels in the skin of the breast. IBC tumors have a high rate of ERBB2 positivity and response to ERBB2 targeted therapies. Due to the rarity of this cancer, the molecular etiology of this disease is poorly understood.Materials & MethodsA 208 gene next-generation sequencing (NGS) panel was used to analyze 20 IBC patient tumor and matched normal samples. Tissues were stained for cell signaling proteins and immune-markers. Cell line studies were performed to understand the impact of genomic variants on therapeutic selection.ResultsCommon pathway alterations reoccur among IBC samples that influence genome stability, PI3K signaling, and ERBB signaling. NGS revealed alterations in both the ERBB/PI3K pathways, including', ' ERBB2 amplification, ERBB3 mutations, and activating PI3K mutations. Immunohistochemistry (IHC) staining for pS6 and pERBB3 identified ERBB/PI3K pathway activity in IBC samples. Cell line studies using siRNA and neutralizing antibodies demonstrate that mutant ERBB3 signaling contributes to IBC proliferation.IBC tumors with high levels of CD8+ immune infiltrate have a significantly higher somatic mutation rate than other IBC tumors. A proposed score (iScore) based on the somatic mutation rate and the average mutant allele frequency, showed greater correlation with the level of CD8+ immune infiltration. Furthermore, tumors with high CD8+ infiltrating lymphocytes were associated with a higher frequency of alterations in DNA mismatch repair (MMR) genes. IHC revealed high levels of the immune checkpoint signaling molecule PD-L1 in the inflammatory infiltrate of IBC tumors.ConclusionsThis study identifies a higher level of ERBB3 mutations than reported in other cancers and an important role for ERBB3 mutation in IBC. ERBB3 targeted therapies in combination with ERBB/PI3K drugs may be important for IBC treatment. Furthermore, high somatic mutations rates in a subset of IBC tumors harboring MMR mutations lead to greater levels of PD-L1+ immune infiltrates, which suggests a possible benefit from immunotherapies such as anti-PD-L1 antibodies. iScore, a more predictive value of immune infiltration in tumors, may be indicative of the level of neoantigen exposure to the immune system. The utility of the newly proposed iScore is currently being investigated as a method to predict immune cell infiltrates and immunotherapy response in other tumor types.']",
        "Doc_id":"AACR_2015-3887",
        "Doc_title":" Genomic analysis identifies drug targetable pathways and predicts immune infiltration in inflammatory breast cancer tumors",
        "_version_":1606188990693638144},
      {
        "Meeting_name":" The Survivin-targeting miR-542-3p overcomes erbB3 signaling-mediated chemo-resistance and enhances the antitumor activity of paclitaxel against erbB2-positive breast cancer.",
        "Background":"['Elevated expression of erbB3 interacts with erbB2 in breast cancer cells to confer chemo-resistance via induction of Survivin. However, the underlying mechanism of erbB3 signaling-induced upregulation of Survivin remains elusive. Ectopic expression or downregulation of erbB3 in erbB2-positive breast cancer cells did not alter Survivin mRNA levels and had no significant effect on Survivin protein stability. We thus hypothesize that the erbB3 signaling modulates certain miRNAs that target Survivin to influence its protein translation. Here we showed that overexpression of erbB3 decreased and specific knockdown of erbB3 enhanced expression of two Survivin-targeting miRNAs, miR-203 and miR-542-3p in breast cancer cells. While the specific inhibitor of either miR-203 or miR-542-3p clearly attenuated an anti-erbB3 antibody (Ab)-mediated reduction of Survivin, a more profound effect on Survivin expression was observed with inhibition of miR-542-3p than miR-203 inhibition. Consistently, miR-542-3p mimic was much more effective than miR-203 mimic not only to downregulate Survivin, but also to enhance paclitaxel-induced apoptosis in the otherwise paclitaxel-resistant breast cancer cells. Moreover, using a murine tumor xenografts model established from a human breast cancer cell line expressing both erbB2 and erbB3, we discovered that the combinations of miR-542-3p mimic and paclitaxel, as compared to either agent alone, significantly inhibited tumor growth in vivo. Collectively, these data demonstrate that the erbB3 signaling upregulates Survivin via inhibition of miR-203 and miR-542-3p in erbB2-positive breast cancer cells. Since miR-542-3p has three binding sites on the 3UTR of erbB3 mRNA, the miR-542-3p mimic serves as an excellent replacement therapeutic agent to downregulate Survivin, and thereby significantly enhances the antitumor activity of paclitaxel against erbB2-positive breast cancer.']",
        "Doc_id":"AACR_2017-4320",
        "Doc_title":" The Survivin-targeting miR-542-3p overcomes erbB3 signaling-mediated chemo-resistance and enhances the antitumor activity of paclitaxel against erbB2-positive breast cancer.",
        "_version_":1606189018579468288},
      {
        "Meeting_name":" Docosahexaenoic acid inhibits heat shock protein 90 complex and client proteins by reducing intracellular ATP levels in breast and lung cancer",
        "Background":"['A major contributor to carcinogenesis is the molecular chaperone heat shock protein 90 (Hsp90). Hsp90 regulates the proper folding and stabilization of several client proteins, including human epidermal growth factor receptor 2 (ErbB2) and hypoxia-inducible factor 1 (HIF-1). ErbB2 is a member of the epidermal growth factor receptor (EGFR) family of receptor-proteins, and is a clinical target for the treatment of metastatic cancer, while HIF-1 is often stabilized and overexpressed in several cancers. The ability for Hsp90 to become a mature complex and to properly fold client proteins is dependent on adenosine triphosphate (ATP) binding with the co-chaperone, p23. Specific Hsp90 inhibitors, like geldanamycin, target the Hsp90 ATP-binding site to prevent formation of the mature complex. Although supplementation with docosahexaenoic acid (DHA; C22', '6 n-3) has not been shown to specifically target the Hsp90 ATP-binding site, the current study demonstrates a similar effect by DHA causing a reduction in available intracellular ATP levels. DHA is the longest, most unsaturated omega-3 polyunsaturated fatty acid (PUFA) existing in biological membranes and has been shown to possess anti-cancer activity in several cancer models. Studies from our laboratory have shown that DHA enrichment can reduce cancer cell metabolism and intracellular ATP levels in both breast and lung cancer models. In this study, a novel mechanism for the ability of DHA to inhibit the Hsp90 chaperone complex is defined. In vitro analyses of BT-474 human breast ductal carcinoma, as well as the A549 human lung adenocarcinoma cell lines were used to determine the impact of DHA-induced decreases of intracellular ATP levels. We found that the reduction in ATP levels by DHA treatment resulted in significant decreases in the association of Hsp90 and p23 in both cell lines. The decreased association of the Hsp90-p23 complex led to decreased levels of ErbB2 and HIF-1 client proteins, suggesting that DHA can modify Hsp90 chaperone function and attenuate client protein levels. Additionally, similar results were found when employing 2-deoxyglucose (2-DG), a glycolytic inhibitor, which confirms that DHA and 2-DG can disrupt Hsp90 molecular chaperone function by decreasing cellular ATP levels. Consistent with these observations, when using a dose of DHA that did not significantly reduce intracellular ATP levels, no change in the Hsp90-p23 chaperone complex or protein levels of ErbB2 and HIF-1 were seen. These results demonstrate a potential use for dietary intervention to improve cancer therapy in tumors that overexpress Hsp90 client proteins.']",
        "Doc_id":"AACR_2014-483",
        "Doc_title":" Docosahexaenoic acid inhibits heat shock protein 90 complex and client proteins by reducing intracellular ATP levels in breast and lung cancer",
        "_version_":1606189007324053504},
      {
        "Meeting_name":" Functional genomics of HER2 and HER3 mutations and response to neratinib",
        "Background":"['Selective kinase inhibitors, such as erolotinib and lapatinib, and monoclonal antibodies, such as cetuximab, trastuzumab and pertuzumab, targeting EGFR and ERBB2 have elicited significant response rates in lung cancer patients harboring mutant EGFR alleles and breast cancer patients whose tumors harbor gene amplification of ERBB2. To date, only a small number of ERBB2 and ERBB3 mutations have been reported and biologically characterized. Moreover, the therapeutic impact of ERBB2 or ERBB3 mutant alleles and their value as an actionable target in patients has not been validated. While ERBB2 itself cannot bind ligand, it is a potent receptor that integrates growth signals via homo- or heterodimerization with other ERBB family members.Genomic alterations increase ERBB2 kinase activity by constitutively activating the kinase domain, enabling ligand-independent receptor activation, by promoting enhanced dimerization or other mechanisms that have yet to be elucidated. Although ERBB3 has limited inherent kinase activity and cannot homodimerize, ligand stimulation promotes dimerization with active kinases like ERBB2 and EGFR that can phosphorylate ERBB2 which then promotes transformation.Thus genomic alterations in ERBB3 may be a key means of promoting oncogenic signaling despite the protein lacking robust enzymatic activity. We performed an analysis of 100 large-scale next generation sequencing datasets newly generated by our group (bladder), our institution (MSKCC-IMPACT), or found in recently published repositories (The Cancer Genome Atlas (TCGA), Broad, Genentech, Sanger, etc) to characterize the distribution and spectrum of mutations in the ERBB2 and ERBB3 genes. Data generated suggests that ERBB2 and ERBB3 mutations are highly prevalent in bladder cancer (each 10%), and recurrent, but with less frequency (<5%), in stomach, breast, colon and lung cancers. Hotspots include mutation of S310F and a cluster of residues in the kinase domain in ERBB2 and the V104M mutation in ERBB3. Preliminary analysis of 300 tumors demonstrated that ERBB2 and ERBB3 mutations present in a typically in a mutually exclusive pattern suggesting that these may be driver events with overlapping biologic effects. Generation and expression of several of these ERBB2 and ERBB3 mutants induced receptor activation, cell transformation and tumor growth in isogenic cell line and xenograft models. Treatment with the dual EGFR/HER2 inhibitor, neratinib, in isogenic cell lines abrogated colony formation in soft agar and receptor activation and downstream signaling. We hope to correlate the in vitro potency of specific ERBB2 and ERBB3 mutations with drug response in patients on ongoing or future clinical trials of targeted ERBB therapies and determine the whether lineage, subclonality and co-altered genes, if present, predict for drug resistance.']",
        "Doc_id":"AACR_2015-1101",
        "Doc_title":" Functional genomics of HER2 and HER3 mutations and response to neratinib",
        "_version_":1606189038759313409},
      {
        "Meeting_name":" Clinicopathologic features as predictors of recurrence score among women with estrogen receptor-positive, lymph node-negative invasive breast cancer.",
        "Background":"['Background', ' The 21-gene molecular profile (Oncotype DX; Genomic Health, Redwood City, CA) estimates recurrence risk and aids clinical decision making for women with estrogen receptor (ER)-positive, lymph node (LN)-negative invasive breast cancer (IBC). Prior studies have identified clinicopathologic features associated with high recurrence score (RS); however, features predictive of low RS are not well understood. This study sought to identify clinicopathologic features that predict low RS. Methods', ' This study reviewed all cases of early stage IBC seen at the Vermont Cancer Center for which the 21-gene molecular profile was available. Cases were classified into risk groups based upon RS', ' low (RS < 19) and intermediate-to-high (RS  19). Nottingham grade, Nottingham score, nuclear grade, tubule score, mitotic index, ER, progesterone receptor (PR), and erbB2 expression were evaluated individually and with multivariate logistic regression for their ability to predict low RS. Results', \" A total of 93 cases of IBC with available molecular profile were identified between July 2006 and July 2009. Among individual predictors, only low Nottingham grade, low nuclear grade, and negative erbB2 predicted low RS with statistical significance by 2-tailed Fisher's exact test. Multivariate regression analysis identified low Nottingham score and high PR expression as significant predictors of low RS. Conclusions\", ' Low Nottingham grade, low nuclear grade, and negative erbB2 individually predict low RS among ER-positive, LN-negative IBCs. Clinicians may wish to consider these clinicopathologic features when evaluating patients for molecular profiling. Predictor']",
        "Doc_id":"ASCO_60033-100",
        "Doc_title":" Clinicopathologic features as predictors of recurrence score among women with estrogen receptor-positive, lymph node-negative invasive breast cancer.",
        "_version_":1606189020400844800},
      {
        "Meeting_name":" Phase II study of lapatinib in combination with vinorelbine in patients with ErbB2-amplified recurrent or metastatic breast cancer.",
        "Background":"['Background', '                                                                                                                                                                                                                                      There is a need for new  treatment options in ErbB2 amplified advanced  breast cancer.Limited efficacy and safety data has  been  reported  for a lapatinib (LAP) and vinorelbine (VNL) combination in this setting. This is a multicenter, phase II study of LAP in combination with VNL in women with ErbB2 positive metastatic or recurrent breast cancer who have received prior taxane and/or antracycline. Methods', '  Patients received 1250mg oral LAP continously  once daily and VNL 25 mg/sqm IV in the first 6 pts, and 20 mg/sqm IV on D1 and D8 every 3 week  after neutropenia was identified as a DLT. The primary endpoints  of the study are response rate and toxicity. Secondary endpoints  include progression free survival(PFS)  and duration of response. 29 pts were planned and enrolled. RECISTis used for response and NCI-CTCAE is used for adverse events  evaluation. We present here the combined results of both VNL doses (6 pts for 25 mg/m2 and 15 pts for 20 mg/m2). Median age of the pts was 60 years (range 33-75). Prior trastuzumab was used in 86% of the pts. Patients with brain metastases without symptoms were included. Results', '   Median number of prior chemotherapy regimens was  2 (range 1-4). Nineteen pts  were evaluable for response. Median follow up was  28,5 weeks(range 7,5-80,5) and 13 patients  progressed during this period. Five of 19 patients  (26%; 95% CI 9,15-51,2) had partial response and 8 patients (42%; 95% CI 20,25-66,50) had stable disease. The median PFS was 20 weeks (95% CI (12,14-27,86). 21 pts and 120 cycles were evaluated for toxicity. Median number of treatment cycles was 4(range, 2-18 cycles). Grade 3-4 neutropenia without fever in  13 patients(62%), grade 3-4 leukopenia in 4 pts (19%), grade 3 anemia in 1 pt (5%), febrile neutropenia in 1 pt (5%). The most common non-hematologic grade 3 adverse events were adinamia in 3(14%), stomatitis and diarrhea in 2 (10%), insomnia, motor neuropathy, anorexia,  abdominal pain, hepatotoxicity, constipation, infection and respiratory distress in1(5%) of  the pts.  Conclusions', '  The VNL and LAP combination at 1250mg  LAP continously oral  once  daily and VNL 20 mg/sqm dose is a tolerable alternative for pts with ErbB2 + metastatic breast  cancer.']",
        "Doc_id":"ASCO_77314-102",
        "Doc_title":" Phase II study of lapatinib in combination with vinorelbine in patients with ErbB2-amplified recurrent or metastatic breast cancer.",
        "_version_":1606188971530911744},
      {
        "Meeting_name":" miR-125b targets erythropoietin and its receptor and their expression correlates with metastatic potential and ERBB2/HER2 expression",
        "Background":"['Background', ' The microRNA 125b is a double-faced gene expression regulator described both as a tumor suppressor gene (in solid tumors) and an oncogene (in hematologic malignancies). In human breast cancer, it is one of the most down-regulated miRNAs and is able to modulate ERBB2/3 expression. Here, we investigated its targets in breast cancer cell lines after miRNA-mimic transfection. We examined the interactions of the validated targets with ERBB2 oncogene and the correlation of miR-125b expression with clinical variables.Methods', ' MiR-125b possible targets were identified after transfecting a miRNA-mimic in MCF7 cell line and analyzing gene expression modifications with Agilent microarrays and Sylamer bioinformatic tool. Erythropoietin (EPO) and its receptor (EPOR) were validated as targets of miR-125b by luciferase assay and their expression was assessed by RT-qPCR in 42 breast cancers and 13 normal samples. The molecular talk between EPOR and ERBB2 transcripts, through miR-125b, was explored transfecting MDA-MD-453 and MDA-MB-157 with ERBB2 RNA and using RT-qPCR.Results', ' We identified a panel of genes down-regulated after miR-125b transfection and putative targets of miR-125b. Among them, we validated erythropoietin (EPO) and its receptor (EPOR) - frequently overexpressed in breast cancer - as true targets of miR-125b. Moreover, we explored possible correlations with clinical variables and we found a down-regulation of miR-125b in metastatic breast cancers and a significant positive correlation between EPOR and ERBB2/HER2 levels, that are both targets of miR-125b and function as competing endogenous RNAs (ceRNAs).Conclusions', ' Taken together our results show a mechanism for EPO/EPOR and ERBB2 co-regulation in breast cancer and confirm the importance of miR-125b in controlling clinically-relevant cancer features.']",
        "Doc_id":"AACR_2014-4785",
        "Doc_title":" miR-125b targets erythropoietin and its receptor and their expression correlates with metastatic potential and ERBB2/HER2 expression",
        "_version_":1606189029383995392},
      {
        "Meeting_name":" Discovery of a new phospho-HER2+/FISH- molecular subtype of human breast cancer by functional pathway mapping.",
        "Background":"['Background', ' Effective treatment of breast cancer through the targeting of the HER2 protein in human breast cancer represents a major advance in oncology, yet the identification of responders has relied on non-quantitative methods (IHC) that measure the erbB2 protein or indirect genomic analysis (FISH) of the erbB2 gene that cannot predict protein pathway activation status. We utilized a new quantitative protein microarray assay to measure total and phosphorylated HER2 in the context of broad-scale EGFR signal pathway mapping in order to generate a new molecular characterization scheme for human breast cancer. Methods', ' Pure tumor epithelium from 149 frozen pre-treatment human breast cancer tissue specimens (from the I-SPY TRIAL', ' CALGB 150007/150012, ACRIN 6657) were procured via Laser Capture Microdissection and protein pathway mapping was performed using Reverse Phase Protein Microarrays (RPMA) whereby the activation of 40 key signaling proteins was quantitatively measured at once. Results', ' While phospho-HER2 and total HER2 as measured by RPMA had excellent concordance with FISH (95%) and IHC (94%), of the 63 cases where both clinical FISH and IHC status of c-erbB2 were known, we discovered that 5/45 (11%) of the FISH-/IHC- cases had phosphorylated HER2 levels as high or higher than the FISH+/IHC positive patients. These results were confirmed and validated by independent analysis with quantitative Western Blot using a separate biopsy specimen from the same patients. Conclusions', ' A new molecular phenotype of human breast cancer has been identified whereby total levels of HER2 are low yet levels of the phosphorlyated receptor are very high. This molecular phenotype is not detectable by FISH analysis nor by measurement of the total HER2 protein itself. Given the central importance of phosphorylation on effective signal transduction of the EGFR family, we are planning to determine the clinical significance of this finding by retrospective analysis of banked material with outcome, and a prospective clinical trial in I-SPY 2. Support', ' ACRIN U01 CA079778; CALGB CA31964, CA33601; NCI SPORE CA58207.']",
        "Doc_id":"ASCO_32961-65",
        "Doc_title":" Discovery of a new phospho-HER2+/FISH- molecular subtype of human breast cancer by functional pathway mapping.",
        "_version_":1606188978441027584},
      {
        "Meeting_name":" Prognostic value of gene expression of p63 by microarray analysis in estrogen receptor positive and negative breast cancer.",
        "Background":"['Background', ' The protein 63 (p63) represents a member of the p53 family (p53/p63/p73) located on chromosome 3q27. This gene family seems to play an important role in carcinogenesis and its members may act as oncogenes or tumor suppressor genes. P63 is overexpressed in many different tumors like head and neck cancer, lung cancers, uterine tumors and breast cancer, and has been associated with poor prognosis in some studies. P63 was found to be overexpressed in a subset of highly aggressive breast cancers that represent a basal and myoepithelial phenotype and have a poor clinical outcome. This protein seems to be a specific myoepithelial cell marker in normal breast tissue and might represent a prognostic factor in breast cancer. Methods', ' Large scale analysis was performed using Affymetrix microarray data from n=1581 breast cancer patients to evaluate p63 expression. Results', \" P63 expression showed a strong correlation with patient's age (2-test, p < 0.001), tumor size (p < 0.003), proliferation rate (p < 0.001), Topo2 expression (p = 0.001) and estrogen receptor expression (p = 0.017). Survival analysis of all patients with available follow up data (n = 1263) showed a significant difference due to high and low p63 expression (log rank p < 0.001). Patients with a low p63 expression had the worst prognosis. In univariate Cox regression analysis p63 showed a hazard ratio (HR) of 1.61 (95% CI 1.31-2.00, p < 0.001) for disease free survival. This prognostic impact remained significant when samples were stratified by estrogen receptor status. High expression of p63 was significantly associated with longer OS in both ER negative (n = 334, log rank p = 0.022) and ER positive (n = 929, log rank p < 0,001) breast cancer. The prognostic impact of p63 expression was independent of Ki67 expression (p = 0.011 and p = 0.001 for high and low Ki67, respectively). Moreover a worse prognosis of low p63 expressing tumors was found in both subgroups of ErbB2 positive tumors (p < 0.001) and ErbB2 negative tumors (p < 0.001). Conclusions\", ' P63 expression is a prognostic factor in both ER positive and negative breast cancer and could be helpful for risk assessment in breast cancer patients.']",
        "Doc_id":"ASCO_30973-65",
        "Doc_title":" Prognostic value of gene expression of p63 by microarray analysis in estrogen receptor positive and negative breast cancer.",
        "_version_":1606188982474899456},
      {
        "Meeting_name":" Targeted therapies to ERBB receptors downregulate expression of PD-L1",
        "Background":"['Background', ' Inflammatory breast cancer (IBC) is the most aggressive and lethal form of primary breast cancer. Inflammatory signaling pathways are active in IBC, but the function of the immune response remains elusive. ErbB receptors play a role in IBC. ERBB2 is amplified in 50% of IBCs, and ERBB3 is also mutated in IBC. Currently, Lapatinib, a dual ErbB inhibitor, is used in IBC patients with ERBB2 amplification.']",
        "Doc_id":"AACR_2017-2636",
        "Doc_title":" Targeted therapies to ERBB receptors downregulate expression of PD-L1",
        "_version_":1606188996858216448},
      {
        "Meeting_name":" Use of the ErbB2/CEP17 ratio to predict prognosis and response to trastuzumab-based therapy in the metastatic breast cancer setting.",
        "Background":"['Background', ' Despite patient selection based upon detection of Her-2/neu overexpression by immunohistochemistry (IHC) and/or presence of amplification of the Her-2/neu-encoding erbB2 oncogene measured by FISH, response to trastuzumab-based therapy is only achieved in a subset of patients with Her-2/neu overexpressing breast carcinomas. Exact quantification of erbB2 copy-number relative to chromosome 17 (CEP17) (ErbB2/CEP17 ratio \"R\") probably adds further important predictive information. Methods', ' Clinical data of 137 patients receiving trastuzumab based treatment for Her-2/neu overexpressing (IHC) metastatic breast cancer were analysed. ErbB2/CEP17 ratio (R) was determined by quantitative FISH analysis in original tumor tissue using Vysis PathVysion DNA-based FISH technology. Results', ' ErbB2/CEP17 (R) provided additional predictive value for progression free survival (PFS) and time to first metastasis (TTM), but not for overall survival (OS) (all from start of trastuzumab containing treatment). The following cutoffs of Her-2/neu were identified', ' group A', ' 0-2.2 R (TTM', ' 49.8; OS', ' 6.7; PFS', ' 6.2); group B', ' 2.2- 6 R (TTM', ' 26.2; OS', ' 5.3; PFS', ' 9.3); group C', ' >6 CN (TTM', ' 20.1; OS', ' 3.9; PFS', ' 13.7) Kaplan-Maier analysis showed significant longer TTM for group A (p<0.01 vs. B/C), significant longer PFS for group C (p<0.01 vs. A/B). Significant differences in complete response (B/C', ' 16.9% vs C', '44.4%), partial response (B/C', ' 20.2% vs. C', ' 33.3%) and progressive disease (B/C', ' 27% vs. 11.1%) were noted. No significant difference in overall survival between the groups was seen. Conclusions', ' ErbB/CEP17 R provides important prognostic information and, in metastatic patients, allows one to better predict response to trastuzumab-based treatment than the widely used binary classification of ErbB2 amplification that is based on a cut-off at a copy number of >2.2.']",
        "Doc_id":"ASCO_35073-65",
        "Doc_title":" Use of the ErbB2/CEP17 ratio to predict prognosis and response to trastuzumab-based therapy in the metastatic breast cancer setting.",
        "_version_":1606189040465346560},
      {
        "Meeting_name":" Use of the FoundationOne next-generation sequencing (NGS) assay to detect actionable alterations leading to clinical benefit of targeted therapies for relapsed and refractory breast cancer.",
        "Background":"['Background', '  Genomically-informed cancer therapy linking therapeutics targeting the molecular alterations driving the malignancy has the potential to transform the care of patients with metastatic breast cancer (MBC).  Methods', ' DNA was isolated from 4 FFPE sections cut at 10 microns from 177 consecutive MBC that had relapsed after surgery, conventional hormonal/chemo and anti-HER2 targeted therapies received by our CLIA lab (Foundation Medicine). DNA sequencing was performed for 3,320 exons of 182 cancer-related genes to average depth of 1017X. Actionable Genomic alterations (GA) were defined as those linked to targeted anti-cancer therapies approved or being evaluated in active registered clinical trials.  Results', '  Genomic profiles were generated from 169/177 (95%) BCs identifying 565 GA, averaging 3.34 GAs per tumor (range 0 to 10). 152 (90%) tumors harbored an actionable alteration mean 1.88 per tumor (range 0 to 6). In 124 (73%) tumors, 1.0 actionable GA was detected that would be missed by current hotspot assays. Notable GA involved PIK3CA (37%), ERBB2 (14%), FGFR1/2 (14%), PTEN (10%), MDM2 (7%), CCND1/CCNE1/CDK4 (7%), BRCA1 and BRCA2 (6% each) and ESR1 and EGFR (3% each). Of 23 ERBB2 GA, 74% were amplifications and 26% were mutation/gene fusion. The frequency of ERBB2 mutation/fusion was significantly enriched in CDH1 mutated ILC (~9% of total BC) with a frequency of 19.0% (4/21) compared to other histological types of  BCs 1.4% (2/148) [p=0.002]. Significant clinical efficacy included patients with HER2 IHC/FISH negative tumors featuring HER2 and EGFR activating mutations benefitting from lapatinib/trastuzumab and erlotinib respectively.  Conclusions', '   Comprehensive genomic profiling with a NGS assay identified actionable GAs in the majority of MBC patients including ERBB2 and EGFR mutations that initiated use of targeted therapies resulting in significant clinical benefit. These data provide a framework for the GAs expected in advanced BC and should facilitate the implementation of molecularly targeted trials supporting the efforts for a modern approach to precision medicine for the disease.']",
        "Doc_id":"ASCO_110129-132",
        "Doc_title":" Use of the FoundationOne next-generation sequencing (NGS) assay to detect actionable alterations leading to clinical benefit of targeted therapies for relapsed and refractory breast cancer.",
        "_version_":1606189033130557440},
      {
        "Meeting_name":" Detection, frequency and actionability of recurrent copy number gains detected by non-invasive liquid biopsy of 3,942 lung and breast cancer samples.",
        "Background":"['Background', ' Circulating tumor DNA (ctDNA) testing must include detection of single nucleotide variants (SNVs), indels, fusions, and copy number amplifications (CNAs) to identify all NCCN-recommended genomic targets. We examined CNA landscape in a large clinical cohort of breast and lung cancer ctDNA samples analyzed with Guardant360 (G360) test, classifying recurrent gene-level copy number changes across distinct oncogenic pathways and disease subtypes. Methods', ' We developed an improved CNA detection pipeline and evaluated its analytical and clinical performance on a set of cell-line spike-ins with known amplifications and 72 clinical plasma samples from patients with stage IV breast cancer with known ERBB2 amplification/overexpression. We then examined 1,935 lung adenocarcinoma and 2,007 breast carcinoma clinical cases', ' CNA patterns in samples with and without known driver mutations were compared using Fishers exact test to identify candidate driver amplification events. Results', ' Analytical sensitivity, specificity, and precision of the new CNA pipeline improved significantly - average coefficient of variation (CV) of copy number estimates across 18 genes on the panel was 1.2% for spike-in replicates, all spike-ins and copy number neutral samples were detected correctly, and signal-to-noise ratio increased 4.3-fold. We observed high concordance between tissue-verified amplification events in breast carcinoma subset when the mutant allele fraction of the driver mutation exceeded 0.5%. In the lung adenocarcinoma cohort, CNA-driver mutations were identified in ~7% of 1,935 samples, excluding cases known functional driver events. Focal amplification events in MET, CCND1, and ERBB2 were enriched in samples lacking other driver oncogene mutations (p-value < 0.001). Conclusions', ' Copy number variation is an important mechanism of oncogene activation in lung and breast cancers. Highly accurate quantification of copy number state in ctDNA allows for clinically meaningful identification of amplified therapeutic targets with otherwise wildtype DNA sequence.']",
        "Doc_id":"ASCO_171421-176",
        "Doc_title":" Detection, frequency and actionability of recurrent copy number gains detected by non-invasive liquid biopsy of 3,942 lung and breast cancer samples.",
        "_version_":1606188980808712192},
      {
        "Meeting_name":" Targeting Mek-Erk pathway abrogates hypoxia-mediated lapatinib resistance in ErbB2-positive breast cancer cells",
        "Background":"['Overexpression/amplification of the tyrosine kinase ErbB2 is often observed in breast cancers. ErbB2 expression activates EGFR signaling pathway promoting tumorigenesis. Breast cancer ErbB2-positive patients are treated with lapatinib, a dual EGFR/ERBB2 inhibitor. Despite lapatinib clinical efficacy, acquired resistance has been reported and its mechanism is poorly understood. Another factor that is associated with mammary tumors is hypoxia. Hypoxia stabilizes hypoxia inducible factor 1 (HIF-1), a transcription factor that regulates cell growth, proliferation and survival. As a result, hypoxic tumors are often chemoresistant.Here, we show that hypoxia decreases lapatinib-mediated growth inhibition and apoptosis in three-dimensional cultures. In agreement with this data, hypoxia also promotes activation of signaling pathways downstream from ErbB2/EGFR including AKT and ERK in the presence of lapatinib. This protective effect depends on HIF-1 and can be abrogated by HIF-1 RNAi. Moreover stable overexpression HIF-1 in ErbB2-expressing cells under normoxic conditions is sufficient to rescue cell proliferation and survival and maintain ERK and AKT signaling in the presence of lapatinib. We also show that activation of ERK signaling is required for hypoxia-mediated lapatinib resistance and inhibition of MEK (a kinase upstream of Erk) reverses hypoxia protective effect on ErbB2-expressing cells. One potential mechanism of how hypoxia/HIF-1 may lead to activation of ERK pathway is via regulation of dual-specificity phosphatase 2 (DUSP2). DUSP2 is a negative regulator of ERK pathway. Here we demonstrate that cells exposed to hypoxia have decreased levels of DUSP2 and it correlate with increased activation of Erk signaling. Moreover, reducing DUSP2 expression alone in ErbB2-positive breast cancer cells is sufficient to reduce lapatinib-mediated effects. And DUSP2 overexpression abrogates hypoxia-mediated protective effect on ErbB2-expressing cells treated with lapatinib.All these data suggests that targeting MEK-Erk signaling pathway may reverse hypoxia mediated lapatinib resistance and might be a viable option for lapatinib resistant ErbB2-posive tumors. Indeed, a combination of lapatinib and an FDA approved MEK inhibitor trametinib abrogates hypoxia protective effect on cell growth inhibition and apoptosis in three dimensional (3D) cultures. Thus targeting MEK/ERK pathway in hypoxic breast cancer may improve an anti-ErbB2 therapy in breast cancer.']",
        "Doc_id":"AACR_2015-716",
        "Doc_title":" Targeting Mek-Erk pathway abrogates hypoxia-mediated lapatinib resistance in ErbB2-positive breast cancer cells",
        "_version_":1606189013405794304},
      {
        "Meeting_name":" Frequent and subtype-related genetic mutational signature suggesting the involvement of specific signaling pathway.",
        "Background":"['Background', ' Studies with expression microarray profiling have enabled the classification of beast cancers into four types', ' luminal A, luminal B, ERBB2 + and basal-like. Little is known about whether there exist an \"mutational profile\" characteristic of each tumour and whether there is any correlation with the classification of luminal A, B, ERBB2+ and basal-like, and the correlation with clinical outcome. Methods', ' In an attempt to have an insight into the involvement of frequently mutated genes in different subtype of breast cancer, we analysed 125 invasive breast tumours which were classed on the basis of immunostaining (IHC) and FISH as Luminal (ER+ and HER2-), ERBB2 + and triple-negative (as a surrogate for basal like). Search for mutations in 5 genes frequently mutated in human cancers', ' TP53, PIK3CA, CDH1, PTEN and KRAS using direct sequencing was conducted. Results', ' Mutations were detected in a total of 80 samples (64%), among which 71 (57%) carried single-gene mutation. Nine tumors harbored more than 2 mutations involving different genes. We found that mutations were not randomly distributed in different subtypes. High frequent mutations of p53 were detected in ERBB2+ and triple-negative tumors (65% and 73%, respectively). On the other hand PIK3CA mutations were prevalent in the luminal subtype. It is also interesting to note that, contrary to previously reported in the literature, the p53 mutations found in ERBB2+ and triple-negative tumors were predominantly framshift and nonsense mutation leading to the disruption of protein synthesis. Conclusions', ' Our data clearly demonstrated that genetic alterations play an important role in breast cancer genesis. The fact that the majority of the tumors carried mutations in one single gene suggested the involvement of specific signaling pathways in each tumor; which could be of importance as to the choice for targeted therapy. The study is still ongoing, especially on the correlation of mutation data to clinical outcome.']",
        "Doc_id":"ASCO_52873-74",
        "Doc_title":" Frequent and subtype-related genetic mutational signature suggesting the involvement of specific signaling pathway.",
        "_version_":1606189015694835712},
      {
        "Meeting_name":" Neratinib in combination with trastuzumab for the treatment of advanced breast cancer",
        "Background":"['Background', ' Neratinib (HKI-272) is an orally administered irreversible pan-ErbB receptor tyrosine kinase inhibitor. In an ongoing phase II study, the preliminary objective response rate was 26% in patients with ErbB2+ advanced breast cancer with prior trastuzumab therapy. This study assessed the safety and preliminary efficacy of the combination of neratinib plus trastuzumab. Methods', ' Patients with advanced ErbB2+ breast cancer that progressed following trastuzumab therapy were enrolled. The primary endpoint was 16-week progression free survival rate (PFS). In part 1 (dose escalation), patients received neratinib 160 mg or 240 mg daily plus trastuzumab 4 mg/kg IV loading dose then 2 mg/kg weekly. In part 2, patients received weekly trastuzumab with neratinib 240 mg daily. Timed blood samples were collected for PK analyses. PK analysis is ongoing. Results', ' 45 patients (part 1 n = 8; part 2 n = 37) were enrolled (mean age 52 yr); 9 are active. In part 1, cohorts 1 and 2 were fully enrolled with 4 patients each. No dose limiting toxicities were observed. Most common AEs, any grade, were diarrhea (91%), nausea (51%), anorexia (40%), vomiting (38%), and asthenia (27%). Grade 3/4 AEs were diarrhea (13%), nausea (4%), vomiting (4%). Two patients receiving neratinib 240 mg reported AEs leading to withdrawal. No AEs of congestive heart failure and no significant drops of left ventricular ejection fraction were reported. Among 33 patients evaluable for efficacy, objective response rate was 27% (95% CI, 13% - 46%); 16-week PFS rate (for part 2) 47% (95% CI, 29% - 63%); median PFS was 19 weeks (95% CI 15 - 32 weeks). Conclusions', ' Neratinib plus trastuzumab was well tolerated with no significant or unexpected toxicities, and demonstrated clinical activity.']",
        "Doc_id":"ASCO_34411-65",
        "Doc_title":" Neratinib in combination with trastuzumab for the treatment of advanced breast cancer",
        "_version_":1606188998849462272},
      {
        "Meeting_name":" Combining multigene profiling of molecular subtypes with the 70-gene profile for classification of breast cancer.",
        "Background":"['Background', ' Classification of breast cancers into molecular subtypes may be important for accurate selection of therapy for patients. Herein we report a multigene profile for classification of breast cancer into molecular subtypes. The profile separates tumors into hormone receptor (HR)+/luminal-like, HER2+/ERBB2-like, and triple negative/basal-like subclasses. Methods', ' A multi-gene profile was developed based on a series of 200 tumor samples of known ER, PR and HER2 receptor status (concordant IHC and gene expression result) hybridized on 44k microarrays. The profile classifies 96% concordant to the molecular subtypes named luminal-, ERBB2- or basal-type as published by Perou et al (Perou et al, Nature, 2000; Fan et al, NEJM, 2005). The profile was validated using 469 independent samples as well as on two publically available gene expression datasets (n=251 and n=159). Results', ' The profile classified 66% (712) as luminal-like, 18% (194) ERBB2-like, and 16% (173) as basal-like. As compared to single-marker readout for the presence of ER, PR and HER2, 13% of the samples that were scored positive for presence of ER/PR did not express a luminal-like gene profile. Samples with a ERBB2-like or basal-like gene profile showed equally poor 5-year survival rates of ~65%. However, the ERBB2-like subset of MammaPrint low risk patients (15%) showed an 89% (95%CI, 71-100) survival rate without trastuzumab treatment. When the luminal-like subtype was separated into \"high-\" and \"low-risk\" by MammaPrint the survival rate was 56% (95%CI, 46-68) for high-risk luminal-like samples and 94% (95%CI, 90-99) for low-risk samples. Conclusions', ' The developed multigene profile can classify breast tumors into luminal-, ERBB2- and basal-like subgroups. By combining this molecular subtyping with MammaPrint risk-classification specific groups of patients can be recognized that that are at high risk of recurrence. The low risk patients within the luminal- and ERBB2-like subclasses have a very low risk of recurrence. Implementation of this knowledge can improve the clinical management of breast cancer patients.']",
        "Doc_id":"ASCO_34987-65",
        "Doc_title":" Combining multigene profiling of molecular subtypes with the 70-gene profile for classification of breast cancer.",
        "_version_":1606188970480238592},
      {
        "Meeting_name":" Identification of genes with clonal mutations for the tumorigenesis of breast cancer subtypes.",
        "Background":"['Background', ' Current analyses on somatic mutations mainly involve counting samples as either carriers or non-carriers. Such a binary approach misses to take into account the fraction of tumor cells that carry a mutation, which is a significant measure of the influence of a mutation on the overall phenotype, such as gene expressions, subtype and pathway activity. Methods', ' In this study, we re-analyzed the 72,084 non-synonymous somatic mutation in 16,164 genes of 817 TCGA breast cancer samples (HER2+', ' 65, Luminal A', ' 415, Luminal B', ' 176, Basal', ' 136 and Normal-like', ' 25) using variant allele frequency (VAF) adjusted by sample purity derived from multiple methods. We obtained a gene-based VAF by choosing the maximum VAF among all mutations found in each gene for each sample. For each breast cancer subtype, we filtered for top 100 genes with highest number of mutation carriers and then ranked them by decreasing average VAF across all samples. We assume genes with higher average VAF are more likely to harbor clonal mutations in early tumor progression. We further evaluated the Pearson correlation between VAF of genes having at least ten mutation carriers and the expression levels of ESR1, PGR and ERBB2 in Luminal A subtype. Results', ' The top two genes with highest VAF for each of the four subtypes are as follows', ' (a) HER2+', ' ERBB2 (VAF = 0.39  0.21, n = 4), KAT6A (0.31  0.09, 4), (b) Luminal A', ' CTCF (0.41  0.19, 13), MAP2K4 (0.37  0.14, 24), (c) Luminal B', ' MAP2K4 (0.46  0.11, 5), TP53 (0.46  0.17, 64), and (d) Basal', ' SCN10A (0.46  0.29, 5), MYH9 (0.43  0.16, 5). The strongest correlations for Luminal A are', ' (i) SPEN (corr. = 0.85, n= 14), KMT2C (0.73, 24) and DMD (0.73, 11) with ESR1, (ii) DMD (0.69, 11) and NBL1 (0.67, 10) with PGR, and (iii) TBX3 (-0.51, 12) and MUC12 (0.47, 14) with ERBB2. Conclusions', ' While carrier count is effective for identifying genes prone to mutations, average VAF opens another perspective for uncovering genes that tend to harbor clonal mutations. Our work shows the potential of VAF analysis for identifying driver genes, understanding tumor progression and evaluating the impact of a mutation on a patient. As future work, we may improve the VAF estimates by adjusting for copy number variations and weight each variant by pathogenicity.']",
        "Doc_id":"ASCO_193808-199",
        "Doc_title":" Identification of genes with clonal mutations for the tumorigenesis of breast cancer subtypes.",
        "_version_":1606189006001799168},
      {
        "Meeting_name":" Demographic features and prognostic profiles of breast cancer patients presenting with nipple discharge in Chinese population.",
        "Background":"['Background', ' Breast cancer patients with nipple discharge (ND) may constitute a distinct clinical entity compared to those without ND, which has not been well elucidated in previous reports. We sought to analyze the demographic features and prognostic profiles of breast cancer patients presenting with nipple discharge in Chinese population. Methods', ' A total of 3234 patients, categorized as ND (2.47%) and non-nipple discharge (NND; 97.53%) according to different initial signs, were retrospectively analyzed. Survival curves were performed with Kaplan-Meier method and annual recurrence hazard was estimated by hazard function. Results', ' ND group tended to have smaller tumors and less axillary lymph node (ALN) involvement than NND group (P < 0.05). In the univariate analysis, we found significantly different recurrence-free survivals (RFS) between subgroups (P = 0.0182), with the rate of 77.78% for ND group and 72.46% for the other at the 11th year respectively. In Cox proportional hazards regression analysis, we found that tumor size (P < 0.001), ALN status (P < 0.001) were independent prognostic factors for RFS. To further evaluate whether prognostic effect of ND status remained unabated over time, the test for lack of proportionality was performed. However, it was statistically significant (global test, P = 0.039), which hinted at a demand for the employment of Cox non-proportional hazards regression in this analysis. In time dependent Cox model, ND status (P = 0.0495) as well as ERBB2 status (P = 0.017), tumor size (P < 0.001), ALN status (P < 0.001) were independent prognostic factors when ND and ERBB2 status were taken as time-varying covariates. Annual hazard rates for recurrence remained lower on ND group until approximately 4.5 years after surgery, while the situation was just the opposite thereafter. Conclusions', ' Our findings suggested that demographic features and prognostic profiles were quite different between breast cancers presenting with and without ND in Chinese population, which may indirectly uncover distinct biological behaviors and potentially enlighten novel therapeutic approaches for patients with different initial signs.']",
        "Doc_id":"ASCO_33687-65",
        "Doc_title":" Demographic features and prognostic profiles of breast cancer patients presenting with nipple discharge in Chinese population.",
        "_version_":1606189040638361600},
      {
        "Meeting_name":" Tumor profiling of 1189 geriatric breast tumors.",
        "Background":"['Background', '  Breast cancer (BC) is a disease of aging and the number of geriatric patients is rising in the US. However, this group of patients is often excluded from clinical trials and under-represented in biomarker literature, complicating treatment selection strategies. Methods', '  BC tumors referred to Caris Life Sciences (Phoenix, AZ) between 2009 and 2015 were tested with a combination of immunohistochemistry (IHC), fluorescent/chromogenic in-situ hybridization (ISH) and sequencing (Next-generation and Sanger). De-identified biomarker data were analyzed. Results', '  A total of 1189 tumors collected from BC patients (M = 21/F = 1168) aged  70 (range', ' 70-97, average 75.6) were analyzed (breast biopsy n = 512; metastatic site n = 677). Of the 1088 tumors with available IHCs of ER, PR and IHC and/or ISH of HER2, 613 (56%) were HR+/HER2-, 72 (7%) were HR+/HER2+, 346 (32%) were TNBC and 57 (5%) were HR-/HER2+. Overall, 39 of 47 genes sequenced carried mutations with frequencies ranging from 0.2% to 37%. Highest mutation rates were seen in PIK3CA (37%), TP53 (37%), BRCA2 (12%), PTEN (5.8%), AKT1 (4.2%), cMET (3.9%), ERBB2 (3.5%), BRCA1 (3.3%) and ATM (3.2%). Among 13 patients with ERBB2 mutation, 3 had it amplified. PD-L1 expression on tumor cells was seen in 13% and PD-1 expression on tumor-infiltrating lymphocytes in 46%, with TNBC subtype showing the highest expression', ' 20% and 60%, respectively. In addition, TOPO1, TLE3, AR, TOP2A, SPARC were overexpressed in 61%, 58%, 55%, 51%, 37% of tumors, respectively, suggesting potential sensitivity to irinotecan, taxanes, anthracyclines and nab-paclitaxel. TS, RRM1 and ERCC1 were under-expressed in 69%, 69% and 53%, respectively, suggesting potential sensitivity to fluoropyrimidines, gemcitabine and platinums. A comparison with 7531 tumors from patients younger than 70, as well as description of abnormalities per molecular subtype of BC will be presented. Conclusions', '  Using multiple testing technologies, potentially targetable biomarker aberrations were identified in a large cohort of geriatric tumors. Our study provides key elements for the design of clinical trials focusing on geriatric patient population.']",
        "Doc_id":"ASCO_155183-163",
        "Doc_title":" Tumor profiling of 1189 geriatric breast tumors.",
        "_version_":1606189000398209024},
      {
        "Meeting_name":" Regulation of PAX2 expression/activity by hypoxia and EGF in breast cancer cells",
        "Background":"['Breast cancer is the most common cancer in women and is associated with the highest mortality rate after lung cancer. The leading cause of deaths associated with this cancer is metastasis, but cellular and molecular mechanisms controlling the metastatic ability of breast cancer cells are only partially elucidated. There is direct and indirect evidence suggesting that PAX2, a transcription factor preferentially activated in breast cancer cells of the luminal subtype, could reduce the invasive and metastatic ability of these cells, by downregulating the expression of ERBB2. It is thus primordial to understand the mechanisms regulating the expression and activity of PAX2 in breast cancer cells. Specifically, because hypoxic conditions prevailing in the center of solid primary tumours are known to regulate the expression of many genes controlling invasion and metastasis, we are investigating the impact of hypoxia-mimicking agent cobalt chloride (CoCl2) on PAX2 expression in breast cancer cells. Similarly, because EGF growth factor regulates the expression and/or activity of many genes controlling invasion and metastasis, we are determining the impact of EGF exposure on PAX2 activation and/or gene expression in ER+ MCF-7 cell line. The identification of factors and mechanisms regulating the expression and activity of PAX2 in breast cancer cells will help understand the biology of this emerging factor in breast cancer cells and may provide multiple strategies to control invasion and metastasis of these cells.']",
        "Doc_id":"AACR_2012-3067",
        "Doc_title":" Regulation of PAX2 expression/activity by hypoxia and EGF in breast cancer cells",
        "_version_":1606189042052890624},
      {
        "Meeting_name":" Circulating tumor DNA (ctDNA) as a molecular monitoring tool in metastatic breast cancer (MBC).",
        "Background":"['Background', '  MBC is an incurable disease with complex molecular features including somatic mutations that evolve in relation to genomic instability and selective treatment pressure. Circulating DNA fragments carrying tumor-specific sequence alterations (ctDNA) are found in blood and offer the possibility of longitudinal non-invasive molecular monitoring of the disease by detecting actionable mutations.  Methods', '  This is a prospective evaluation of 18 patients with locally advanced or metastatic breast cancer who failed standard therapies and had plasma analyzed for ctDNA detection. Selection criteria', ' progression of disease after standard therapies, need to detect novel molecular abnormalities for possible therapeutic targeting, or confirmation of genomic abnormalities already demonstrated in tissue analysis. Guardant Health performed the plasma analysis; first ctDNA was isolated from plasma using a Qiagen circulating nucleic acid kit, then a panel of 54 gene mutations associated with solid tumors as reported in the COSMIC database were sequenced using single-molecule digital sequencing technology.  Results', '  89% of patients had metastatic disease; 55% of patients were ER+/HER2-, 6% ER+/HER2+, 22% ER-/HER2+,  17% ER-/HER2-, and 78% had IBC. All patients with MBC had ctDNA alterations. The most common mutations', ' TP53 (44%), PIK3CA (44%), ALK (39%), ERBB2 (33%), and EGFR(28%).  Seven patients also had NGS analysis of tissue biopsy and 71% of these patients demonstrated having at least one concordant mutation. HER2 targeted therapy was continued in 3 patients with HER2+ disease after ctDNA confirmed ERBB2 alteration or amplification.  Moreover, HER2 targeted therapy was initiated on two HER-2 negative patients that had ERBB2 mutations in ctDNA.  Two patients were initiated on everolimus (Afinitor) combinations prior to ctDNA testing, had therapeutic benefit and ctDNA revealed alternations in PIK3CA.  Conclusions', '  This is a sensitive test, 100% of patients with MBC had ctDNA alterations. ctDNA offers the possibility of non-invasive genomic analysis of MBC, providing tailored information on mutation status, new molecular targets for therapeutic interventions and allowing molecular monitoring of disease.']",
        "Doc_id":"ASCO_130854-144",
        "Doc_title":" Circulating tumor DNA (ctDNA) as a molecular monitoring tool in metastatic breast cancer (MBC).",
        "_version_":1606188982440296448},
      {
        "Meeting_name":" Identification of patients at high risk of recurrent disease development by detection of HER2-positive disseminated tumor cells in bone marrow of patients with HER2-negative tumors.",
        "Background":"['Background', '  A subpopulation of patients with HER2-negative tumors benefit from HER2 therapy.  HER2 expression can be discordant between primary tumors and metastases.  We have examined the bone marrow (BM) of early stage breast cancer patients for HER2-expression by disseminated tumor cells (DTCs) and the association with disease recurrence.  Methods', '  BM was collected from clinical stage II-III breast cancer prior to treatment between 2007-2011. Gene expression of ERBB2 was determined by multiplex PCR (Fluidigm Biomark [FB]).  Positive expression was defined as at least 1.4 fold above a pool of normal BM. Expression was confirmed by single gene PCR and Nanostring nCounter (NC) assays.  Cox proportional model was used to estimate hazard ratios (HR).  Results', '  BM from 74 patients was analyzed.  Median follow-up was 3.4 years (range 8 months-84 months). 24% of the patients developed metastatic disease. For ERBB2 detection, there was excellent correlation between NC and the FB assays (kappa=0.87, 95% CI [0.62, 1.00]).  Nine patients expressed ERBB2 in their BM. Five of the 9 patients had Her2-positive tumors and were treated with trastuzumab. One of 5 (20%) of these patients relapsed whereas 75% (3 of 4) of the patients with HER2-negative tumors but ERBB2-positive DTCs relapsed.   Patients with HER2-negative tumors/ERBB2-positive BM  were found to have a greater hazard of recurrence than patients with HER2-negative tumors/ERBB2-negative BM or ERBB2-positive DTCs treated with trastuzumab (p=.0069; Table). Those patients with ERBB2-positive BM who did not receive trastuzumab had a decreased disease free survival (p=.016).  Conclusions', '  We have found discordant expression of  HER2/ERBB2 in tumors and BM of stage II-III breast cancer patients. The presence of ERBB2 expressing DTCs in patients with HER2-negative tumors identifies a subset of patients at increased risk of recurrence who may benefit from targeted HER2-therapy.   HER2 status of tumor and DTCs and risk of recurrence.']",
        "Doc_id":"ASCO_116529-132",
        "Doc_title":" Identification of patients at high risk of recurrent disease development by detection of HER2-positive disseminated tumor cells in bone marrow of patients with HER2-negative tumors.",
        "_version_":1606189001777086464},
      {
        "Meeting_name":" A randomized open-label, phase II study of lapatinib/capecitabine, lapatinib/vinorelbine, or lapatinib/gemcitabine in patients (pts) with ErbB2-amplified metastatic breast cancer (MBC) progressing after taxane treatment-GLICO-0801.",
        "Background":"['Background', ' Despite recent reports showing decreased mortality for breast cancer (BC) the disease continues to be a major public health problem. Different studies have demonstrated the value of lapatinib in combination with capecitabine in metastatic BC overexpressing ErbB2. There is enough rationale to design trials that use lapatinib in combination with other citotoxic drugs than capecitabine; these studies could support the employ of novel combinations and improve the outcome of these patients. The data generated will help to address the potential activity and safety of novel L + chemotherapy combinations in ErbB2 + MBC pts. Objectives', ' The primary objective of the trial is to determine the clinical benefit rate (CR+PR+SD for 24 wk) with the three combinations. Secondary objectives include', ' PFS, OS, ORR, DR, tolerability, and safety. The study aims to determine whether either, or both, L/vinorelbine or L/gemcitabine can be considered reasonable alternatives to the established L/Cap. Methods', ' Trial Design', ' GLICO-0801 aims to evaluate the potential role of different lapatinib-based chemotherapy combinations as 1st/2nd line treatment for ErbB2 amplified MBC progressing after taxane treatment. This is an open-label, randomized, international (Argentina, Brazil, and Peru), phase II trial that will include 165 pts and explores lapatinib (L) in two novel combinations', ' with gemcitabine or vinorelbine as well as with capecitabine (Cap). Inclusion Criteria', ' Pts with advanced, RECIST measurable ErbB2 positive MBC with documented progression after taxane treatment will be included. Pts may or not have received previous anti-ErbB2 therapy with trastuzumab (T). A maximum of one prior regimen for MBC will be allowed. Pts will be stratified according to liver metastasis, previous use of T and taxanes. Protocol Procedures/Timelines', ' Pts will be followed with standard imaging every 3 m until progression. The trial was initiated in Nov 2009 and as per Jan 8, 2010, 6 patients have been randomized. Completion of accrual is expected in 14 m.']",
        "Doc_id":"ASCO_54119-74",
        "Doc_title":" A randomized open-label, phase II study of lapatinib/capecitabine, lapatinib/vinorelbine, or lapatinib/gemcitabine in patients (pts) with ErbB2-amplified metastatic breast cancer (MBC) progressing after taxane treatment-GLICO-0801.",
        "_version_":1606188986205732864},
      {
        "Meeting_name":" Disregulation of phosphorelated Amplified In Breast Cancer3 (AIB3) contributes to poor prognosis and mediates trastuzumab efficacy in breast cancer patients",
        "Background":"['Trastuzumab (Herceptin) is the first line HER2 (ErbB2)/neu-directed therapy for the treatment of patients with metastatic breast cancer. Although the efficacy of trastuzumab depends on the HER2/neu status of the tumour, the single-agent response rate ranges from 12 to 30% and ew patients respond to trastuzumab monotherapy largely due to various resistance mechanisms. Amplifeid In Breast Cancer3 (AIB3) is a transcriptional coactivator. AIB3 plays an important role in embryonic development, adipocyte differentiation, metabolism. AIB3 was initially found to be amplified in subgroup of breast cancer patients. Our previous data using knockout mouse mode combined cell culture indicate that AIB3 plays important role in breast tumorigenesis. Here we report that AIB3 can be phosphorylated by MAPK at S884 site and phosphorylation at S884 of AIB3 dramatically reduced ligand-dependent AIB3 interactions with estrogen receptors when compared with the wild-type unphosphorylated form, although there was a significant increase of interactions with the unliganded receptor. Misexpression of phosphorylated AIB3 was observed in human breast cancer tissues and disregulation of phosphorylated AIB3 was associated with patients poor prognosis. Breast cancer is a heterogeneous disease and intrinsic subtypes play an extremely important role in improve on current standards for breast cancer prognosis and prediction of chemotherapy. Noticeably, phosphorylated AIB3 was highly expressed in Her2-enriched subtype of human breast cancer patients, as well as in the mammary tumor of MMTV-Her2 transgenic mice. Mechanism studies reveal that phosphorylated AIB3 alters trastuzumab efficacy in cultured breast cancer cells. The association between pAIB3 and important clinical outcomes confers pAIB3 a significant prognostic marker in breast cancer. Phosphorylated AIB3 as a modulator in ErbB2-MAPK regulating loop represents a potentially novel mechanism for trastuzumab (herceptin) efficacy. The implied interaction between pAIB3 and Her2 suggests the potential of dual targeting of Her2 and pAIB3 as a promising therapeutic approach for personalized breast cancer therapy.']",
        "Doc_id":"AACR_2012-5584",
        "Doc_title":" Disregulation of phosphorelated Amplified In Breast Cancer3 (AIB3) contributes to poor prognosis and mediates trastuzumab efficacy in breast cancer patients",
        "_version_":1606188970662690816},
      {
        "Meeting_name":" Overcoming cancer therapeutic resistance by targeting dysregulated glucose metabolism",
        "Background":"['Heat shock transcription factor 1 (HSF1) is the master regulator of the heat shock responses in eukaryotes. Upon exposure to a variety of stresses, HSF1 activates its target genes, subsequently activating the heat shock responses. Although not well understood, the functions of HSF1 are far beyond the classical induction of heat shock responses. Recent reports have shown that HSF1 plays an important role in cancer development. We investigated the role and mechanism of HSF1 in regulating oncogene-mediated dysregulated cellular metabolism and cell growth in cancer cells. We found that oncogene ErbB2-overexpressing cancer cells possessed significantly higher level of glycolysis when compared to ErbB2-low expressing cells, and the downregulation of ErbB2 markedly decreased glycolysis. Overexpression of ErbB2 increased the expression of HSF1 and two critical glycolysis-regulating molecules, lactate dehydrogenase A (LDH-A) and Hexokinase (HK). ErbB2 activated HSF1, indicated by the increased HSF1 trimer formation and DNA binding activity, and promoted the rate of HSF1 protein translation. HSF1 bound to the promoter of LDH-A and transcriptionally activated LDH-A. Meanwhile, the downregulation of HSF1 reduced the expression of LDH-A and subsequently decreased cancer cell glycolysis and growth. These results demonstrate that in cancer cells, ErbB2 promotes glycolysis and cell growth through HSF1-mediated upregulation of LDH-A. Trastuzumab (Herceptin) and Paclitaxel (Taxol) are important drugs in treatment of breast cancers when used alone or in combination with other chemotherapeutics. However, acquired resistance develops in most treated patients, necessitating alternate treatment strategies. Increased aerobic glycolysis is a hallmark of cancer and inhibition of glycolysis may offer a promising strategy to preferentially kill cancer cells. We investigated the antitumor effects of trastuzumab and Taxol in combination with glycolysis inhibitors in breast cancer. We found that trastuzumab inhibits glycolysis via downregulation of HSF1 and LDH-A in ErbB2-positive cancer cells, resulting in tumor growth inhibition. Moreover, increased glycolysis via HSF1 and LDH-A contributes to trastuzumab and Taxol resistance. Strikingly, we found that combining trastuzumab or Taxol with glycolysis inhibition synergistically inhibited both drug-sensitive and -resistant breast cancers in vitro and in vivo, due to more efficient inhibition of glycolysis. These results show how glycolysis inhibition can dramatically enhance the therapeutic efficacy of trastuzumab in ErbB2-positive breast cancers, potentially useful as a strategy to overcome trastuzumab resistance. This work was supported by NIH Grant RO1CA149646, The Vincent F. Kilborn, Jr. Cancer Research Foundation, and Radiumhospitalets Legater Project 334003.']",
        "Doc_id":"AACR_2012-3208",
        "Doc_title":" Overcoming cancer therapeutic resistance by targeting dysregulated glucose metabolism",
        "_version_":1606189028939399168},
      {
        "Meeting_name":" Evaluation of gene expression by RNA-seq after single dose of trastuzumab (T) reveals predictors of pathologic complete response (pCR) in HER2-positive early breast cancer.",
        "Background":"['Background', '  The use of a brief exposure to single agent T allows the measurement of dynamic changes in the transcriptome that may predict response to T-based combinations. We have shown that most gene expression changes in HER2+ tumors treated with T occur in tumors that ultimately achieve a pCR. Our further analysis suggests several patterns of transcriptional change in pCR tumors suggesting different mechanisms of action of T. RNA-seq analysis provides more in-depth annotation of these mechanisms. Methods', '  Fresh tumor core biopsies were taken at a 2 week time point after a single dose of T (8mg/m2) from 80 HER2+ early breast cancer patients enrolled on a clinical trial of T>T+C. Nucleic acids were extracted using Qiagen AllPrep and were analyzed with Illumina HT12v3 Beadchip and Illumina 610 QUAD V1 SNP arrays. RNA was also processed for sequencing using the Ovation RNA-Seq System and paired-end sequenced using an Illumina Genome Analyzer IIxRNA-seq data was analyzed with Tophat/Cufflinks. Network analysis was performed with Metacore. Results', '  Among pCR tumors, distinct patterns of differential expression pre/post T were observed, in both microarray and RNA-seq data. ERBB2 down-regulation was characteristic of pCR in one subgroup by microarray. In this group, differentially expressed genes belonged to interaction networks involved in apoptosis and cell cycle regulation. In contrast, tumors with no change in ErbB2 showed differentially expressed genes that belonged to networks related to chromatin assembly and regulation of immune pathways. NOLC1, RPL41, ZCHHC17, and B2M had altered alternative splicing product distributions in both groups. In the ERBB2 down-regulated group, genes with changed expression were enriched for targets of STAT3 and YY1. Conclusions', '  RNA-seq and microarray reveal distinct responses in tumors that achieve pCR to T-containing regimens. These methods provide predictive markers for validation in subsequent clinical trials.']",
        "Doc_id":"ASCO_100477-114",
        "Doc_title":" Evaluation of gene expression by RNA-seq after single dose of trastuzumab (T) reveals predictors of pathologic complete response (pCR) in HER2-positive early breast cancer.",
        "_version_":1606189040171745281},
      {
        "Meeting_name":" Oncogenic ERBB3 mutations in human cancers",
        "Background":"['The human epidermal growth factor receptor (HER) family of tyrosine kinases are deregulated in multiple cancers either through amplification, overexpression or mutation. ERBB3/HER3, the only ERBB family member with an impaired kinase domain, upon ligand binding heterodimerizes with ERBB2 to promote signaling. While amplification and overexpression of ERBB3 is observed in some cancers, occurrence and relevance of ERBB3 somatic mutations in oncogenesis is not established. Here we report the identification of ERBB3 somatic mutations in 11% of colon and gastric cancers. We found that the ERBB3 mutants together with ERBB2 promote oncogenic signaling and transformed colonic and breast epithelial cells in a ligand independent manner. Further, we found that multiple target therapeutics that acts on ERBB3, ERBB2 or their downstream signaling components are effective in blocking ERBB3-mutant mediated oncogenic signaling and disease progression in vivo. Identification of activating ERBB3 mutations along with the established contribution of ERBB3 to acquired resistance to EGFR/ERBB2-targeted drugs provides a rational to therapeutically target ERBB3.']",
        "Doc_id":"AACR_2014-4428",
        "Doc_title":" Oncogenic ERBB3 mutations in human cancers",
        "_version_":1606189018440007680},
      {
        "Meeting_name":" Patient-derived xenograft (PDX) models for triple negative breast cancer (TNBC)",
        "Background":"['In the United States, TNBC comprises 15-20% of breast cancers and are characterized by the lack of expression of estrogen receptor, progesterone receptor and receptor tyrosine protein kinase ERBB2 or Her-2/neu oncogene amplification. As a result, this type of breast cancer is difficult to treat as most of the chemotherapies target these 3 receptors. TNBC is highly aggressive and is associated with high morbidity, mortality and shorter disease-free survival. Given its heterogeneous clinical presentation, histology and response to therapy, prognosis and management of TNBC is complicated. In this study, we report development and characterization of the TNBC PDX model. We used patient derived TNBC tissues to generate 5 new TNBC models in NOD-SCID mice. Patient tumors were pre-screened for their ER, PR and Her-2/Neu expression by IHC, prior to inoculation in mice. Efficacy of two standard of care drugs, Cisplatin and Vinorelbine in the TNBC PDX model demonstrates the potential utility of the TNBC model in drug discovery effort in oncology for treatment of TNBC.']",
        "Doc_id":"AACR_2015-3226",
        "Doc_title":" Patient-derived xenograft (PDX) models for triple negative breast cancer (TNBC)",
        "_version_":1606189036678938624},
      {
        "Meeting_name":" Anoikis evasion in inflammatory breast cancer cells is mediated by Bim-EL sequestration",
        "Background":"['Inflammatory breast cancer (IBC) is a rare and highly invasive type of breast cancer, and patients diagnosed with IBC often face a very poor prognosis. IBC is characterized by the lack of primary tumor formation and the rapid accumulation of cancerous epithelial cells in the dermal lymphatic vessels. Given that normal epithelial cells require attachment to the extracellular matrix (ECM) for survival, a comprehensive examination of the molecular mechanisms underlying IBC cell survival in the lymphatic vessels is of paramount importance to our understanding of IBC pathogenesis. Due to the inherent invasive nature of IBC cells, we hypothesized that IBC cells could evade detachment-induced apoptosis (anoikis), and rely on tightly regulated intracellular signaling pathways to do so. Here we demonstrate that in contrast to normal mammary epithelial cells, IBC cells robustly survive in ECM-detached conditions. ErbB2 and EGFR knockdown in KPL-4 and SUM149 cells, respectively, causes decreased colony growth in soft agar and increased caspase activation following ECM detachment, suggesting overexpression/hyperactivation of these oncogenes is vital for IBC evasion of anoikis. Downstream of ErbB2 and EGFR, ERK/MAPK signaling was found to protect cells from anoikis by phosphorylating Bim-EL at serine 59. This phosphorylation of Bim-EL results in a physical interaction between Bim-EL, LC8, and Beclin-1 and prevents Bim-EL from localizing to the mitochondria and promoting cell death. Mutation of the serine 59 site results in increased cell death and a diminished capacity to form a protein complex with LC8 and Beclin-1. Bim-EL knockdown also rescued ECM-detachment-induced death in IBC cells, suggesting Bim-EL is necessary for the induction of anoikis in IBC cells. Interestingly, Bim-EL levels were found to be elevated in ECM-detached IBC cells and present in a significant percentage of IBC patient samples, despite their evasion of anoikis. Therefore, the sequestration of Bim-EL away the mitochondria provides a compelling rationale for how IBC cells survive in the presence of high Bim-EL levels. Furthermore, this mechanism provides a unique and novel opportunity for chemotherapeutic approaches aimed at freeing the already elevated Bim-EL levels from sequestration to specifically induce cell death in IBC cells.']",
        "Doc_id":"AACR_2015-1268",
        "Doc_title":" Anoikis evasion in inflammatory breast cancer cells is mediated by Bim-EL sequestration",
        "_version_":1606189015831150593},
      {
        "Meeting_name":" A phase II randomized trial of lapatinib with either vinorelbine or capecitabine in ErbB2-overexpressing first- and second-line metastatic breast cancer (MBC).",
        "Background":"['Background', ' Lapatinib (L), a dual kinase inhibitor of EGFR and ErbB2, is approved in the treatment of metastatic ErbB2+ breast cancer in combination with capecitabine (C) following progression after trastuzumab, anthracylines, and taxanes. Vinorelbine (V) is an important chemotherapy option in this setting, and multiple phase II trials have been conducted in combination with trastuzumab. The combination of L+V has been studied in two phase I trials, but no phase II trials have completed. Furthermore, treatment with L following progression on L remains an unanswered question. Methods', ' A randomized, open-label, multicentre, phase II study (LAP112620, VITAL) is currently recruiting in over 20 centres in 5 countries to determine the efficacy and safety of L with either V or C in women with ErbB2 overexpressing MBC. 105 patients (currently 5) with disease progression who have received no more than one chemotherapeutic regimen in the metastatic setting will be randomized 2', '1 to either Arm A', ' L 1250 mg orally once daily (QD) continuously plus V 20 mg/m2 intravenously on days 1 and 8, every third week, or Arm B', ' L 1250 mg orally QD continuously plus C 2000 mg/m2/day orally in 2 doses 12 hours apart on days 1-14 every third week. The primary endpoint is progression-free survival. As this phase II dose selection was based on two ongoing Phase I trials, an interim safety cohort (n=30) is employed with prospectively determined stopping rules for the L+V arm based on clinically-acceptable limits for febrile neutropenia (5%) and Grade 4 neutropenia (20%). Utilizing 95% confidence intervals, these limits may be exceeded with 4 events in 20 patients (20%) for febrile neutropenia and 9 events in 20 (45%) patients for Grade 4 neutropenia. Additionally, a sub-study will evaluate 24 hour V pharmacokinetics with and without concurrent L. For patients who progress while receiving L in this study, an optional cross-over phase to switch chemotherapy (VC or CV) with continued L will allow further exploration of the efficacy and safety of L following progression. Recruitment update will be presented.']",
        "Doc_id":"ASCO_47409-74",
        "Doc_title":" A phase II randomized trial of lapatinib with either vinorelbine or capecitabine in ErbB2-overexpressing first- and second-line metastatic breast cancer (MBC).",
        "_version_":1606188988567126016},
      {
        "Meeting_name":" A phase I/II study of MM-111, a novel bispecific antibody that targets the ErB2/ErB3 heterodimer, in combination with trastuzumab in advanced refractory HER2-positive breast cancer.",
        "Background":"['Background', '  The ErbB2/ErbB3 oncogenic heterodimer is the most potent ErbB receptor pairing with respect to strength of interaction, receptor tyrosine phosphorylation, and downstream signaling through mitogen activated protein kinase and phosphoinositide-3 kinase pathways.  MM-111 is a novel bispecific antibody fusion protein that specifically targets the ErbB2/ErbB3 heterodimer and abrogates binding of ErbB3s ligand heregulin. In preclinical models of HER-2+ solid tumors, MM-111 inhibits ligand-induced ErbB3 phosphorylation, cell cycle progression, and tumor growth.  ErbB2 (HER2) is a well established target of anticancer agents such as trastuzumab and lapatinib for HER2+ cancers, specifically breast and gastric. ErbB3 signaling has emerged as an important mechanism of resistance to ErbB2 (HER-2) targeted agents in clinical use, and preclinical data demonstrates that MM-111 potentiates the antitumor activity of trastuzumab.  This first-in-human phase I/II study evaluates the safety and tolerability of MM-111 in combination with trastuzumab and preliminarily explores efficacy in HER-2+ advanced breast cancer (ABC).  Methods', '  This is a phase I/II, open label, multicenter, dose-escalation study that will evaluate the safety,  pharmacokinetics (PK), and efficacy of MM-111 + trastuzumab.  There is a dose escalation phase followed by an expansion cohort. The dose escalation phase utilizes a standard 3 + 3 design where doses of MM-111 will be escalated until the phase II dose is identified in combination with trastuzumab given at the approved dose and regimen. Once the MTD or phase II dose is identified, an expansion cohort will be enrolled to further evaluate the safety and efficacy of doublet.  Key exploratory analyses will include an evaluation of safety and efficacy and levels of expression and/or amplification of HER2 and heregulin.  As of January 1 2011, cohorts 1 thru 2 have been completed without DLT. A total of 7 patients have been treated. Enrollment to cohort 3 is ongoing.']",
        "Doc_id":"ASCO_79100-102",
        "Doc_title":" A phase I/II study of MM-111, a novel bispecific antibody that targets the ErB2/ErB3 heterodimer, in combination with trastuzumab in advanced refractory HER2-positive breast cancer.",
        "_version_":1606189031696105472},
      {
        "Meeting_name":" TRAF2 is required for the survival of ErbB2-transfored mammary tumor cells.",
        "Background":"['TRAF2 regulates signaling pathways downstream of many members of the TNF receptor superfamily, such as TNFR1 and CD40. Recently, we found that TRAF2 also plays an important role in breast cancer cell survival under conditions of endoplasmic reticulum (ER) stress. It is known that TRAF2 knockout (KO) mice die within a week of birth and this lethality can be rescued by KO of TNF or TNFR1. In order to determine the role of TRAF2 in mammary tumor development and progression, we crossed MMTV-ErbB2 mice (FVB) with TNF-/-/TRAF2-/+ mice (B6), and generated MMTV-ErbB2 (ErbB2), MMTV-ErbB2-TNF-/- (ErbB2/T-KO) and MMTV-ErbB2-TNF-/-/TRAF2-/- (ErbB2/T/T2-DKO) mice all in FVB/B6 mixed background. In 43 weeks, only 1 of 10 ErbB2/T/T2-DKO mice developed a mammary tumor, while 50% of ErbB2 and ErbB2/T-KO mice developed multiple and larger tumors in 30-32 weeks. Interestingly, the tumor derived from the ErbB2/T/T2-DKO mice did not show decreased cyclin D1 expression, nor the tumor cells cultured in vitro show decreased NF-B activation in response to RANKL. In addition, ErbB2/T/T2-DKO cells formed mammospheres of similar appearance with that of ErbB2 cells in HEMA-coated plates. However, after dispersion of the mammospheres into single cells, ErbB2/T/T2-DKO cells formed dead cell aggregates, while ErbB2 and ErbB2/T-KO cells formed secondary mammospheres, suggesting that the self-renewal capacity of ErbB2/T/T2-DKO cells is impaired. Mechanistic studies reveal that ErbB2/T/T2-DKO cells are sensitive to death caused by ER stress but not by TRAIL or DNA damage, and that this sensitivity is significantly inhibited by knockdown of RIP1. Collectively, these findings suggest that TRAF2 plays a critical role in mammary tumor development and progression by suppressing the pro-death activity of RIP1, and that TRAF2 and RIP1 interaction could be an attractive target for development of new anti-breast cancer drugs.']",
        "Doc_id":"AACR_2017-4793",
        "Doc_title":" TRAF2 is required for the survival of ErbB2-transfored mammary tumor cells.",
        "_version_":1606188993092780032},
      {
        "Meeting_name":" The impact of germline single nucleotide polymorphisms (SNPs) in ERBB-family genes and genes associated with homologous recombination deficiency (HRD) on response to taxotere, platinum and trastuzumab (TCH) based therapy in the treatment of HER2-positive breast cancer patients.",
        "Background":"['BACKGROUND', ' We have shown that ERBB (EGFR, ERBB2, ERBB and ERBB4) germline single nucleotide polymorphisms (SNPs) have a negative impact on the outcome of trastuzumab treated HER2-positive breast cancer (BC) patients. Currently TCH (taxotere, platinum and trastuzumab) based therapy is used to treat early stage HER2-positive BC. We investigate the importance of germline SNPs in ERBB genes and those genes involved in homologous recombination deficiency (HRD), on how patients respond to TCH therapy.']",
        "Doc_id":"AACR_2017-3402",
        "Doc_title":" The impact of germline single nucleotide polymorphisms (SNPs) in ERBB-family genes and genes associated with homologous recombination deficiency (HRD) on response to taxotere, platinum and trastuzumab (TCH) based therapy in the treatment of HER2-positive breast cancer patients.",
        "_version_":1606188996803690496},
      {
        "Meeting_name":" The other triple-negative breast cancer",
        "Background":"['Background', '    The triple-negative (TN) immunohistochemical (IHC) definition for basal-like breast cancer lacks specificity. This aggressive subtype is best identified with the addition of EGFR and CK5/6 biomarkers; however, the subgroup of TN breast cancers that lack expression of these biomarkers (5NP) is mostly uncharacterized. Recently, an additional intrinsic subtype, claudin-low, was identified using microarray-based gene expression data. These tumors are characterized by the low expression of ERBB2, ESR1, and cell-cell adhesion proteins such as claudins 3/4/7 and E-cadherin.  Methods', '    Microarray gene expression and IHC data were collected from two independent cohorts', ' Washington University (WU, n=114) and University of North Carolina (UNC, n=98). Tumors were assigned as claudin-low or not using a genomic predictor. An IHC surrogate for the claudin-low subtype was developed, and applied to a tissue microarray (TMA) from the University of British Columbia (UBC, n=3473) linked with extensive clinicopathological and outcome data.  Results', '    Against a gene expression gold standard, an IHC combination of ER(-), Her2(-), and E-cadherin(-) best identified claudin-low tumors (PPV=24% WU, 67% UNC; NPV=94% WU, 87% UNC).  This IHC panel identified 226 claudin-low tumors (6.5%) from the UBC TMA. Compared to the basal-like tumors, claudin-low tumors had a similar distribution for patient age, tumor size and lymph node status. However, the claudin-low tumors were less often grade 3 (88% vs. 80%, p = 0.036) or high expressors of Ki67 (61% vs. 82%, p <0.001). Claudin-low subgroup had superior breast cancer specific survival when compared to the basal-like (10-yr BCSS 69% vs. 60%) with a multivariate HR of 0.69 (p = 0.030), adjusted for clinicopathological variables and adjuvant treatment.  Conclusions', '    The ER(-)/Her2(-)/E-cadherin(-) IHC definition identified the claudin-low subtype of breast cancer, although with a PPV insufficient for clinical use. The addition of this definition to the standard IHC panel for intrinsic breast cancer subtypes (ER, PR, Her2, Ki67, EGFR and CK5/6) isolates a subgroup of TN tumors that are clinically distinct from basal-like breast cancers.']",
        "Doc_id":"ASCO_79618-102",
        "Doc_title":" The other triple-negative breast cancer",
        "_version_":1606189037203226624},
      {
        "Meeting_name":" High mobility of triple-negative breast cancer cells is due to repression of plakoglobin gene by SLUG",
        "Background":"['One of highly pathogenic breast cancer cell types are the SLUG-high claudin-low triple negative (negative in the expression of estrogen, progesterone and ERBB2 receptors) breast cancer (TNBC) cells. These cells are highly metastatic and have low levels of the motility regulatory catenin plakoglobin. In order to link high levels of the transcriptional repressor SLUG in the TNBC cells with low levels of plakoglobin we found that SLUG inhibits the expression of plakoglobin gene directly in these cells and thus, among other downstream effects, help disseminating these tumor cells. Overexpression of SLUG in the SLUG-deficient cancer cells significantly decreased the levels of mRNA and protein of plakoglobin. On the contrary, knockdown of SLUG in SLUG-high cancer cells elevated the levels of plakoglobin. Overexpression of SLUG in the SLUG-deficient cells elevated the invasiveness and motility of these cells. On the other hand, knockdown of plakoglobin in these low motility non-invasive breast cancer cells did not affect the ability of the cancer cells to penetrate Matrigel matrix but increase the growth and migration rates of these cells. This study thus implicates high levels of SLUG and low levels of plakoglobin as determinants in the progression of highly disseminating breast cancer. Supported in parts by the DOD-CDMRP grants BC050641, BC086542 and BC103645 to GC.']",
        "Doc_id":"AACR_2012-1287",
        "Doc_title":" High mobility of triple-negative breast cancer cells is due to repression of plakoglobin gene by SLUG",
        "_version_":1606189019017773056}]
  }}
